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 Chapter 1
  General introduction and 
aims of this thesis

General introduction 11
LaSERS
Lasers have been an ongoing field of interest and development since Albert Einstein’s 
‘Quantum Theory of Radiation’ in 1917. This contained all the necessary formulas and 
theoretical concepts to build a laser, but it wasn’t until the 1960’s that the first lasers 
became operational.
The word ‘LASER’ is an acronym for Light Amplification by the Stimulated Emission 
of Radiation. The explanation of the creation of laser light starts with the structure of 
an atom. An atom is composed of a positively charged central nucleus, with negatively 
charged electrons orbiting around the nucleus. Orbits closer to the nucleus have lower 
energy, and the closest one is called the ground state (E0; stable configuration). When 
an atom absorbs energy (a photon), a negatively charged electron can get excited and 
move to a higher energy orbit; this is called the excited state (E1; unstable configura-
tion). After a short period of time, the excited electron will return to the stable ground 
state by emitting a photon equal to the energy difference (i.e. spontaneous emission). 
Normally, this spontaneous absorption and release of light occurs in a disorganized and 
random fashion and results in incoherent light 1.
Lasers are different from other light sources, as they have unique characteristics: co-
herence, monochromaticity, and collimation. Coherent light is light where all the waves 
are in phase with each other in both time and place. The coherence of laser light is due 
to the process of stimulated emission. In stimulated emission, an external power source 
creates excitation of the atoms in a medium. When more atoms are in their unstable 
high energy state than in their stable resting configuration, population inversion is cre-
ated. This is necessary for light amplification. If an atom is already in an excited state 
when it collides with a photon, two photons are released in phase with one another as 
the electron returns to its normal, stable configuration (Fig. 1). This results in a cascade 
of reactions and the release of numerous photons of identical wavelength, energy, and 
phase. Light of a single wavelength is called monochromatic light. The third character-
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figure 1. Electron transitions in an atom. Reproduced with permission of the Department of Physics, The Chi-
nese University of Hong Kong.
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istic is collimation, which refers to the parallel nature of the waves, without signifi cant 
divergence.
Lasers are composed of diff erent components: a medium, optical cavity, power sup-
ply, and a delivery system. The medium can be solid (e.g. ruby), liquid (e.g. rhodamine 
dye), or gas (e.g. CO2). Each laser medium has a very characteristic photon wavelength 
and determines the wavelength of the emitted light. The optical cavity surrounds the 
medium and contains the amplifi cation process. After the energy input by an external 
power source, photons start to build up with the same wavelength. The light is refl ected 
in a chamber between two mirrors (creating collimation), and can be released out one 
end and delivered through the handpiece to the target.
In order for a tissue reaction to occur, the laser light needs to be absorbed by the tar-
get tissue (for example) in the skin. When light is absorbed, the radiant energy is trans-
formed into a diff erent form of energy by a specifi c interaction with the tissue. The most 
common reaction is a photothermal reaction, where the light energy is transformed into 
and dissipated as heat. Other common reactions are: photoacoustic or photomechani-
cal (formation of shockwaves), photochemical (light energy starts a chemical reaction), 
and photoablation (use of light to ablate tissue). However, only when light is highly 
absorbed by a specifi c component of the skin, a precise biologic eff ect occurs.
Besides absorption, laser light can also interact with tissue in diff erent ways: trans-
mission, refl ection and scattering (Fig. 2). Transmission is the passage of laser energy 
through a biologic tissue without producing any eff ect. Refl ection refers to the repelling 
of light off  the surface without any entry into the tissue. Approximately 4% to 7% of light 
is refl ected off  the skin 2. The least amount of refl ection occurs when the laser beam is 
directed perpendicular to the tissue. Scattering is imprecise absorption of laser energy 
due to the heterogeneous structure of the tissue, and spreads out the laser beam result-
ing in a diff use eff ect on tissue. In the skin most scattering is caused by dermal collagen, 
Reflection
Scattering
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figure 2. Laser – tissue interactions.
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which limits the penetration depth 3. The amount of scattering is inversely proportional 
to the wavelength of the laser, with longer wavelengths penetrating deeper into the 
tissue 3. Also, larger spot sizes cause less scattering.
Anderson and Parrish introduced the theory of selective photothermolysis in 1983 4. The 
concept of selective photothermolysis states that in order to destroy a specific target, 
a wavelength is needed that is more absorbed by the target chromophore than any 
other competing chromophores in the skin. The three main components of the skin that 
absorb laser light are melanin, hemoglobin, and water. The absorption spectra of these 
different chromophores have been established and can be used to design specific lasers 
for specific targets (Fig. 3).
The wavelength also determines the penetration depth. In general, longer wavelengths 
penetrate deeper into the skin than shorter wavelengths (because of less scattering). 
This applies to the wavelengths within the spectrum of visible light. However, the near-
infrared wavelengths of light are absorbed by water in the cells at the surface of the skin, 
and therefore their penetration depth is decreased drastically.
The second part of the theory states that for the best selectivity, and to avoid non-
selective damage, the heat should be confined to the target during the light pulse. This 
right amount of energy with the proper pulse duration is known as thermal relaxation 
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figure 3. Absorption spectra of chromophores. Oxyhemoglobin has three main absorption peaks in the 
blue-green-yellow portion of the visible range (418 nm, 542 nm, 577 nm) 3, 5. Melanin absorbs light of wave-
lengths from ~250 nm – 1200 nm, with decreasing absorption as the wavelength increases 6. Water absorbs 
mainly infrared laser energy (700 nm – 1 mm ).
14 Chapter 1
time (TRT). The TRT is the time required for the target to dissipate 50% of its heat and is 
based on the size of the target (Table 1) 3. Small targets have a small TRT and need a laser 
with a short pulse duration. Large targets have a long TRT and therefore need lasers with 
a long pulse duration. The pulse duration should be shorter than the TRT to prevent the 
spread of thermal energy beyond the targeted chromophore.
However, Murphy and Torstensson recently suggested that not the physical dimen-
sions of the target, but the tissue’s intrinsic structure determines the time required to 
induce irreversible protein denaturation within the target 7.
Finally, sufficient energy must be delivered to the target to destroy the chromophore. 
Irradiance determines the ability of a laser to incise, vaporize, or coagulate tissue and 
is expressed in watts/cm2 1. The energy fluence (EF) determines the amount of energy 
delivered in a single pulse and is expressed in joules/cm2. The EF can be calculated using 
the following formulas:
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The fluence necessary to destruct the target is dependent on the fraction of light 
absorbed by the target 5. When the wavelength is weakly absorbed by the target, for 
example when the target is located deep in the dermis, or when the target contains less 
chromophore, higher fluences are needed to achieve the desired effect. The develop-
ment and use of epidermal cooling systems minimized the non-selective epidermal 
Table 1. Thermal relaxation times of common laser targets 3, 8.
Target Size Thermal relaxation time
Tattoo ink particle 0.04-0.7 µm 10 ns
Melanosome 1 µm 1 µs
Erythrocyte 7 µm 20 µs
Epidermis* 50 µm 1 ms
Blood vessel 50 µm 1 ms
Ectatic blood vessel 100 µm 15 ms
Hair follicle 200 µm 20 – 100 ms
* The thickness of the epidermis, and thereby its TRT, varies for different anatomic locations (from approxi-
mately 30 - 150 μm).
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thermal injury and allowed for higher fluences to be used. Additionally, epidermal cool-
ing reduced treatment-related pain.
Today, lasers are increasingly used for different medical and cosmetic purposes and have 
gained an important role in dermatology. By altering the wavelength and pulse duration 
of the laser, a wide variety of dermatological indications can be treated, including vascu-
lar lesions, pigmented lesions, tattoos, hairs, and (ablative and non-ablative) resurfacing.
Although laser systems have improved in the last few decades, treatments are fre-
quently far from perfect, and patients may have unrealistically high expectations when 
it comes to the results of their laser treatment. The ideal laser treatment would have 
100% effective treatment results, no recurrences, no side effects, a short treatment dura-
tion, no pain, a quick recovery (minimal downtime), and excellent esthetic results. As 
none of the currently available laser treatments can reach these goals, there is still room 
for improvement, and even established laser treatments can be optimized.
An example is the Pulsed Dye Laser (PDL) treatment used for port wine stains (PWS). 
The PDL was the first laser that was designed based on the principles of selective 
photothermolysis, and is today still the gold standard treatment for PWS. However, PDL 
treatment results are unpredictable and complete clearance is only achieved in a minor-
ity of patients 9. Therefore, there is a clear necessity to further optimize the results of this 
established laser treatment.
Another, more general, optimization strategy for laser treatments is to minimize the 
pain experienced during treatment. Laser treatments can be painful and optimizing this 
discomfort can increase patient satisfaction and also treatment efficacy as pain some-
times makes it necessary to use lower laser settings.
Since lasers are one of the most rapidly advancing fields in dermatology, the opportu-
nity to discover new laser indications is nowhere near exhausted. Therefore, innovative 
laser treatments for alternative indications should be further investigated, for example 
as an alternative non-surgical treatment option for pre-malignant skin lesions such as 
lentigo maligna.
In the next section of this introduction, obstacles during PWS laser therapy, the 
general obstacle of pain during laser treatments, and the obstacles during non-surgical 
treatments of lentigo maligna are further discussed.
OPTIMIZaTIOn Of ESTabLISHED LaSER TREaTMEnTS
Port wine stains
Port wine stains are congenital vascular malformations of the skin and occur in 0.3% - 
0.5% of the population 10. Unlike capillary hemangiomas, PWS do not involute spontane-
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ously. Clinically, PWS appear as pink macules in infancy, and over time develop a deeper 
red or purple color due to underlying progressive vascular ectasia (Fig. 4.)
Nodular components and hypertrophy of the underlying soft tissue occur in 65% of the 
people by the age of 50 11. Port wine stains can cause significant psychological problems 
as most lesions occur in the head and neck region 12, 13.
The pathogenesis of PWS remains largely unknown. Histologically, PWS are character-
ized by ectatic capillaries and post-capillary venules in the papillary and mid-reticular 
layers of the dermis 14. The diameter of the vessels can increase over time. A hypothesis 
for the pathogenesis of PWS is a decreased nerve density and an increased vessel-to-
nerve ratio, resulting in an abnormal neural regulation of blood flow 15. As a result, the 
blood vessels are unable to constrict normally and remain permanently dilated.
Mutations in RASA1 and vascular endothelial growth factor (VEGF) expression also 
appear to play a role in the pathogenesis of PWS 16, 17. Recently, a somatic activating 
mutation in the GNAQ gene was found to cause Sturge-Weber syndrome and PWS 18.
Most PWS occur in isolation and are not associated with other health problems. How-
ever, PWS can be associated with Sturge-Weber syndrome, Klippel-Trenaunay syndrome, 
Cobb syndrome, von Hippel-Lindau syndrome, and cutis marmorata teleangiectatica 
congenital.
Laser treatment of PWS
Laser therapy is the treatment of first choice for PWS. The target tissues in PWS are 10-
500 μm dilated capillaries and postcapillary venules in the papillary and reticular dermis 
19. The target chromophore is hemoglobin, which absorbs light strongly at 400 - 600 nm, 
while absorption is less at 700 - 1100 nm 20. When laser light is absorbed by hemoglobin 
figure 4. Clinical presentation of a port wine stain.
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it causes photocoagulation and aggregation of erythrocytes through a photothermal 
reaction, and ultimately necrosis of the endothelial cells 21. The highest absorption peak 
for hemoglobin is at 418 nm, however the penetration of this wavelength is limited to 
the dermal-epidermal junction (about 100 µm).
The first laser that was commonly used for the treatment of PWS was the argon laser 
1. The argon laser emitted light at wavelengths of 488 - 514 nm, which is preferentially 
absorbed by oxyhemoglobin and melanin. The pulse duration varied from 50 - 200 ms. 
This continuous wave laser with relatively long pulse widths had an exposure time that 
was too long for selective photohermolysis and resulted in nonspecific thermal dam-
age (textural alteration, scarring, pigmentary changes) to the surrounding tissue 5. Also, 
treatment with this laser was painful and infiltration anaesthesia was often needed.
Continuous wave dye lasers were developed with longer wavelengths of light (and 
therefore a deeper penetration), which were thought to be more suitable for the treat-
ment of PWS. These lasers operated at a wavelength of 577 nm, which coincides with the 
beta absorption peak of hemoglobin. However, the light was emitted in a continuous 
fashion and pulse durations were still quite long (50 – 200 ms), which resulted in non-
specific thermal damage, and was the major disadvantage of these lasers. The operator 
could move the beam across the surface to reduce exposure time, but these results were 
very dependent on the skills of the operator. Alternatively, automated robotic scanning 
devices were used to create shorter pulse durations, uniformity of energy placement 
and faster treatment.
The first laser that was designed based on the concept of selective photothermolysis 
was the PDL. The active medium is rhodamine dye selected to produce yellow light at 
577-595 nm. The first generation PDLs produced light at 577 nm, which coincides with 
the hemoglobin absorption peak while having a lower absorption of melanin than the 
488 nm and 514 nm wavelengths of the argon laser 22. However, the 577 nm PDL did not 
penetrate deep enough for successful treatment of PWS 14, and therefore the 585 nm 
PDL was developed. Additionally, this wavelength had a lower melanin-to-hemoglobin 
absorption coefficient than the 577 nm PDL. It was shown that penetration depth with 
the 577 nm PDL increased from 0.5 mm to 1.2 mm with the 585 nm PDL in a pig skin 
model 23. However, the penetration depth remained too shallow for the deeper vessels, 
and since the absorption of light by oxyhemoglobin is greater at 577 nm than 585 nm, 
clearance was not significantly improved 14. Subsequently, the modern 595-600 nm PDLs 
were developed further enhancing penetration depth.
The first generation PDLs used a pulse duration of 0.45 milliseconds. Short pulse dura-
tions can cause vaporization of blood, local rupture of microvessels, and purpura. These 
purpura can last for 7-10 days and are often cosmetically unacceptable. The second 
generation PDLs were developed with longer pulse widths. This longer pulse width was 
thought to be more appropriate for larger caliber vessels, based on the estimated TRT 
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of PWS vessels at 0.45 – 10 ms 4, 24. These longer pulse durations produced little or no 
immediate purpura 25 and resulted in a better treatment outcome 14.
With all these wavelengths, there is, besides absorption of oxyhemoglobin and de-
oxyhemoglobin, also absorption of melanin. Therefore, skin cooling is needed to protect 
the epidermis from thermal damage, and to allow for the use of higher fluences without 
increasing the risk of epidermal damage.
The development of the PDL highly increased the effectiveness of PWS treatment. 
However, treatment results remain unpredictable, and complete clearance is only 
achieved in a minority of patients 9. A commonly occurring limitation of PDL treatment 
is recurrence of the PWS after treatment, which occurs in 16.3% – 50% of patients as 
early as five years after treatment 26, 27.
Obstacles in the treatment of PWS
The efficacy of selective photothermolysis and completeness of photocoagulation of 
the blood vessels depends on the extent of epidermal pigmentation, optical shielding 
by blood and superimposed vessels, and PWS vascular anatomy and morphology 14. A 
high melanin content, superimposed vasculature, increased PWS size, vessel depth, and 
skin thickness reduce light penetration and result in a decreased treatment efficacy 14, 28. 
Vessels of moderate size are correlated with a better clinical response to PDL treatment 
than small (< 20 µm) vessels 29.
Also, it has been suggested that treatment failure of PWS, or recurrence of PWS after 
laser treatment, is in part due to regeneration and revascularization of photocoagulated 
vessels 30. After successful laser photothermolysis, the blood supply to the skin is sig-
nificantly reduced due to vessel photocoagulation. This results in the induction of local 
hypoxia. The normal wound healing response of the skin detects hypoxia and initiates 
appropriate defense mechanisms such as vasodilation and angiogenesis. In order to 
achieve PWS clearance, hyperdilated PWS vasculature has to be replaced by normal 
lower-volume capillaries. However, in therapy-resistant PWS, neo-angiogenesis may 
occur too extensively during the short-term vascular remodeling phase and hampers 
the reduction in dermal blood content 30.
Options for treatment-resistant PWS
Over the years, different approaches have been undertaken to optimize the laser treat-
ment of therapy-resistant PWS. For example, longer wavelength lasers, such as the 755 
nm Alexandrite and 1064 nm neodymium-doped yttrium aluminium garnet (Nd:YAG), 
may be especially useful for hypertrophic and nodular PWS lesions as they penetrate 
deeper 14. However, since there is also a decreased absorption by hemoglobin, higher 
fluences are often needed, which are associated with a higher risk of adverse events. 
Non-coherent light sources, like the Intense Pulsed Light (IPL), appear to be less effec-
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tive than PDL treatment 31, but may be considered as an alternative treatment for PDL-
resistant PWS 14. Other techniques that have been used to improve PWS clearance are 
different spotsizes, multiple passes, pulse stacking, and dual laser approaches. However, 
Chen et al. performed a review of literature between 1990 and 2012, and concluded 
that, in this period, no substantial progress had been made in PWS laser treatment 
clearance 14. They showed that 12% - 85% of patients achieved less than 50% clearance, 
regardless of treatment modality. Therefore, there is a clear necessity for the continued 
development of optimization strategies for refractory PWS.
Different experimental treatments or techniques to improve the outcome of laser 
treatment of PWS include photo dynamic therapy (PDT), pneumatic skin flattening (PSF), 
fractional ablative resurfacing, indocyanine green-augmented diode laser therapy, and 
anti-angiogenic agents (e.g. sirolimus).
Sirolimus
Mammalian target of rapamycin (mTOR) signaling is an important component of the 
cellular response to hypoxia through upregulation of hypoxia-inducible factor 1-al-
pha (HIF-1a), which increases the expression of hypoxia-responsive genes. Sirolimus 
(rapamycin [RPM]) is a specific inhibitor of mTOR and has a long history of use as an 
immunosuppressive agent 32. Because of its ability to inhibit mTOR-mediated functions, 
such as protein synthesis, cell proliferation and tumor angiogenesis, the use of sirolimus 
as an anticancer drug has been investigated 33, 34. As an anti-angiogenic agent, sirolimus 
may also enhance the therapeutic efficacy of PWS laser therapy. Sirolimus inhibits the 
figure 5. Schematic diagram of RPM-mediated inhibition of PDL-induced angiogenesis pathways 36. 
Figure reproduced from Tan et al. Lasers Surg Med. 2012 with permission, © 2012 Wiley Periodicals, Inc.
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proliferation of vascular endothelial cells driven by vascular endothelial growth factor 
(VEGF) and suppresses the induction of HIF-1a 35. Therefore, sirolimus potentially may 
inhibit the growth of vascular endothelial cells and smooth muscle cells, which are criti-
cal elements for new blood vessel formation (Fig. 5.).
OPTIMIZInG LaSER TREaTMEnTS In GEnERaL
Pain
Pain is a frequently occurring side-effect of laser treatments and can decrease patient 
satisfaction. Pain can also decrease treatment efficacy as it may force the treating physi-
cian to use lower laser settings.
Invasive anaesthetics can be used to reduce treatment-related pain. However, these 
injectable anaesthetics are often painful to administer, and patients can be needle pho-
bic. Alternatively, non-invasive anaesthetic methods can be used, which are painless to 
administer. Non-invasive anaesthetic methods for pain reduction during dermatological 
laser treatments include skin cooling, PSF, and topical anaesthetic drugs.
Different skin cooling methods are available, including cold air, dynamic skin cool-
ing (cryogen spray), application of cold gels, and contact cooling. Cooling lowers the 
skin temperature and thereby decreases pain sensation and discomfort. Secondly, skin 
cooling protects the epidermis from thermal injury, as melanin in the epidermis is an 
unwanted site for absorption of light, except when treating epidermal pigmented le-
sions 5. Skin cooling may be applied before, during and/or after laser treatment. The 
depth of cooling that is desired differs with different laser applications.
Pneumatic skin flattening utilizes a vacuum chamber, covered by a transparent sap-
phire window, to generate negative pressure. This activates tactile and pressure skin 
Inhibitory interneurone
Brain
Aβ fibre
C fibre
figure 6. Gate control theory of pain. “Slow” C-fibres transmit pain from the periphery. “Fast” Aβ-fibres 
transmit mechanical stimulation impulses. Competitive activation by “fast” fibres activates the inhibitory 
neurone (closing the “gate”), and modulates the transmission and subsequent cortical perception of pain. 
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receptors, which block the transmission of pain, based on the gate control theory of 
pain (Fig. 6) 37, 38. The laser light can be delivered through the sapphire window, and the 
vacuum is released at the end of the treatment pulse.
Topical anaesthetic drugs inhibit sodium influx through voltage-gated sodium chan-
nels and prevent nerve cell depolarization and input to the central nervous system 39. 
Cocaine was the first topical anaesthetic drug that was discovered 40. Later, ester anaes-
thetics (e.g. tetracaine) were developed, however, allergic contact dermatitis frequently 
occurred as an adverse effect 41. Subsequently, amide anaesthetics (e.g. lidocaine, prilo-
caine) were created and became the preferred anaesthetic. Epinephrine may be added 
to topical anaesthetic drugs to prolong the anaesthetic effect and decrease systemic 
absorption through vasoconstriction. Additionally, non-steroidal anti-inflammatory 
drugs (NSAIDs) can be used topically. They reduce pain by inhibiting cyclo-oxygenase 
enzymes, and thereby the synthesis of prostaglandins. Today, various prescription and 
over-the-counter topical anaesthetics and combinations are available.
Which of these non-invasive methods for anaesthesia provides the best pain reduc-
tion during different dermatological laser procedures has never been systematically 
investigated.
DEVELOPMEnT Of InnOVaTIVE LaSER TREaTMEnTS
Lentigo maligna
Lentigo maligna (LM) is the most common subtype of melanoma in situ, histologically 
showing atypical melanocytes confined to the epidermis and appendageal epithelium 
(Fig. 7).
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The clinical appearance of LM is characterized by a slowly growing pigmented macular 
lesion on chronically sun-exposed skin of middle-aged or elderly individuals (Fig. 8). Most 
lesions are located on the head and neck region 42. Lentigo maligna has the potential for 
dermal invasion and progression to lentigo maligna melanoma (LMM). However, this risk 
of progression is not well known. One epidemiological study from 1987 estimated the 
lifetime risk of LM progressing to LMM to vary from 2.2% to 4.7% 43.
The primary treatment goal is to madicate the lesion completely and prevent recur-
rences. However, since LM occurs mainly in the head and neck region 44, important sec-
ondary goals are to minimize functional impairments and cosmetic deformities as well.
Surgical excision is the accepted standard of treatment for LM 45. The main advantages 
are that the atypical melanocytes in both the surface epidermis and appendages can 
figure 7. Histopathology of lentigo maligna. Continuous proliferation of atypical melanocytes along the 
dermo-epidermal junction, with downward extension along the hair follicle. In the background severe solar 
elastosis. Arrows point out atypical melanocytes (HE 100x).
figure 8. Clinical presentation of a lentigo maligna.
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be completely removed, and that it allows for careful histological examination, staging, 
and the assessment of margin clearance. The treatment of first choice, according to the 
current guidelines, is wide local excision with 5 mm margins 46, 47. However, as clinical 
margins are often difficult to delineate, this may be considered inadequate, and a form 
of staged surgical excision might be more appropriate 48, 49.
Surgical excision is not always reasonable and appropriate, especially for large lesions 
in cosmetically sensitive areas or elderly patients. In these cases, alternative non-surgical 
therapies, or even a wait-and-see policy may be considered 45.
Non-surgical treatments that are available for LM include laser therapy, topical thera-
pies such as imiquimod, cryotherapy and radiation therapy.
Laser therapy
Both lasers targeting pigment and lasers targeting water have been used in the treat-
ment of LM. When using pigment lasers, the target chromophore is epidermal and 
appendageal melanin. Melanin absorbs a wide range of wavelengths of 250 – 1200 nm. 
Therefore several lasers and intense pulsed light sources can effectively treat pigmented 
lesions. When light of q-switched lasers is absorbed by melanin, it causes a photoacous-
tic or photomechanical reaction and selectively ruptures the skin melanosomes. The 
rate of local heating and rapid material expansion can be so severe that structures are 
torn apart by shock waves, cavitation, or rapid thermal expansion 1. Infrared lasers, on 
the other hand, are highly absorbed by water, converting the light energy to heat and 
vaporizing the tissue (e.g. LM lesion). The first laser that was used in the treatment of LM 
was the argon laser in 1981 50. More recently, the Q-switched ruby, Q-switched Alexan-
drite, Q-switched Nd:YAG, and ablative lasers such as the carbon dioxide laser have been 
used for the treatment of LM.
The potential advantages of laser treatment are rapid treatment time, tolerable side 
effect profile, reduced post-treatment care requirements, wide treatment margins, and 
good functional and cosmetic outcomes. However, limitations are the lack of histopatho-
logical control, the poor complete response rates (ranging between 54.5% to 100%), and 
recurrence rates up to 100% 51. Read at al. pooled data of all patients undergoing laser 
treatments (n=61), and generated a mean recurrence rate of 34.4% (and statistical het-
erogeneity of I2 = 67.9%) 51. These poor response and high recurrence rates may be due 
to incomplete eradication of malignant cells, primarily in the appendageal structures 
and possibly at the periphery of the lesion.
Imiquimod
The topical toll-like receptor (TLR) 7 and 8 agonist imiquimod can induce an inflamma-
tory immune response that clears atypical melanocytes. Also, a direct apoptotic effect 
has been described of melanocytes that were treated with imiquimod 52, 53. Ten studies 
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(including 245 patients) investigated imiquimod for the treatment of LM 51. Initial clinical 
response rates ranged from 50% to 93%, and the calculated mean recurrence rate was 
24.5% (with a heterogeneity of I2 = 62.6%). Benefits are the excellent functional and 
cosmetic outcomes, and the use of wide margins. Limitations are the lack of histopatho-
logical control, the side effects (e.g. flu-like symptoms), and the long treatment duration.
Cryotherapy
Cryotherapy induces low temperatures that can destroy the epidermis, including the 
atypical melanocytes (-4°C to -7°C) 54 . Evidence is limited to case series and case reports. 
Recurrences rates are described from 0 – 40% 55. Benefits are the ease of use and rapid 
treatment time. Limitations are the lack of histopathological control, and the side effects 
that can frequently occur (i.e. hypopigmentation, atrophy, hyperpigmentation).
Radiotherapy
Read et al. systematically reviewed the available evidence for radiotherapy of LM. Ten 
studies, including 454 patients, demonstrated complete response rates of 87% - 100%, 
and a mean recurrence rate of 11.5% (with a statistical heterogeneity of I2 = 72.7%) 51. 
Benefits are that radiotherapy is well tolerated, cosmetic results are good, and wide 
margins can be used. Limitations are the lack of histopathological control, the numerous 
treatments and subsequent hospital visits and costs, and the (long-term) side effects 
that can occur when using radiation therapy, including telangiectasia’s, pigmentary 
changes, radiation necrosis, squamous cell carcinoma, and erythema 55.
Combination treatments
Non-surgical treatments (e.g. imiquimod, radiotherapy) are often used as an adjuvant to 
surgical excision. However, another strategy may be to combine two non-surgical treat-
ments. In this way, the benefits of non-surgical treatment modalities are preserved, and 
it may result in higher clearance and lower recurrence rates than either treatment alone.
Aiming to find a non-surgical treatment with low recurrence rates and excellent 
cosmetic and functional outcomes, we have introduced a novel treatment combina-
tion of ablative laser therapy followed by topical application of imiquimod 5% cream. 
This combination treatment resulted in the absence of recurrences in 12 patients after 
a mean follow-up of 22 months, and with good-to-excellent functional and cosmetic 
results 56. However, patient numbers and follow-up time need to be increased to obtain 
more information about this experimental treatment.
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aIMS Of THIS THESIS
The aim of this thesis was to develop and evaluate several optimization strategies for 
laser therapy in dermatology. Three different strategies were chosen: optimizing an 
established laser treatment, optimizing laser treatment-related pain in general, and 
optimizing laser treatment as an alternative for a surgical treatment indication.
The aim of Chapter 2 was to enhance the standard of care Pulsed Dye Laser (PDL) 
treatment of port wine stains. Anti-angiogenic agents have been proposed to optimize 
treatment efficacy. In Chapter 2.1 we evaluated the efficacy and safety of PDL treat-
ment followed by topical application of sirolimus (with and without laser ablation of 
the stratum corneum) in a randomized controlled trial. Chapter 2.2 describes a case of 
allergic contact dermatitis to sirolimus.
The aim of Chapter 3 was to optimize laser treatments in general by minimizing 
pain and discomfort during these treatments. In Chapter 3.1 we summarized the avail-
able data on non-invasive anaesthetic methods for dermatological laser treatments 
by means of a systematic review. Since we found that there was a lack of high-quality 
studies, and especially head-to-head studies, we performed two randomized controlled 
trials. In Chapter 3.2 we compared the efficacy of two commonly used local anaesthet-
ics, lidocaine/prilocaine cream (EMLA®) versus lidocaine/tetracaine cream (Pliaglis®) in 
reducing self-reported pain during two painful laser indications: acne keloidalis nuchae 
and tattoo removal.
The aim of Chapter 4 was to evaluate the efficacy, safety and feasibility of an in-
novative non-surgical combination treatment of ablative laser therapy and topical 
imiquimod for the treatment of lentigo maligna (LM). In Chapter 4.1 we determined 
the incidence rates of LM and lentigo maligna melanoma (LMM) in The Netherlands and 
estimated the risk of progression of LM to LMM. In Chapter 4.2 we increased the size of 
our cohort and the follow-up time of LM patients treated with the two-stage treatment 
of ablative laser therapy followed by topical imiquimod application, and determined 
the recurrence rates and patient satisfaction. Since we found that recurrences of LM 
after our non-surgical combination therapy occurred almost exclusively on the nose, we 
investigated histological parameters that might be related to a higher recurrence risk 
on this anatomic location in Chapter 4.3. In Chapter 4.4 we described micrographically 
controlled staged surgical excision for LM, and determined the recurrence rates after 
this treatment, as a surgical perspective to our non-surgical treatment.
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abSTRaCT
background and objective
Pulsed Dye Laser (PDL) is currently the gold standard treatment for port wine stains 
(PWS), although the degree of lesion blanching is variable and often unpredictable. 
This appears to be due to reformation and reperfusion of blood vessels. Rapamycin has 
shown potential as an anti-angiogenic agent and may prevent the revascularization 
after PDL treatment.
The objective of this study was to evaluate the efficacy of adjuvant use of (commer-
cially available) topical rapamycin after PDL treatment in patients with PWS.
Materials and Methods
We conducted a prospective, intra-patient, randomized study. Four treatment areas of 
1 cm2 were created in each PWS. PDL-only treatment was compared to the following 
three treatments: PDL + rapamycin, PDL + Erbium YAG laser ablation of the stratum 
corneum + rapamycin, and rapamycin monotherapy. We also compared PDL + Erbium 
YAG + rapamycin with PDL + rapamycin. The primary endpoint was the percentage 
clearance assessed colorimetrically at six months follow-up. Secondary outcomes were 
photographic evaluation by an expert panel, patient satisfaction, treatment-related 
pain, and safety.
Results
Fourteen patients completed the treatment protocol. The highest percentage clearance 
was achieved with PDL-only treatment (mean [SD] 16% [34]), but there were no statisti-
cally significant differences between treatments. The best photographic evaluation and 
highest patient satisfaction were also achieved with PDL-only treatment, but only the 
difference between PDL-only and rapamycin monotherapy was statistically significant. 
The treatment-related pain was well tolerated. Application-site pruritus was a frequent 
occurring adverse event. Allergic contact dermatitis to rapamycin occurred in one pa-
tient. There were no serious adverse events.
Conclusion
Topical application of the commercially available solution of rapamycin (Rapamune® 
0.1%) as an adjuvant to PDL treatment does not appear to improve PWS blanching.
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InTRODUCTIOn
Port wine stains (PWS) are congenital (micro)vascular malformations of the skin. They 
occur in 0.3%- 0.5% of the population 1, are progressive and do not involute spontane-
ously. Nodular components and hypertrophy of the underlying soft tissue occur in 65% 
of the people by the age of 50, resulting in spontaneous bleeding and dysmorphism 
2. Most lesions occur in the head and neck region, causing significant psychological 
problems 3, 4.
The Pulsed Dye Laser (PDL) is currently the treatment of first choice for PWS. However, 
the degree of lesion blanching after PDL treatment is variable and unpredictable and 
complete blanching is achieved in only 0-22% 5-9. This appears to be (partly) due to 
reformation and reperfusion of blood vessels, through hypoxia-inducible factor 1-alpha 
(HIF-1α) and vascular endothelial growth factor (VEGF)-mediated pathways 10, 11.
Sirolimus (also known as rapamycin) is a specific inhibitor of the mammalian target 
of rapamycin (MTOR) and shows potential as an anti-angiogenic agent 12-14. PDL com-
bined with oral rapamycin showed promising results in one patient compared to PDL 
monotherapy 15. However, systemic use of rapamycin is associated with a wide range 
of possible adverse effects, and a topical formulation could minimize these potential 
risks associated with systemic exposure. So far, only one clinical trial has evaluated the 
efficacy of PDL combined with topical rapamycin in 23 PWS patients with Sturge-Weber 
syndrome, and it appeared to be an effective treatment 16. In this study, a formulation of 
1% rapamycin cream was fabricated, however, this cream is not commercially available. 
On the other hand, the commercially available oral solution of rapamycin 0.1% (Rapa-
mune®) used as a topical formulation has not been formally evaluated in the treatment 
of PWS patients thus far.
When using topical therapeutics, the stratum corneum is the most important barrier 
for transdermal drug delivery. To optimize topical delivery to the vasculature, the stra-
tum corneum can selectively be removed by ablative lasers and better penetration and 
distribution of topically applied drugs can be facilitated 17-19.
The aims of this study were to evaluate the efficacy of PDL treatment followed by 
– commercially available – topical rapamycin (with and without laser ablation of the 
stratum corneum), and of rapamycin monotherapy in PWS patients.
MaTERIaLS anD METHODS
Study design and setting
This prospective, intra-patient randomized controlled trial was approved by the medical 
ethical review board of the Erasmus Medical Center (MEC-2014-022), and registered at 
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ClinicalTrials.gov (NCT02214706). This was a single center study and all patients were 
treated at the Erasmus University Medical Centre in Rotterdam, The Netherlands.
Study population
Patients (age ≥18 years) with an extra-facial, homogenous PWS were eligible. Key exclu-
sion criteria included a nodular or hypertrophic component in the treatment area, preg-
nant or breast-feeding women, and laser treatment of the PWS in the last three months. 
All patients provided written informed consent before participating in the study.
Interventions
Four treatment areas of 1 cm2 were created in each PWS to compare the following four 
interventions:
1. PDL treatment.
2. PDL treatment followed by topical rapamycin application.
3. PDL treatment followed by topical rapamycin application after erbium yttrium-
aluminum-garnet (Er:YAG) laser ablation of the stratum corneum.
4. Topical rapamycin monotherapy.
A template (of matte finish metal) with squares of 1 cm2 was used to create four equal 
treatment areas in each PWS. All patients received a total of five treatments with two-
week intervals. Two tattoo ink points were placed in the PWS at baseline to assure an 
identical position of the template during each treatment (Fig. 1).
Laser treatment
Laser treatments were performed with a 585 nm PDL (Cynosure Cynergy, Westford, MA). 
The following parameters were used: fluences between 7 and 11 J/cm2, pulse durations 
of 0.5-2ms, and a spotsize of 7 mm. Five slightly overlapping passes were applied per 
figure 1. Treatment method: (a) Two tattoo points are used to mark the placement of the template; (b) 
the template is placed on the PWS and secured with tape; (c) the squares which are randomized to receive 
rapamycin are marked before the template is removed; (d) rapamycin is placed on the marked squares in 1 
cm2 chambers, (e) the PWS is covered with water-resistant bandages and left in situ for seven days.
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treatment square. Standardized air-cooling (Zimmer air cooler) was administered during 
treatment for thermal protection of the epidermis.
Ablative laser treatments were performed with a 2,940 nm Er:YAG laser (Alma Lasers, 
Burane XL). A spotsize of 5 mm and fluence of 4 J/cm2 were used. One or two passes were 
applied to remove the stratum corneum.
Topical treatment
Rapamycin (Rapamune® 1mg/ml oral solution) was applied topically under occlusion, 
using 1 cm2 square chambers (van der Bend Chambers®), with 40 µl Rapamune® per 1 
cm2, and left in situ for seven days.
Colorimetric assessment
The colours of the four treatment areas and of the contralateral normal skin were mea-
sured with a colorimeter (CR-300, Konica Minolta). The colorimeter was calibrated before 
each measurement. The colours were expressed by the Commission Internationale de 
l’Eclairage (CIE) colour measurement system: L* (lightness), a* (values from green to red) 
and b* (values from blue to yellow).
The color difference (ΔE) between the PWS lesion and contralateral normal skin was 
determined according to: ΔE = √(ΔL*)2 + (Δa*)2 + (Δb*)2, where ΔL*, Δa* and Δb* represent 
the differences in the respectively measured L*, a* and b* values between the PWS le-
sion and its contralateral site 5, 20, 21.
The blanching effect (i.e. percentage clearance) was then calculated based on the 
colour differences before and after treatment (at six months follow-up) according to: 
blanching rate (%) = 1 - (ΔEafter treatment / ΔEbefore treatment) X 100 20.
Photographic evaluation by an expert panel
Standardized digital photographs were taken by a medical photographer at pre-
treatment and at six months follow-up. Blanching of the PWS lesion was assessed by 
three independent experts for each treatment area. Clearance scores were graded as: 
five, excellent (>75% clearance); four, good (51-75% clearance); three, fair (25-50% clear-
ance); two, poor (<25% clearance); and one, no clearance.
Randomization
The sequence of the four treatments was randomly assigned to the four squares, using 
a standard generated randomization list provided by the department of Biostatistics.
Questionnaires
Patient satisfaction was evaluated six months after the last treatment for each of the four 
treatment areas, using a 0-100 scale.
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Pain during and after the laser treatments was assessed with a 0-100 scale for each of 
the four treatment areas.
Safety
Blood samples were taken regularly to assess safety parameters. The serum concentra-
tion of rapamycin was measured approximately 24 hours after the fifth treatment to 
evaluate potential systemic absorption. This time point was chosen as the most likely 
moment to measure any possible (cumulative) systemically absorbed rapamycin. The 
assay used to measure the rapamycin drug concentrations had a lower limit of detection 
of 0.1 µg/L.
Study outcome
The primary objective was the percentage clearance assessed colorimetrically at six 
months follow-up (compared to baseline). Four different hypotheses were tested: PDL 
was compared to the three “experimental” treatments: PDL + rapamycin, PDL + Er:YAG 
+ rapamycin, and rapamycin monotherapy, and to determine the effect of stratum 
corneum removal PDL + Er:YAG + rapamycin was also compared to PDL + rapamycin.
Secondary outcomes were photographic evaluation by an expert panel, patients sat-
isfaction, pain during and following treatment, adverse effects and systemic rapamycin 
exposure.
Sample size
A sample size of 20 patients was estimated to provide 80% power to detect an improve-
ment of 20% (SD 22%) in the “experimental” treatments compared to the gold standard 
treatment, with a two-sided type I error level of 1.25% (Bonferroni correction (α=0.05/4)). 
A t-test for paired samples was used.
Statistical analysis
Normality of the variables was tested using a Shapiro-Wilk test. At six months follow-up, 
the differences in therapeutic response (determined colorimetrically, by photographic 
evaluation, and patient satisfaction) between two treatments were analysed using 
a t-test for paired samples (if the variables were normally distributed) or a Wilcoxon 
signed-rank test (if the variables were not normally distributed). Normally distributed 
data were summarized with means and standard deviations (SD), and not normally 
distributed data with medians and interquartile ranges (IQR). Agreement between the 
three independent experts was determined using the intraclass correlation coefficient 
(ICC two-way mixed model). P-values < 0.0125 were considered statistically significant. 
All analyses were performed using SPSS Statistics 21.
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RESULTS
Patients
Between August 2014 and January 2015, a total of 17 patients were enrolled in this 
study. Demographic details are shown in Table 1. Due to multiple adverse events, the 
inclusion was terminated at 17 patients.
Three patients did not complete the five treatments and were not included in the 
(per protocol) analysis (since there was no 6 months follow-up data available for these 
patients); one patient did not show up again after two treatments, one patient devel-
oped mild scarring after one treatment after which participation was terminated, and 
one patient with a history of diabetes developed a mild wound on her lower extremity 
(on the Er:YAG treatment site), and withdrew consent. Fourteen patients completed the 
treatment per protocol and were included in the analysis (Table 1).
Treatment evaluation
Colorimetric assessment
At six months follow-up, there were no statistically significant differences in percentage 
clearance between the gold standard PDL treatment and each of the three experimental 
treatments (Table 2). There was also no statistically significant difference in percentage 
clearance with or without Er:YAG laser removal of the stratum corneum (mean difference 
of 3% (95% CI, - 4 to 9; P = 0.373).
Table 1. Baseline Demographic and Clinical Characteristics
Characteristics Patients (n=17) Patients (n=14)
Age (years), median (IQR) 29 (23 - 45) 31 (23 - 45)
Female, n (%) 13 (77) 10 (71)
Caucasian, n (%) 17 (100) 14 (100)
Fitzpatrick skin type, n (%)
II 8 (47) 6 (43)
III 9 (53) 8 (57)
Prior laser treatment, n (%) 3 (18) 2 (14)
Location, n (%)
Shoulder / upper back 5 (29) 5 (36)
Lower back 2 (12) 2 (14)
Thorax 2 (12) 2 (14)
Upper extremity 3 (18) 2 (14)
Lower extremity 5 (29) 3 (21)
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Photographic evaluation
The agreement between the three independent experts was 0.907 (95% CI, 0.844-0.945). 
The clearance with PDL treatment was graded with a median score of 1.8 (IQR 1.0-2.9), 
with PDL + rapamycin with a median of 1.5 (IQR 1.0-2.3), with PDL + Er:YAG + rapamycin 
with a median of 1.7 (IQR 1.0-2.5), and with rapamycin monotherapy with a median of 1.0 
(IQR 1.0-1.3). There was a statistically significant difference between PDL monotherapy 
and rapamycin monotherapy (P = 0.007), but not between the other treatments.
Patient satisfaction
The highest treatment satisfaction was achieved by PDL treatment with a median of 65 
(IQR 8-80), followed by PDL + Er:YAG + rapamycin with a median of 60 (IQR 25-75), and 
PDL + rapamycin with a median of 50 (IQR 13-70), and rapamycin monotherapy with a 
median of 0 (0-7). There was a statistically significant difference between PDL treatment 
and rapamycin treatment (P = 0.007), but not between the other treatments.
Treatment-related pain
The highest pain scores during treatment were given to PDL + Er:YAG + rapamycin treat-
ment with a median of 24 (IQR 9-41), followed by PDL + rapamycin treatment with a 
median of 13 (IQR 8-40), and PDL with also a median of 13 (IQR 8-36), and rapamycin 
monotherapy with a median of 0 (IQR 0-4). Pain scores in the two weeks after treatment 
were low with a median of 12 (IQR 0-21) for PDL + Er:YAG + rapamycin, a median of 10 
(IQR 0-15) for PDL + rapamycin, a median of 5 (IQR 0-9) for PDL, and a median of 1 (IQR 
0-10) for rapamycin. However, it should be noted that distinction between the treatment 
areas was, for some patients, difficult to make.
Table 2. Percentage clearance at six months follow-up, and the difference between PDL and each of the 
three experimental treatments
Treatment Percentage clearance; 
mean (SD)
Mean difference with 
PDL treatment
P-value
PDL 16% (34) -
PDL + rapamycin 8% (29) 8% (95% CI, -11 to 27) P = 0.21
PDL + Er:YaG + rapamycin 5% (34) 11% (95% CI, -7 to 28) P = 0.381
Rapamycin monotherapy -11% (38)a 27% (95% CI, 3 to 51) P = 0.033b
PDL, Pulsed Dye Laser; Er:YAG, erbium yttrium-aluminum-garnet
a In three patients, only the rapamycin monotherapy treatment area still showed erythema at six months 
follow-up, which could explain the negative percentage. Only in one patient all rapamycin treated sites had 
negative outcomes because of erythema.
b Not statistically significant when corrected for multiple testing.
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Safety
Adverse events
A summary of the adverse events is presented in Table 3. The most common adverse 
event was application-site pruritus (occurred in 12 out of 17 patients). Due to pruritus six 
patients (in total on 16 occasions) had to remove the bandages with rapamycin before 
the seven days were completed. One patient developed an itching rash on her entire 
upper body after the fifth treatment, which was confirmed by patch testing as an allergic 
contact dermatitis to rapamycin. No serious adverse events occurred.
Systemic rapamycin exposure
Blood examinations throughout the study did not show any abnormalities. Of the 14 pa-
tients who completed the treatment protocol, nine were available 24 hours after the last 
treatment to determine the serum level of rapamycin. In seven patients, the rapamycin 
level was below the lower limit of detection, and two patients had detectable levels of 
2.1 µg/L, and 2.2 µg/L, respectively.
Table 3. Adverse events
adverse events number
Application-site pruritus 29
Erythema 4
Xerosis cutis 4
Allergic contact dermatitis 1
Allergy to bandages (skin rash) 1
Crustae 1
Pustule 1
Burning sensation 1
Hyperpigmentation 1
Blistering 1
Erosive skin 1
Tinnitus 1
Constipation 1
Eye infection 1
Wound 1
Scarring (mild) 1
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DISCUSSIOn
This study shows that the commercially available solution of rapamycin (Rapamune® 
0.1% oral solution), used as an adjuvant topical treatment during PDL treatment, does 
not appear to improve PWS blanching. The addition of ablation of the stratum corneum 
with the Er:YAG laser to optimize (trans)dermal absorption of rapamycin, did not result 
in better PWS blanching. Treatment with rapamycin was associated with frequently oc-
curring local skin reactions, which led us to terminate the study before the total number 
of 20 patients was included.
The greatest difference in efficacy at six months follow-up was observed between PDL 
and rapamycin monotherapy. This difference is most likely due to the lack of efficacy of 
rapamycin as monotherapy without PDL pre-treatment and thereby lack of activation 
of the HIF-1α and VEGF-mediated pathways in PWS. Rapamycin monotherapy could be 
considered as a negative control in this study. Also, due to erythema on the rapamycin 
monotherapy treatment area in three patients at six months follow-up (resulting in 
negative clearance), the difference in clearance with PDL monotherapy was even larger.
The use of topical rapamycin in the treatment of PWS showed promising results in 
in vitro and animal studies 12-14, 22, 23, and also in one clinical trial 16, and one case report 
24. However, the creams used in these clinical studies are not commercially available, 
and the stability and efficacy of these compounded creams cannot be ensured 25. The 
use of the commercially available oral solution of rapamycin (Rapamune® 1mg/ml) used 
as a topical formulation was thought to be more feasible for everyday clinical practice. 
However, in our study, we did not find significant improvement with topical rapamycin 
as an adjuvant to PDL treatment compared to PDL monotherapy. This could be caused 
by a lack of efficacy of rapamycin in PWS blanching, or by the lack of efficacy of the 
rapamycin solution used in this study.
Most studies on topical rapamycin for PWS or facial angiofibromas chose to apply 
topical rapamycin once or twice daily 16, 26-31. Since the design of our study (multiple 
adjacent squares with different treatment combinations) made home/self-application 
impossible, we decided to leave the rapamycin on the test areas for seven days to inhibit 
neo-angiogenesis, which is most active in the first week after PDL treatment 12. Theo-
retically, our study design, where rapamycin is applied only once under occlusion, could 
have led to a shorter suppression of the mTOR pathway. Consequently, this could be a 
reason why the rapamycin treatment areas were not positively impacted.
The 0.1% concentration of rapamycin used in this study was lower than the concen-
tration used in other clinical studies (1% 16 and 0.5% 24). The concentrations used in 
the in vitro and animal studies were also higher, ranging from 0.5 to 2%. We tried to 
compensate for the lower concentration of the commercially available rapamycin used 
in our study by removing the stratum corneum, leading to increased absorption of the 
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compound. Higher concentrations may be more effective, although Jia et al. did not 
find the reperfusion rate to be linearly proportional to the rapamycin concentration in 
animals 22. Also, higher concentrations could potentially induce more side effects.
The solution we used in this study caused frequent local skin reactions (i.e. pruritus, 
skin irritation), which may have prevented effective treatment since rapamycin often 
had to be removed before the seven days were completed. These side effects could be 
caused either by rapamycin itself (confirmed in one of our patients) or by ingredients of 
the rapamycin solution (e.g. ethanol). Skin irritation after topical use of the commercially 
available solution of rapamycin twice daily has been described before, but when it was 
used once daily it was tolerated 26, 28. However, since we applied rapamycin under occlu-
sion for seven days, this may have decreased skin tolerability. Occlusion by the chamber 
itself tapped to the skin for seven days could also have caused, or contributed to the 
pruritus complaints.
In two patients a detectable level of systemically absorbed rapamycin was measured. 
The levels were low (2.1 µg/L and 2.2 µg/L) and did not result in any adverse effects. 
Systemic absorption of topical rapamycin has been described before 16.
Faurschou et al. found that PDL treatment resulted in more than 25% reduction in 
redness in 50-100% of participants 32. We found an average blanching rate of 16% with 
PDL monotherapy. This difference may be explained by the fact that we only included 
extra-facial PWS. Nguyen et al. found anatomic location to be the most important 
predictor of treatment response 33. The PWS located over bony areas of the face (e.g., 
forehead, peripheral face) showed the most successful response, where central facial 
lesions were more resistant 33, 34. However, extremities, and especially the lower limb 
showed the lowest clearance rates 35, 36.
Strengths of this study are the intra-patient comparison, the randomization of treat-
ment location, and the use of a solution of rapamycin that is available for everyday 
clinical practice. Limitations are the early termination of patient inclusion, the exclusion 
of facial lesions, and the frequent occurrence of adverse effects preventing optimal 
treatment evaluation. Also, the potential use of rapamycin under occlusion on larger 
areas would be challenging for some anatomic locations.
In summary, our results did not demonstrate adjuvant topical rapamycin after PDL 
treatment to improve PWS blanching. There may be a lack of efficacy of rapamycin 
in PWS blanching, or the commercially available solution of rapamycin (Rapamune® 
0.1%) may not be optimal for topical use, due to frequent local skin reactions, and the 
relatively low concentration. Future studies should focus on determining the efficacy of 
rapamycin in PWS blanching. Oral rapamycin has shown promising results in one patient 
15, and should be further investigated regarding efficacy, adverse effects (during short-
term use), and cost effectiveness. Also, the risk of allergic contact dermatitis to topical 
rapamycin should be considered.
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Sirolimus (rapamycin) is a specific inhibitor of mammalian target of rapamycin, and, 
because of its anti-angiogenic properties, its use as an adjuvant for the laser treatment 
of port wine stains (PWS) has recently been suggested 1. We report a case of allergic 
contact dermatitis caused by sirolimus (Rapamune® 0.1% oral solution) which was used 
as an adjuvant topical treatment during laser treatment of a PWS.
CaSE REPORT
A 32-year-old healthy woman participated in our clinical trial in which a PWS on her left 
flank was treated with laser therapy, directly followed by topical application of sirolimus 
on three separate areas of 1cm2 (small areas were chosen in order to allow comparison 
of different experimental treatment combinations in one PWS, before treating the whole 
PWS with the ‘best’ treatment). Sirolimus was applied topically under occlusion on the 
treated PWS and left in situ for seven days. This treatment was repeated five times, with 
2-week intervals. After the second and third treatments, the patient developed mild 
dermatitis (erythema) at the sirolimus application sites, which forced her to remove the 
occlusive bandage after five days. The skin irritation cleared spontaneously within two 
weeks. The treatment was repeated two more times according to the study protocol, 
but, because of increased itching and dermatitis, the occlusive bandages had to be re-
moved after two days on both occasions. After the last treatment, the patient developed 
an itching rash on her entire upper body, in addition to the erythematous skin reaction 
at the application site, which slowly resolved within two weeks after daily applications 
of desoximetasone cream.
To evaluate the possibility of allergic contact dermatitis, patch tests were performed 
with the European baseline and additional series supplemented with topical Rapamune® 
(1mg sirolimus/ml) ‘as is’, 1:3 in olive oil, and 1:3 aq. Patch tests were conducted with van 
der Bend Chambers® on the patient’s back, and read on day (D)2 and D3, according to 
ICDRG criteria 2. Readings showed extreme positive reactions to Rapamune®, and some 
positive reactions to common allergens, which were deemed to be of no relevance to 
this case. The positive results are summarized in Table 1.
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Sirolimus is a macrolide immunosuppressant, and, to evaluate the possibility of cross-
reactivity with, and subsequent allergy to macrolide antibiotics 3, further patch tests 
were performed five months later with azithromycin, clarithromycin, and erythromycin. 
To evaluate the possibility of an allergy not to sirolimus itself but to constituents of the 
solution, propylene glycol (5% pet.) and polysorbate (5% pet.) were also tested. The 
other ingredients of Rapamune® solution (i.e. phosphatidylcholine, monodiglycerides, 
ethanol, soya fatty acids, and ascobyl palmitate) were not available for patch testing 
but were considered unlikely allergens. All additional patch tests, again read D2 and D3, 
showed no reactions.
We did not perform patch tests with Rapamune® in control patients; however, in our 
clinical trial, 16 other PWS patients had been treated with topical Rapamune® under 
occlusion (in van der Bend Chambers®, to match the 1cm2 treatment areas exactly); five 
of these developed irritant skin reactions, but no allergic reactions.
DISCUSSIOn
We conclude that our patient most likely experienced an allergic reaction to topically 
applied sirolimus. Although there are some reports of skin irritation caused by topical 
sirolimus 4, 5, to our knowledge this is the first report of a true allergic contact dermatitis.
As there is increasing interest in the use of topical sirolimus in the treatment of PWS, 
and also of angiofibromas 5, attention should be drawn to the risk of allergic contact 
dermatitis.
Table 1. Patch test results
allergens D2 D3
Rapamune® pure ++ +++
Rapamune® 1:3 olive oil + ++
Rapamune® 1:3 aq. + +
p-Phenylenediamine ++ ++
Caine mix III ++ +
Quaternium 15 - +
Formaldehyde ++ ++
Methyldibromo glutaronitrile + +
Carba mix - +
1,2-benzisothiazolin-3-one - +
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abSTRaCT
Pain is a common side-effect of dermatological laser procedures. Non-invasive anaes-
thetic drugs and anaesthetic procedures can be used to provide pain relief and increase 
patient satisfaction and treatment efficacy. However, it remains unclear which method 
provides the best pain relief. The objective of this systematic review was therefore to 
assess the efficacy and safety of non-invasive anaesthetic methods during dermato-
logical laser procedures. A systematic literature search was conducted. Randomized and 
non-randomized controlled clinical trials (RCTs and CCTs) were included. Two authors 
independently assessed study eligibility, extracted data and assessed the risk of bias. 
The quality of evidence was rated using Grading of Recommendations Assessment, 
Development and Evaluation (GRADE). Twenty RCTs and 12 CCTs were included, involv-
ing nine different laser indications: hair removal (n = 9), resurfacing/rejuvenation (n = 
5), port wine stains (n = 8), leg telangiectasia (n = 3), facial telangiectasia (n = 2), tattoo 
removal (n = 2), nevus of Ota (n = 1), solar lentigines (n = 1), and human papilloma virus 
lesions (n = 1). The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin 
cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application 
time and types of pain scales varied widely among the included studies. All of the studies 
had an unclear or high risk of bias and the overall quality of evidence was rated as low. In 
general, active non-invasive anaesthetic methods seemed to provide favourable results 
compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed 
to result in a better pain reduction than skin cooling. However, the current evidence is 
insufficient to provide recommendations for daily clinical practice. There is a need for 
more high quality (head-to-head) RCTs. Future studies should also evaluate sex differ-
ences in pain perception, have uniformity with regard to validated pain measurement 
scales, and address clinically significant differences in pain reduction besides statistically 
significant differences.
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InTRODUCTIOn
Pain is a bothersome side effect during dermatological laser procedures and can 
decrease patient satisfaction and also treatment efficacy as pain sometimes makes it 
necessary to use lower laser settings.
Local anaesthetics can be used to reduce treatment-related discomfort and pain. 
However, invasive anaesthetics are often painful to administer and are less suitable for 
needle phobic patients. Non-invasive anaesthetic drugs and anaesthetic procedures on 
the other hand, are painless to administer, and, in case of non-invasive drugs, decrease 
the risk of systemic exposure.
Non-invasive methods for pain reduction during dermatological laser procedures in-
clude topical anaesthetic drugs, skin cooling, and pneumatic skin flattening (PSF), which 
all have different modes of action.
Topical anaesthetic drugs block the influx of sodium and prevent nerve cell depo-
larization and the sensory input to the central nervous system 1. The first topical an-
aesthetic that was discovered was cocaine 2. Later, ester anaesthetics (e.g. tetracaine) 
were developed, but allergic contact dermatitis was a frequently occurring adverse 
effect 3. Subsequently, amide anaesthetics (e.g. lidocaine, prilocaine) were created and 
became the preferred anaesthetic. Non-steroidal anti-inflammatory drugs (NSAIDs) can 
also be used as local anaesthetic drugs. Their mode of action is based on the inhibition 
of the cyclo-oxygenase enzymes (COX-2) that synthesize prostaglandins 4. Today, vari-
ous prescription and over-the-counter topical anaesthetic drugs and combinations are 
available.
Skin cooling can lower the skin temperature during laser procedures, and thereby 
improve pain and discomfort. Furthermore, skin cooling is often used to protect the 
epidermis from thermal injury as melanin in the epidermis is an unwanted site for ab-
sorption of light, with the exception of epidermal pigmented lesions 5. Different skin 
cooling methods are available, including cold gels, contact cooling, dynamic cooling 
(using cryogen spray), and cold air. Cooling can be delivered pre-, during-, and post-
treatment.
Pneumatic skin flattening utilizes a vacuum chamber covered by a transparent sap-
phire window through which the laser light can be delivered 6. When the handpiece 
is placed on the skin, negative pressure is automatically generated. The high vacuum 
activates enough pressure receptors in the skin to reduce pain through afferent inhibi-
tion of pain transmission to the dorsal horn (gate control theory of pain) 7, 8. The vacuum 
is released at the end of the light pulse.
Which non-invasive method of anaesthesia provides the best pain reduction during 
different dermatological laser procedures has never been systematically investigated. 
This information could be used to facilitate decision making in daily clinical practice.
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The aim of this systematic review was therefore to provide an overview of the efficacy 
and safety of all non-invasive methods for skin anaesthesia during dermatological laser 
procedures.
METHODS
Types of study
Both randomized controlled trials (RCTs) and non-randomized controlled clinical trials 
(CCT’s) were included. Language was restricted to English or Dutch. No restrictions were 
made as to publication date.
Types of participants
Patients of all ages undergoing laser or intense pulsed light (IPL) procedures for derma-
tological indications were included. Patients undergoing endovenous laser treatment or 
photodynamic therapy were excluded.
Types of interventions
All non-invasive anaesthetic methods were included. Control interventions could be any 
other non-invasive anaesthetic method, placebo, or no treatment.
Types of outcome measures
The primary outcome was patient self-reported pain, measured on any pain scale. The 
secondary outcome was adverse events.
Search strategy
We searched the following databases from inception until 15 February 2016: EMBASE, 
MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of science 
and PubMed (Supplementary Table 1). References of the included articles were screened 
to identify additional relevant studies.
Study selection
The preliminary selection was done by two independent investigators (KG and LL) based 
on titles and abstracts. Subsequently, a second selection was made based on the full 
text. This selection was done by two independent investigators as well (KG and LL) and 
based on predefined inclusion and exclusion criteria. Any disagreements were resolved 
by discussion.
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Data extraction and quality assessment
Two authors (KG and LL) independently extracted data from the included studies, using 
a predefined data extraction form. The following data was extracted: authors, year of 
publication, study design, sample size, male/female ratio, intervention, comparative 
control, type of laser, laser settings, type of pain rating scale, outcomes, adverse effects, 
conflicts of interest and sponsors. In case of unclear information in the included studies, 
authors were approached for clarification.
Methodological quality of the articles was rated by two independent authors (KG 
and LL) using the Cochrane Collaboration’s tool for assessing risk of bias 9. Selection 
bias, performance bias, detection bias, attrition bias, and reporting bias were evalu-
ated. Disagreements were resolved, and consensus was reached. The overall quality of 
evidence was rated using Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) 10.
The results of our systematic review were reported according to the PRISMA guide-
lines for reporting systematic reviews 11.
RESULTS
Study characteristics
The database search yielded 4185 articles, of which 2635 remained after removing du-
plicates. Titles and abstracts of these studies were screened, and 2535 references were 
excluded. We obtained full text of the remaining 100 studies and included 32 studies 
based on our inclusion and exclusion criteria (figure 1). No additional articles were 
included after the reference search.
Twenty RCTs and 12 CCTs, published between 1990 and 2012 and comprising 983 
participants, were included in this review.
The included trials investigated the following dermatological laser indications: hair 
removal, resurfacing/rejuvenation, port wine stains, leg telangiectasia, facial telangiec-
tasia, tattoo removal, nevus of Ota, solar lentigines, and human papilloma virus (HPV) 
related lesions.
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Hair removal
Nine studies, including a total of 258 patients, reported on non-invasive anaesthetic 
methods during laser-assisted hair removal. Study characteristics and results are shown 
in Table 1.
Figures 
Figure 1. Flow chart of search strategy and study selection 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database searching 
(EMBASE, MEDLINE, CENTRAL, Web of science, 
Pubmed) 
(n = 4185) 
Full-text articles assessed 
for eligibility 
(n = 100) 
Full-text articles excluded, with 
reasons 
(n = 68) 
- Different indications analyzed together: n=8 
- Different types lasers analyzed together: n=2 
- Invasive anesthetic: n=3 
- Type of laser not described: n=2 
- Indication not described: n=1 
- Retrospective: n=2 
- Duplicate: n=13 
- No laser used: n=1 
- No pain evaluation scale used: n=2 
- Full text article not available: n=4 
- Treatment description: n=1 
- Study objective not pain: n=16 
- Not controlled: n=6 
- Laser used as pain stimulus: n=4 
- Other language: n=2 
- Lack of uniformity in outcome measurements   
reported in the article and in the abstract = 1 
 
Records after duplicates removed 
(n = 2635) 
Records screened 
(n = 2635) 
Records excluded 
(n = 2535) 
Studies included in 
qualitative synthesis 
(n = 32) 
figure 1. Flow chart of our search strategy and study selection
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Overall, topical anaesthetic drugs, PSF and skin cooling resulted in a better pain reduction 
than placebo or no anaesthesia 12-15. There was no difference in efficacy found between 
EMLA (lidocaine 2.5% / prilocaine 2.5%) cream and piroxicam gel 16, or between EMLA 
cream and lidocaine 5% cream 17. One CCT showed better results with EMLA cream than 
diclofenac gel, while both were superior to skin cooling 18. Pneumatic skin flattening was 
compared to skin cooling and resulted in a better pain reduction 7, 19.
Resurfacing / rejuvenation
Five studies, including a total of 78 patients reported on non-invasive anaesthetic meth-
ods during laser resurfacing or rejuvenation. Study characteristics and results are shown 
in Table 2. Pain was better reduced with topical anaesthetic drugs or skin cooling, than 
with placebo or no anaesthesia 20, 21. S-Caine peel (lidocaine 7% / tetracaine 7%, alterna-
tive brand name: Pliaglis®) provided better pain reduction than EMLA 22, and pain was 
better reduced when the stratum corneum was ablated before lidocaine 5% application 
23. One CCT compared PSF to skin cooling, and, like for hair removal, showed a better 
pain reduction with PSF 24.
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Port Wine Stains
Eight studies, including a total of 235 patients, reported on non-invasive anaesthetic 
methods during laser port wine stain treatment. Study characteristics and results are 
shown in Table 3. Overall, topical anaesthetic drugs and skin cooling provided a better 
pain reduction than placebo or no anaesthesia 25-31. There was no difference in efficacy 
between iontophoresis of lidocaine 4% with or without epinephrine 27. However, ion-
tophoresis of lidocaine 5% with epinephrine was more effective than iontophoresis 
of mepivacaine 2% with epinephrine 32, and amethocaine 4% was found to be more 
effective than EMLA cream 29.
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Leg telangiectasia
Three studies (total of 178 patients) investigated non-invasive anaesthetic methods 
during laser treatment of leg telangiectasia. Study characteristics and results are shown 
in Table 4. Lower mean pain scores were reported for sides treated with cryogen spray 
than for sides treated with second skin moist gel pad and no cooling 33. S-caine peel 
(lidocaine 7% / tetracaine 7%) was found to be superior to placebo after 30, 60, and 90 
minutes application 34, 35.
70 Chapter 3.1 A systematic review on non-invasive anaesthetic methods 71
Ta
bl
e 
4.
 L
eg
 te
la
ng
ie
ct
as
ia
 –
 c
ha
ra
ct
er
is
tic
s 
of
 in
cl
ud
ed
 s
tu
di
es
 a
nd
 s
um
m
ar
y 
of
 re
su
lts
Au
th
or
St
ud
y t
yp
e
N
%
 
m
al
e
In
te
rv
en
tio
n
Co
nt
ro
l
La
se
r (
ty
pe
)
Fl
ue
nc
e
Pu
lse
 
du
ra
tio
n
Pa
in
 
ra
tin
g 
sc
al
e
Re
su
lts
; 
m
ea
n 
(S
D)
Ad
ve
rs
e 
ev
en
ts
Co
nfl
ict
 of
 
in
te
re
st
 / S
po
ns
or
Bu
sch
er,
 20
00
33
CC
T, 
sp
lit
 
les
ion
18
0
Dy
na
m
ic 
Co
oli
ng
 
De
vic
e (
cry
og
en
 
sp
ra
y)
No
 co
oli
ng
*+
 Se
co
nd
 Sk
in 
M
ois
t G
el 
Pa
d
PD
L
59
5 n
m
20
 J/
cm
2, 
an
d 2
4 
J/c
m
2
1.5
 m
s
Sc
ale
 of
 1 
to
 
3: 
0 (
no
ne
), 
1 (
sli
gh
t),
 2 
(m
od
er
at
e)
, a
nd
 
3 (
se
ve
re
)
W
ith
 co
oli
ng
: 1
.36
W
ith
ou
t c
oo
lin
g:
 1.
8
*P
-v
alu
es
 w
er
e n
ot
 
re
po
rte
d
- I
nc
ide
nc
e o
f b
lis
te
rin
g:
 
16
.7%
 fo
r s
kin
 co
ole
d 
sit
es
 ve
rsu
s 1
2.2
%
 fo
r t
he
 
no
n-
co
ole
d s
ite
s
- H
yp
er
pig
m
en
ta
tio
n o
c-
cu
rre
d s
lig
ht
ly 
m
or
e o
fte
n 
on
 th
e s
ite
s t
re
at
ed
 w
ith
 
sk
in 
co
oli
ng
No
t r
ep
or
te
d
Ch
en
, 2
00
33
4
2 R
CT
s, 
sp
lit
 
les
ion
St
ud
y 
1: 
60
St
ud
y 
2: 
40
?
S-
Ca
ine
 pe
el
*s
tu
dy
 1:
 30
 or
 60
 
m
inu
te
s
*s
tu
dy
 2:
 60
 or
 90
 
m
inu
te
s
Pla
ce
bo
Nd
:YA
G 
10
64
 nm
14
0 t
o 4
00
 J/
cm
2
30
 to
 10
0
m
s
VA
S (
0-
10
0)
St
ud
y 1
: p
ain
 sc
or
es
 lo
we
r 
fo
r S
-C
ain
e p
ee
l s
ite
s
*P
 =
 0.
04
6
* m
ea
n V
AS
 sc
or
es
 no
t 
re
po
rte
d
St
ud
y 2
:
S-
Ca
ine
 pe
el 
vs
 pl
ac
eb
o
60
 m
in:
 25
.2 
(2
0.6
) v
s 4
8.0
 
(2
8.1
)
*P
 =
 0.
01
90
 m
in:
 15
.2 
(1
7.7
) v
s 4
2.5
 
(2
0.2
)
* P
 =
 0.
00
1
No
 di
ffe
re
nc
es
 be
tw
ee
n 
sit
es
 in
 oc
cu
rre
nc
e o
f 
er
yt
he
m
a, 
bla
nc
hin
g o
r 
ed
em
a
Za
rs 
inc
. s
po
n-
so
re
d t
his
 st
ud
y 
an
d s
up
pli
ed
 
m
at
er
ial
s u
se
d i
n 
th
is 
stu
dy
Jih
, 2
00
43
5
RC
T, 
sp
lit
 
les
ion
60
0
S-
Ca
ine
 pe
el
Pla
ce
bo
Nd
:YA
G 
10
64
 nm
Ce
nt
er
 1:
 25
0-
37
0 
J/c
m
2
Ce
nt
er
 2:
12
6 J
/cm
2
Ce
nt
er
 1:
 
45
-6
0 m
s
Ce
nt
er
 2:
8 m
s
VA
S (
0-
10
0)
 
S-
Ca
ine
 pe
el:
 26
.9 
m
m
 
(ra
ng
e 0
-8
6)
Pla
ce
bo
: 4
2.7
 m
m
 (r
an
ge
 
3-
97
)
*P
 <
 0.
00
1
No
 di
ffe
re
nc
es
 be
tw
ee
n 
sit
es
 in
 oc
cu
rre
nc
e o
f 
er
yt
he
m
a, 
bla
nc
hin
g o
r 
ed
em
a.
No
t r
ep
or
te
d
72 Chapter 3.1
Facial telangiectasia
Two studies (total of 36 patients) investigated non-invasive anaesthetic methods during 
laser treatment of facial telangiectasia. Study characteristics and results are shown in 
Table 5.
Anaesthesia with cold air to 20 degrees was compared to 17 degrees and to no cooling 
36. The lowest mean pain scores were measured with cooling to 17 degrees, then cooling 
to 20 degrees, and the highest mean pain scores without cooling. It was stated that 
patients preferred cooling to 20 degrees. Skin cooling with a water cooled handpiece 
chilled to 4 degrees Celsius was compared to skin cooling with the water cooled hand-
piece combined with a 2 mm film of aqueous gel (Surgilube gel) 37. Lower pain scores 
were found when skin cooling was combined with the aqueous gel.
Table 5. Facial telangiectasia – characteristics of included studies and summary of results
author Hammes, 200536 Kauvar, 200237
Study type CCT, split lesion RCT, split lesion
n 17 19
% male 12 ?
Intervention - Cold air cooling to 20 degrees
- Cold air cooling to 17 degrees
Water cooled handpiece
Control No Cooling Water cooled handpiece + 2mm film 
of aqueous gel (Surgilube gel)
Laser (type) PDL
585 nm
KTP
532 nm
fluence 3.5 J/cm2 9.5 J/cm2
Pulse duration 0.45 milliseconds 10 ms
Pain rating scale Numerical analog scale (NAS) from 0 
(meaning no) to 3 (meaning high)
0=none; 1=mild; 2=moderate; 
3=severe
Results; mean (SD) Without cooling: 2.41
Cooling to 20 degrees: 1.06
Cooling to 17 degrees: 0.76
*No P-values reported
Without aqueous gel: 5% mild pain, 
68% moderate pain, and 26% severe 
pain;
With aqueous gel 16% no pain, 68% 
mild pain, 16% moderate pain, and 
0% severe pain
*No mean pain scores were 
reported
*Statistical analyses were not done
adverse events Cooling reduced purpura compared 
to no cooling
Use of the aqueous gel decreased 
the incidence and severity of 
erythema, edema, and crusting.
Conflict of interest / Sponsor Not reported Not reported
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Tattoo removal
Two studies (total of 41 patients) investigated non-invasive anaesthetic methods during 
laser tattoo removal. Study characteristics and results are shown in Table 6. The topical 
anaesthetic drug S-Caine peel (lidocaine 7% / tetracaine 7%) and PSF reduced pain bet-
ter than placebo or no anaesthesia 38, 39.
Nevus of Ota
One CCT (37 patients, ten male) investigated non-invasive anaesthesia during Q-
switched Alexandrite 755 nm laser treatment of nevus of Ota 40. To measure pain, a 10-
cm horizontal line was used. The study was supported by a research grant given by the 
Hong Kong Research Grant Council. Skin cooling (Cool sapphire plate [DermaCool]) was 
compared to no cooling in a split-lesion design. On both sides, EMLA cream (under oc-
clusion) was applied to the lesion 2 hours before treatment. Skin cooling was superior to 
no cooling, with mean pain scores of 2.97, and 3.91 respectively (P = 0.001). No adverse 
effects were reported.
Solar lentigines
One CCT (20 patients, 0 male) investigated non-invasive anaesthesia during IPL treat-
ment of solar lentigines 41. To measure pain, a 10-level scale modified McGill Pain 
Table 6. Tattoo removal – characteristics of included studies and summary of results
author Chen, 200538 Lapidoth, 200739
Study type RCT, split lesion CCT, split lesion
n 30 11
% male 27 18
Intervention S-Caine peel Pneumatic Skin Flattening
Control Placebo No treatment
Laser (type) Q-switched Nd:YAG 1064 nm Q-switched Nd:YAG 1064 nm
fluence 4-5 J/cm2 *Medlite: 3-5 J/cm2
* Quantum: 4.2 J/cm2,
Pulse duration Unknown Unknown
Pain rating scale VAS (0-100) Modified McGill pain questionnaire: 
five level scale
Results; mean (SD) S-caine peel: 42.5
Placebo: 66.3
*P = 0.001
Without PSF: 4.09
With PSF: 2.36
*Z = 0.003
adverse events No difference between treatment 
sites
None reported
Conflict of interest / Sponsor Material for this study was provided 
by Zars inc.
Not reported
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Questionnaire was used. Conflict of interest or sponsors were not reported. Lower pain 
scores were achieved with PSF than without PSF, with mean pain scores of 0.82 and 
3.76 respectively. No P-values were reported. Erythema and edema occurred more often 
without PSF than with PSF. No other adverse events occurred.
HPV lesions
One RCT (80 patients, 0 male) investigated non-invasive anaesthesia during CO2 10600 
nm laser treatment of HPV lesions 42. A VAS scale (100 mm) was used to measure pain. 
Conflict of interest or sponsors were not reported. EMLA (lidocaine 2.5% / prilocaine 
2.5%) (n = 60) was compared to placebo (n = 20), after an application time of 1-75 min-
utes. Pain scores were lower when EMLA cream was used, with median (IQR) pain scores 
of 12 (0-96) with EMLA and 80 (34-100) with placebo (P < 0.01)42. Erythema was reported 
more often in the EMLA group.
Quality of the studies
We assessed the studies for risk of bias. All studies had a high or unclear risk of bias 
(Supplementary Table 2). Most trials, except two for hair removal 12, 16, one for PWS 32, and 
one for HPV lesions 42 used intra-patient comparisons.
Effects of interventions
A summary of the primary outcome and the evidence quality assessed using GRADE is 
presented in Table 7. The overall quality of evidence was rated as low.
A systematic review on non-invasive anaesthetic methods 75
Ta
bl
e 
7.
 S
um
m
ar
y 
of
 fi
nd
in
gs
. O
ut
co
m
e:
 s
el
f-r
ep
or
te
d 
pa
in
Tr
ea
tm
en
t
O
ut
co
m
e
Co
m
pa
ra
to
r
n
o 
of
 P
ar
ti
ci
pa
nt
s 
(s
tu
di
es
)
La
se
r
M
in
im
al
 im
po
rt
an
t 
di
ff
er
en
ce
1
Q
ua
lit
y 
of
 e
vi
de
nc
e 
(G
Ra
D
E)
H
a
IR
 R
EM
O
Va
L
Pi
ro
xi
ca
m
>
Pl
ac
eb
o
50
 (1
 R
C
T)
N
d:
YA
G
Ye
s
++
Ο
Ο
Lo
w
a,
b
=
EM
LA
50
 (1
 R
C
T)
N
d:
YA
G
N
.A
.
Li
do
ca
in
e 
5%
>
N
o 
tr
ea
tm
en
t
20
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e 
/ D
io
de
?
++
Ο
Ο
Lo
w
a,
b
=
EM
LA
64
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
N
d:
YA
G
N
.A
.
EM
La
=
Pi
ro
xi
ca
m
50
 (1
 R
C
T)
N
d:
YA
G
N
.A
.
++
Ο
Ο
Lo
w
a,
b
=
Li
do
ca
in
e 
5%
64
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
N
d:
YA
G
N
.A
.
>
D
ic
lo
fe
na
c 
ge
l
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
>
Co
ol
in
g
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
D
ic
lo
fe
na
c 
ge
l
>
Co
ol
in
g
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
++
Ο
Ο
Lo
w
a,
b
<
EM
LA
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
PS
f
>
N
o 
tr
ea
tm
en
t
10
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
D
io
de
?
++
Ο
Ο
Lo
w
a,
b
>
Co
ol
in
g
40
 (2
 R
C
Ts
, s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e 
/ N
d:
YA
G
Ye
s, 
?
Co
ol
in
g
>
N
o 
tr
ea
tm
en
t
10
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
?
++
Ο
Ο
Lo
w
a,
b
<
EM
LA
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
<
D
ic
lo
fe
na
c
32
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e
Ye
s
<
PS
F
20
 (2
 R
C
Ts
, s
pl
it 
le
si
on
)
A
le
xa
nd
rit
e 
/ N
d:
YA
G
Ye
s, 
?
76 Chapter 3.1
Ta
bl
e 
7.
 S
um
m
ar
y 
of
 fi
nd
in
gs
. O
ut
co
m
e:
 s
el
f-r
ep
or
te
d 
pa
in
 (c
on
tin
ue
d)
Tr
ea
tm
en
t
O
ut
co
m
e
Co
m
pa
ra
to
r
n
o 
of
 P
ar
ti
ci
pa
nt
s 
(s
tu
di
es
)
La
se
r
M
in
im
al
 im
po
rt
an
t 
di
ff
er
en
ce
1
Q
ua
lit
y 
of
 e
vi
de
nc
e 
(G
Ra
D
E)
RE
JU
V
En
aT
IO
n
S-
Ca
in
e 
pe
el
>
Pl
ac
eb
o
20
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
D
io
de
Ye
s
++
Ο
Ο
Lo
w
a,
b
>
EM
LA
20
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
CO
2
Ye
s
Co
ol
in
g
>
N
o 
tr
ea
tm
en
t
15
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
Fr
ac
tio
na
te
d 
CO
2
?
++
Ο
Ο
Lo
w
a,
b
<
PS
F
11
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
N
d:
YA
G
Ye
s
EM
La
<
S-
Ca
in
e 
pe
el
20
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
CO
2
Ye
s
++
Ο
Ο
Lo
w
a,
b
PS
f
>
Co
ol
in
g
11
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
N
d:
YA
G
Ye
s
++
Ο
Ο
Lo
w
a,
b
Er
:Y
a
G
 +
 
lid
oc
ai
ne
 5
%
>
Li
do
ca
in
e 
5%
12
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
Er
:Y
AG
Ye
s
++
Ο
Ο
Lo
w
a,
b
PW
S
Io
nt
op
ho
re
si
s 
lid
oc
ai
ne
 4
%
>
Pl
ac
eb
o 
/ n
o 
tr
ea
tm
en
t
11
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
=
Io
nt
op
ho
re
si
s 
lid
oc
ai
ne
 4
%
 w
ith
 
ep
in
ep
hr
in
e
11
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
N
.A
.
Io
nt
op
ho
re
si
s 
lid
oc
ai
ne
 4
%
 +
 
ep
in
ep
hr
in
e
>
Pl
ac
eb
o 
/ n
o 
tr
ea
tm
en
t
11
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
=
Io
nt
op
ho
re
si
s 
lid
oc
ai
ne
 4
%
11
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
N
.A
Io
nt
op
ho
re
si
s 
lid
oc
ai
ne
 5
%
 w
it
h 
ep
in
ep
hr
in
e
>
Pl
ac
eb
o 
(io
nt
op
ho
re
si
s 
0.
9%
 
N
aC
l)
36
 (1
 R
C
T)
PD
L
Ye
s
++
Ο
Ο
Lo
w
a,
b
>
Io
nt
op
ho
re
si
s 
m
ep
iv
ac
ai
ne
 2
%
 
w
ith
 e
pi
ne
ph
rin
e
36
 (1
 R
C
T)
PD
L
Ye
s
A systematic review on non-invasive anaesthetic methods 77
Ta
bl
e 
7.
 S
um
m
ar
y 
of
 fi
nd
in
gs
. O
ut
co
m
e:
 s
el
f-r
ep
or
te
d 
pa
in
 (c
on
tin
ue
d)
Tr
ea
tm
en
t
O
ut
co
m
e
Co
m
pa
ra
to
r
n
o 
of
 P
ar
ti
ci
pa
nt
s 
(s
tu
di
es
)
La
se
r
M
in
im
al
 im
po
rt
an
t 
di
ff
er
en
ce
1
Q
ua
lit
y 
of
 e
vi
de
nc
e 
(G
Ra
D
E)
Io
nt
op
ho
re
si
s 
m
ep
iv
ac
ai
ne
 2
%
 
w
it
h 
ep
in
ep
hr
in
e
>
Pl
ac
eb
o 
(io
nt
.0
.9
%
 
N
aC
l)
36
 (1
 R
C
T)
PD
L
Ye
s
++
Ο
Ο
Lo
w
a,
b
<
Io
nt
. l
id
o 
5%
 w
ith
 
ep
in
ep
hr
in
e
36
 (1
 R
C
T)
PD
L
Ye
s
Co
ol
in
g
>
N
o 
tr
ea
tm
en
t
72
 (3
 C
C
Ts
, s
pl
it 
le
si
on
)
PD
L
Ye
s, 
?,
 ?
++
Ο
Ο
Lo
w
a,
b
Li
do
ca
in
e 
25
%
 
in
 7
0%
 D
M
SO
-
et
ha
no
l
>
N
o 
tr
ea
tm
en
t
14
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
a
m
et
ho
ca
in
e 
4%
>
Pl
ac
eb
o
29
 (1
RC
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
>
EM
LA
29
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
EM
La
>
Pl
ac
eb
o 
/ n
o 
tr
ea
tm
en
t
10
2 
(2
 R
C
Ts
, s
pl
it 
le
si
on
)
PD
L
?,
 Y
es
++
Ο
Ο
Lo
w
a,
b
<
A
m
et
ho
ca
in
e 
4%
29
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
LE
G
 T
EL
a
n
G
IE
CT
a
SI
a
S-
Ca
in
e 
pe
el
>
Pl
ac
eb
o
16
0 
(3
 R
C
Ts
, s
pl
it 
le
si
on
)
N
d:
YA
G
?,
 Y
es
, Y
es
++
Ο
Ο
Lo
w
a,
b
Co
ol
in
g
>
Se
co
nd
 s
ki
n 
m
oi
st
 
ge
l p
ad
18
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
fa
CI
a
L 
TE
La
n
G
IE
CT
a
SI
a
Co
ol
in
g 
17
 o
r 2
0 
de
cr
ee
s
>
N
o 
tr
ea
tm
en
t
17
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
Co
ol
in
g 
17
 
de
gr
ee
s
>
Co
ol
in
g 
20
 d
eg
re
es
17
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
PD
L
?
++
Ο
Ο
Lo
w
a,
b
78 Chapter 3.1
Ta
bl
e 
7.
 S
um
m
ar
y 
of
 fi
nd
in
gs
. O
ut
co
m
e:
 s
el
f-r
ep
or
te
d 
pa
in
 (c
on
tin
ue
d)
Tr
ea
tm
en
t
O
ut
co
m
e
Co
m
pa
ra
to
r
n
o 
of
 P
ar
ti
ci
pa
nt
s 
(s
tu
di
es
)
La
se
r
M
in
im
al
 im
po
rt
an
t 
di
ff
er
en
ce
1
Q
ua
lit
y 
of
 e
vi
de
nc
e 
(G
Ra
D
E)
Co
ol
in
g 
+ 
2 
m
m
 
fil
m
 o
f a
qu
eo
us
 
ge
l
>
Co
ol
in
g
19
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
KT
P
?
++
Ο
Ο
Lo
w
a,
b
Ta
TT
O
O
 R
EM
O
Va
L
S-
Ca
in
e 
pe
el
>
Pl
ac
eb
o
30
 (1
 R
C
T,
 s
pl
it 
le
si
on
)
Q
-s
w
itc
he
d 
N
d:
YA
G
Ye
s
++
Ο
Ο
Lo
w
a,
b
PS
f
>
N
o 
tr
ea
tm
en
t
11
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
Q
-s
w
itc
he
d 
N
d:
YA
G
?
++
Ο
Ο
Lo
w
a,
b
n
EV
U
S 
O
f 
O
Ta
Co
ol
in
g
>
N
o 
tr
ea
tm
en
t
37
 (1
 C
C
T,
 s
pl
it 
le
si
on
)
Q
-s
w
itc
he
d 
A
le
xa
nd
rit
e
Ye
s
++
Ο
Ο
Lo
w
a,
b
SO
La
R 
LE
n
TI
G
In
ES
PS
f
>
N
o 
tr
ea
tm
en
t
20
 (1
 C
C
T,
 s
pl
it 
le
si
on
s)
IP
L
?
++
Ο
Ο
Lo
w
a,
b
H
PV
 L
ES
IO
n
S
EM
La
>
Pl
ac
eb
o
80
 (1
 R
C
T)
CO
2
Ye
s
++
Ο
Ο
Lo
w
a,
b
>;
 b
et
te
r t
ha
n,
 =
; e
qu
al
 to
, <
; w
or
se
 th
an
 , 
N
.A
.; 
no
t a
pp
lic
ab
le
1.
Th
e 
sm
al
le
st
 c
ha
ng
e 
in
 in
st
ru
m
en
t s
co
re
 th
at
 p
at
ie
nt
s p
er
ce
iv
e 
is
 k
no
w
n 
as
 th
e 
m
in
im
al
 im
po
rt
an
t d
iff
er
en
ce
 (M
ID
), 
an
d 
fa
ci
lit
at
es
 th
e 
in
te
rp
re
ta
tio
n 
of
 re
su
lts
. T
he
 M
ID
 
fo
r t
he
 V
A
S 
is
 9
-1
8 
m
m
 o
n 
a 
10
0 
m
m
 v
is
ua
l a
na
lo
g 
sc
al
e 
(V
A
S)
 51
-5
3 , 
an
d 
fo
r n
um
er
ic
 ra
tin
g 
sc
al
e 
(N
RS
) a
 re
du
ct
io
n 
of
 1
8%
 54
.
a.
 D
ow
ng
ra
de
d 
fo
r r
is
k 
of
 b
ia
s
b.
 D
ow
ng
ra
de
d 
fo
r i
m
pr
ec
is
io
n,
 b
ec
au
se
 th
e 
ev
id
en
ce
 is
 b
as
ed
 o
n 
th
e 
re
su
lts
 o
f o
ne
 o
r f
ew
 s
tu
di
es
.
A systematic review on non-invasive anaesthetic methods 79
DISCUSSIOn
This systematic review provides an overview of the efficacy and safety of non-invasive 
anaesthetic methods that are used during dermatological laser procedures. The types of 
non-invasive anaesthetic methods varied widely. Also, the types of lasers, laser settings, 
application time and pain scales were often dissimilar. This precluded pooling of the 
data and subsequent meta-analysis. Additionally, all included studies had an unclear-
to-high risk of bias, and the overall quality of evidence was low. Therefore, any recom-
mendations should be made with caution.
Most of the reviewed studies compared active anaesthetic methods to placebo or 
no treatment. For all dermatological laser indications investigated in this review, active 
anaesthetic methods of any kind (topical drugs, skin cooling, PSF) showed favourable 
results with regard to pain reduction compared to placebo or no treatment. To facilitate 
recommendations for daily clinical practice, active treatments should preferably (also) 
be compared to other active treatments in head-to-head clinical trials. In general, 
topical anaesthetic drugs and PSF seemed to provide a better pain reduction than skin 
cooling during the laser treatment of hairs, PWS, and resurfacing/rejuvenation. For the 
indications leg telangiectasia, facial telangiectasia, tattoos, nevus of Ota, solar lentigi-
nes, and HPV lesions no head-to-head studies were included in this systematic review. 
All anaesthetic methods were well-tolerated, and no serious adverse events occurred.
Different topical anaesthetic drugs were explored in the studies included in this 
review. The efficacy of topical anaesthetic drugs can be enhanced in several ways, of 
which some were used in the above-mentioned studies. One way is to optimize the rate 
of (trans)dermal absorption, which is normally limited by the stratum corneum barrier. 
Different methods can be used to overcome this barrier. Yun et al. used laser ablation 
to remove the stratum corneum 23, but also tape stripping, or degreasing with acetone 
have been described 43. Occlusion and heat can enhance the penetration through the 
skin by increasing temperature and hydration of the stratum corneum. Iontophoresis is a 
method of delivering a topical anaesthetic using a mild electric current, which facilitates 
the passage of ionized local anaesthetics into and across the skin barrier 43. Another op-
tion is adding epinephrine to topical anaesthetic drugs, which causes vasoconstriction 
and thereby prolongs the anaesthetic effect and decreases systemic absorption.
When choosing a non-invasive anaesthetic, not only the efficacy should be taken into 
account, but also the ease of use, side effects, and costs are important factors. The need 
to apply some topical anaesthetic drugs under occlusion can be bothersome, especially 
for certain anatomical locations. Also, the duration of the application time may be a 
disadvantage for both patients and physicians, and there may be a risk of excessive sys-
temic absorption when applied to larger areas or in case of disruption of the stratum 
corneum 44. No serious adverse events were described in the included studies. However, 
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allergic reactions are often reported with the ester type of anaesthetics, and methemo-
globinemia has been described for other local anaesthetics, particularly prilocaine 45. 
Skin cooling and PSF are both easy to use, and adverse events are mild and transient. 
Cost-effectiveness was beyond the scope of this article, but should be included in the 
decision-making process.
Pain is a very subjective outcome measurement and therefore difficult to investigate. 
Additionally, there are differences in pain perception and analgesic response between 
men and woman. These sex differences may be explained by biological, psychological, 
and sociocultural factors, including sex hormones, endogenous opioid function, genetic 
factors, pain-related catastrophizing, and gender roles 46, 47. Since the majority of patients 
in the included studies in this review were female, this may complicate extrapolating 
results to the general population.
Strengths of this review are the extensive search, the fact that pain reduction was the 
primary objective in all the included studies, and that all non-invasive methods of an-
aesthesia were evaluated. Limitations of this review are the small sample sizes in most of 
the studies, the unclear to high risk of bias, and the fact that the quality of the included 
studies was low. Remarkably, several studies did not perform or report their statistical 
analysis and did not provide P-values or confidence intervals. Some studies did not use 
randomisation, however, this might be less important in case of a split-lesion design. 
Also, blinding was not always possible, which may be especially important since pain is a 
subjective outcome measurement. Furthermore, there is a possibility of publication bias 
as only published studies were considered.
In summary, we conclude that the current evidence is insufficient to compare the 
efficacy and safety of the different non-invasive anaesthetic methods. Therefore recom-
mendations for daily clinical practice should be made with caution. In general, active 
non-invasive anaesthetic methods seemed to provide favourable results compared to 
no anaesthesia. Therefore, when patients experience pain during laser therapy, a certain 
method of anaesthesia may be used to improve patient satisfaction and treatment ef-
ficacy. Topical anaesthetic drugs and PSF seemed to result in a better pain reduction 
than skin cooling. As the number of laser procedures is increasing worldwide, more 
high-quality head-to-head RCTs are needed in order to facilitate recommendations for 
daily clinical laser practice. Future studies should also evaluate cost-effectiveness and 
sex differences, and uniformity in validated pain measurement scales is recommended. 
For example, the VAS or NRS, since they are equally sensitive and appropriate for a 
patient’s subjective feeling of the intensity of pain 48. Furthermore, not only statistically 
significant differences, but also minimal important differences should be addressed 
since only this translates to real life situations in clinical practice 49, 50.
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SUPPLEMEnTaRY TabLES
Supplementary Table 1. Digital search strategy
Database Search string
EMbaSE
n = 1986
(‘local anesthetic agent’/de OR EMLA/de OR ‘local anesthesia’/exp OR cryoanesthesia/
de OR ‘transdermal patch’/de OR ‘low temperature procedures’/de OR cooling/de OR 
((gel/de OR ‘transdermal drug delivery system’/de OR ‘topical treatment’/de OR ‘topical 
drug administration’/de OR ‘transdermal drug administration’/de OR ‘cutaneous 
drug administration’/de ) AND (anesthesia/de OR analgesia/de)) OR cryogel/de OR 
hydrogel/de OR (cryoanalgesi* OR cryoanesth* OR cryoanaesth* OR ((analgesi* OR 
anesth* OR anaesth* OR lidocaine OR tetracain* OR prilocain*) NEAR/3 (local OR topical 
OR cutaneous OR wipe OR wipes OR cold OR plaster* OR patch* OR peel OR gel OR gels 
OR transdermal OR cutaneous OR cream*)) OR cooling OR emla OR pliaglis OR ((local 
OR topical ) NEAR/3 (pain OR discomfort) NEAR/3 (manage* OR relief OR reduc*)) OR 
((medicat* OR drug* OR cain) NEAR/3 (plaster* OR patch* OR peel)) OR hydrogel* OR 
cryogel*):ab,ti) AND (‘laser’/exp OR ‘low level laser therapy’/de OR ‘laser surgery’/de OR 
‘IPL device’/de OR ‘intense pulsed light therapy’/de OR (laser* OR ‘intense pulsed light’ 
OR ipl):ab,ti) AND (dermatology/de OR ‘skin disease’/exp OR (dermatolog* OR skin OR 
cutaneous)) NOT ([animals]/lim NOT [humans]/lim)
MEDLInE (OVID)
n = 1002
(“Anesthesia, Local”/ OR (Lidocaine/ AND Prilocaine/) OR Cryoanesthesia/ OR 
“Transdermal Patch”/ OR ((Gels/ OR “Administration, Topical”/ OR “Administration, 
Cutaneous”/ ) AND (anesthesia/ OR analgesia/)) OR Cryogels/ OR Hydrogels/ OR 
(cryoanalgesi* OR cryoanesth* OR cryoanaesth* OR ((analgesi* OR anesth* OR anaesth* 
OR lidocaine OR tetracain* OR prilocain*) ADJ3 (local OR topical OR cutaneous OR wipe 
OR wipes OR cold OR plaster* OR patch* OR peel OR gel OR gels OR transdermal OR 
cutaneous OR cream*)) OR cooling OR emla OR pliaglis OR ((local OR topical ) ADJ3 
(pain OR discomfort) ADJ3 (manage* OR relief OR reduc*)) OR ((medicat* OR drug* OR 
cain) ADJ3 (plaster* OR patch* OR peel)) OR hydrogel* OR cryogel*).ab,ti.) AND (exp 
“lasers”/ OR “Laser Therapy”/ OR “Intense Pulsed Light Therapy”/ OR (laser* OR “intense 
pulsed light” OR ipl).ab,ti.) AND (dermatology/ OR exp “skin diseases”/ OR (dermatolog* 
OR skin OR cutaneous)) NOT (exp animals/ NOT humans/)
CEnTRaL
n = 176
((cryoanalgesi* OR cryoanesth* OR cryoanaesth* OR ((analgesi* OR anesth* OR 
anaesth* OR lidocaine OR tetracain* OR prilocain*) NEAR/3 (local OR topical OR 
cutaneous OR wipe OR wipes OR cold OR plaster* OR patch* OR peel OR gel OR gels 
OR transdermal OR cutaneous OR cream*)) OR cooling OR emla OR pliaglis OR ((local 
OR topical ) NEAR/3 (pain OR discomfort) NEAR/3 (manage* OR relief OR reduc*)) OR 
((medicat* OR drug* OR cain) NEAR/3 (plaster* OR patch* OR peel)) OR hydrogel* OR 
cryogel*):ab,ti) AND ((laser* OR ‘intense pulsed light’ OR ipl):ab,ti) AND ((dermatolog* 
OR skin OR cutaneous))
Web of science
n = 1000
TS=(((cryoanalgesi* OR cryoanesth* OR cryoanaesth* OR ((analgesi* OR anesth* 
OR anaesth* OR lidocaine OR tetracain* OR prilocain*) NEAR/2 (local OR topical OR 
cutaneous OR wipe OR wipes OR cold OR plaster* OR patch* OR peel OR gel OR gels 
OR transdermal OR cutaneous OR cream*)) OR cooling OR emla OR pliaglis OR ((local 
OR topical ) NEAR/2 (pain OR discomfort) NEAR/2 (manage* OR relief OR reduc*)) OR 
((medicat* OR drug* OR cain) NEAR/2 (plaster* OR patch* OR peel)) OR hydrogel* OR 
cryogel*)) AND ((laser* OR “intense pulsed light” OR ipl)) AND ((dermatolog* OR skin OR 
cutaneous)) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine OR rabbit OR 
rodent* OR swine OR pig OR pigs OR porcine) NOT (human* OR patient*)))
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Supplementary Table 1. Digital search strategy (continued)
Database Search string
PubMed
n = 21
(“Anesthesia, Local”[mh] OR (Lidocaine[mh] AND Prilocaine[mh]) OR Cryoanesthesia[mh] 
OR “Transdermal Patch”[mh] OR ((Gels[mh] OR “Administration, Topical”[mh] OR 
“Administration, Cutaneous”[mh] ) AND (anesthesia[mh] OR analgesia[mh])) OR 
Cryogels[mh] OR Hydrogels[mh] OR (cryoanalgesi*[tiab] OR cryoanesth*[tiab] 
OR cryoanaesth*[tiab] OR ((analgesi*[tiab] OR anesth*[tiab] OR anaesth*[tiab] OR 
lidocaine OR tetracain*[tiab] OR prilocain*[tiab]) AND (local OR topical OR cutaneous 
OR wipe OR wipes OR cold OR plaster*[tiab] OR patch*[tiab] OR peel OR gel OR gels OR 
transdermal OR cutaneous OR cream*[tiab])) OR cooling OR emla OR pliaglis OR ((local 
OR topical ) AND (pain OR discomfort) AND (manage*[tiab] OR relief OR reduc*[tiab])) 
OR ((medicat*[tiab] OR drug*[tiab] OR cain) AND (plaster*[tiab] OR patch*[tiab] OR 
peel)) OR hydrogel*[tiab] OR cryogel*[tiab])) AND (“lasers”[mh] OR “Laser Therapy”[mh] 
OR “Intense Pulsed Light Therapy”[mh] OR (laser*[tiab] OR “intense pulsed light” OR 
ipl)) AND (dermatology[mh] OR “skin diseases”[mh] OR (dermatolog*[tiab] OR skin OR 
cutaneous)) NOT (animals[mh] NOT humans[mh]) AND publisher[sb]
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 Chapter 3.2
Comparison of lidocaine/tetracaine cream 
and lidocaine/prilocaine cream for local 
anaesthesia during laser treatment of acne 
keloidalis nuchae and tattoo removal: results 
of two randomized controlled trials.
K. Greveling
E.P. Prens
N. ten Bosch
M.B.A. van Doorn
Br J Dermatol. 2017 Jan;176(1):81-86.
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abSTRaCT
background
Pain is a common adverse effect of dermatological laser procedures. Currently, no stan-
dard topical anaesthetic cream exists for deeper dermal laser procedures.
Objective
To compare the efficacy of lidocaine/tetracaine cream and lidocaine/prilocaine cream 
in reducing self-reported pain during deeper dermal laser treatments of acne keloidalis 
nuchae (AKN) and tattoos.
Methods
We conducted two randomized, double-blind, controlled clinical trials with intra-patient, 
split-lesion designs: study A included patients with AKN (n = 15); study B included pa-
tients with black tattoos (n = 15). The primary endpoint was the patients’ self-reported 
pain on a 10-cm visual analog scale (VAS). Secondary objectives were the percentage of 
patients with adequate pain relief, willingness to pay €25 for the cream that provided 
the best pain relief, and safety of the creams.
Results
In both studies, VAS scores were lower for lidocaine/prilocaine cream, with a mean 
VAS difference in study A of 1.9 (95% confidence interval [CI], 1.0-2.8) and in study B of 
0.6 (95% CI, –0.7-1.9). In study A, adequate pain relief was achieved in 13% (2/15) with 
lidocaine/tetracaine cream vs. 73% (11/15) with lidocaine/prilocaine cream (P = 0.004), 
and in study B in 53% (8/15) versus 80% (12/15) respectively (P = 0.289). In study A, 47% 
(7/15) was willing to pay an additional €25 vs. 73% (11/15) in study B. No serious adverse 
events occurred.
Conclusion
Lidocaine/prilocaine cream under plastic occlusion is the preferred topical anaesthetic 
during painful laser procedures targeting dermal chromophores.
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InTRODUCTIOn
Pain is a common and bothersome adverse effect during dermatological laser proce-
dures. To prevent thermal damage to the epidermis and to alleviate laser-induced pain, 
most laser devices use simultaneous local skin cooling. However, local cooling often 
does not provide adequate pain relief. In such cases, local anaesthetics can be used to 
reduce procedure-related pain and increase patient satisfaction. Anaesthetics inhibit the 
sensory input to the central nervous system by blocking voltage-gated sodium chan-
nels 1. The blockade of sodium influx prevents action potentials and inhibits nerve cell 
depolarization. B fibres (myelinated autonomic preganglionic fibres) are blocked first, 
followed by C fibres (non-myelinated fibres) and, finally, A fibres (myelinated somatic 
fibres), which regulate pain and temperature 2, 3.
Injectable anaesthetics can be painful to administer and cannot be used in patients 
with needle phobia. Topical anaesthetics may be an alternative option. One of the most 
widely used products is an eutectic mixture of 2.5% lidocaine and 2.5% prilocaine cream 
(EMLA®, AstraZeneca, London, U.K.; henceforth referred to as ‘LP cream’). A practical 
disadvantage of LP cream is the need for it to be applied under plastic occlusion. A 
recently (re-)introduced topical anaesthetic, which contains the highest concentration 
of active anaesthetic ingredients available in a Food and Drug Administration-approved 
topical cream, is an eutectic mixture of 7% lidocaine and 7% tetracaine cream (Pliaglis®, 
Galderma Laboratories, Fort Worth, TX, U.S.A.; henceforth referred to as ‘LT cream’). As 
LT cream forms a self-occlusive film when exposed to air, it is said to not require plastic 
occlusion. LT cream has shown superiority over placebo in pain reduction during several 
dermatological laser procedures 4-7, and lower pain scores compared to LP cream dur-
ing (superficial) single-pass CO2 laser skin resurfacing 8. However, apart from this single 
study, no head-to-head studies have been performed for other dermatological indica-
tions or laser systems. It is, therefore, unknown whether LT cream is also superior to LP 
cream in providing anaesthesia when targeting dermal chromophores.
Two examples of common indications for laser treatment in dermatology which 
require deeper dermal anaesthesia are hair removal, such as in acne keloidalis nuchae 
(AKN), and tattoo removal. AKN is a chronic, scarring folliculitis in which hair follicles are 
the principle contributors to inflammation 9. Laser-assisted hair removal causes coagula-
tion necrosis of the viable hair follicles and hair shafts in the deep dermis, and has shown 
positive results for AKN 10, 11. In tattoos, using nanosecond Q-switched laser pulses, the 
ink particles are fragmented into smaller pieces, which can then be phagocytosed by 
macrophages and cleared from the skin via the lymph vessels to the draining lymph 
nodes 12.
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The aims of these studies were to evaluate the efficacy of LT cream compared with 
LP cream in reducing self-reported pain during laser treatments of AKN (study A) and 
tattoos (study B).
MaTERIaLS anD METHODS
Study population
Eligible for inclusion in study A were patients aged ≥18 years with AKN, and eligible for 
inclusion in study B were those aged ≥18 years with a black, professionally placed tat-
too. Key exclusion criteria for both studies included known hypersensitivity or contact 
allergy to any components of the test materials, use of any other pain medication 24 h 
prior to the study visit, pregnant or breast-feeding women, and damaged skin at the 
designated treatment area.
Study design and randomization
These double-blind, randomized, controlled trials with intra-patient, split-lesion design 
were approved by the medical ethical review board of the Erasmus Medical Centre 
(MEC-2014-517; 14-11-2014) and registered at ClinicalTrials.gov (NCT02372786). All pa-
tients provided written informed consent before study participation. Both studies were 
of single-centre design and all patients were treated at the Erasmus University Medical 
Centre in Rotterdam, The Netherlands.
Study design and treatment protocols were similar for both studies. The treatment 
areas (i.e. necks in study A, and tattoos in study B) were divided into two equal, anatomi-
cally similar treatment sides (left and right). Both sides were separated by an area of 1 
cm, which was left untreated to avoid possible spill-over effects of the two anaesthetic 
creams. Both creams were applied to each patient, and the order of cream application 
was randomized. A computer-generated randomization list was provided by the depart-
ment of Biostatistics of the Erasmus MC, and was only available to the unblinded study 
nurse. The creams were applied by our unblinded study nurse according to the manu-
facturer’s instructions and according to randomization. LT cream dried when exposed to 
air (self-occlusive), and LP cream was applied under occlusion using an occlusive plastic 
film (Fig. 1). The creams were removed by the unblinded study nurse after 60 minutes, 
after which the patient was transferred to the laser treatment room. The skin was then 
examined by the blinded investigator and any local reactions were recorded. All laser 
procedures were started within five minutes after removal of the anaesthetic creams. 
In all cases, the laser treatment began on the left treatment side followed by the right 
treatment side, to minimalize any potential order effect. Immediately after laser treat-
Comparison of lidocaine/tetracaine cream and lidocaine/prilocaine cream for local anesthesia during laser treatment 95
ment of each side, pain scores were assessed using a standard 10-cm visual analog scale 
(VAS), with lower scores indicating less pain.
One week after the visit all patients were contacted by telephone, to assess potential 
adverse events after treatment.
Laser treatment
Laser settings were determined based on the safe clinical responses to previously 
performed test spots. Test spots are part of the normal routine procedure in our daily 
clinical practice, and were executed before study participation.
Study A (Acne keloidalis nuchae)
A neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Cynosure Cynergy, West-
ford, MA, U.S.A.) emitting a wavelength of 1,064 nm was used for hair removal in patients 
with AKN. A spot size of 7 or 10 mm, fluences between 35 to 60 J/cm2, pulse duration of 
25 ms, and frequency of 1 Hertz (Hz) were used. Two passes were applied. Standardized 
air-cooling (Zimmer air cooler; Zimmer, Irvine CA, U.S.A.) was administered during treat-
ment for thermal protection of the epidermis, and additional pain relief, whereby both 
sides were (pre)cooled in an identical manner.
Study B (tattoos)
A Q-switched Nd:YAG laser (Quanta Systems, Solbiate Olona, Italy), emitting a wave-
length of 1,064 nm was used for tattoo removal. A spot size of 3 mm, fluences between 
6 to 10 J/cm2, and frequency of 1 Hz were used. A single pass was applied.
figure 1. Application of lidocaine/tetracaine cream (self-occluding) on the left treatment side and lido-
caine/prilocaine cream under plastic occlusion on the right treatment side in a patient with acne keloidalis 
nuchae.
96 Chapter 3.2
Study objectives
The primary objective of both studies was to compare the efficacy of LT cream and LP 
cream in reducing self-reported pain, using a 10-cm VAS, during a single laser procedure. 
Secondary objectives of both studies were to evaluate the percentage of patients who 
reported adequate pain relief (yes/no), to monitor the nature and frequency of adverse 
events, and to evaluate if patients were willing to pay approximately €25 for the treat-
ment that provided superior pain reduction. This last question was included as LP cream 
is, in The Netherlands, reimbursed by health insurance and LT cream has to be purchased 
for approximately €25 (per 15 grams).
Statistical analysis
For both studies, a sample size of 15 patients was calculated to provide 80% power to 
detect a difference of 2 (SD 2.5) in VAS, which is determined to be (approximately) the 
minimal clinically important difference that a patient can detect 13, with a two-sided 
type I error level of 5%. A t-test for paired samples was used.
The results of the two studies were analysed separately. The differences in VAS scores 
between the LT and LP creams were analysed using a t-test for paired samples. Normality 
of the variables was tested using a Shapiro-Wilk test. The differences between LT cream 
and LP cream regarding adequate pain relief were analysed using a McNemar test. The 
side on which the treatment was least painful and willingness to spend approximately 
€25 for the cream used on this side are shown as percentages and absolute numbers of 
cases. P-values < 0.05 were considered statistically significant. SPSS Statistics 21 (IBM, 
Armonk, NY, U.S.A.) was used for all analyses.
RESULTS
Between February and September 2015, a total of 15 patients were enrolled in study A 
(AKN), and between February and July 2015 a total of 15 patients were enrolled in study 
B (tattoos). Demographic details of both studies are shown in Table 1. There were no 
dropouts or exclusions after randomization in both studies.
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Study A: acne keloidalis nuchae
The mean (SD) VAS scores were 5.5 (1.7) for LT cream and 3.7 (2.6) for LP cream (Fig. 2), 
with a mean VAS difference of 1.9 (95% confidence interval [CI], 1.0-2.8; P = 0.001).
Adequate pain relief during the laser procedure was achieved in 13% (2/15) of the 
patients receiving LT cream and 73% (11/15) of the patients receiving LP cream (P = 
0.004) (Fig. 3).
Seven percent (1/15) rated the side treated with LT cream as least painful vs. 80% 
(12/15) of the patients receiving LP cream. Thirteen percent (2/15) of the patients did 
not have a preference for either side. Of all patients, 47% (7/15) were willing to pay €25 
for future treatment with the cream that provided the best pain relief.
Table 1. Patient demographics
Study a (aKn) Study b (tattoos)
Patients (n) 15 15
Gender (n)   
Male 15 5 
female 0 10 
Mean (SD) age (years) 41 (12) 39 (10)
fitzpatrick skin type (n)   
I - 1 
II - 7 
III 1 3 
IV 2 1 
V 9 3 
VI 3 0 
Previous laser treatment (n, %)   
no 15 (100) 7 (47) 
Yes - 8 (53) 
Mean number of previous treatments - 5 
Localization (n)   
face - 1 
neck 15 1
Chest - 1 
Upper extremities - 10 
Lower extremities - 2 
AKN; acne keloidalis nuchae, n; number, SD; standard deviation.
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Study B: tattoos
The mean (SD) VAS scores were 4.3 (1.8) for LT cream and 3.7 (2.3) for LP cream (Fig. 4). The 
mean VAS difference of 0.6 (95% CI, -0.7 to 1.9; P = 0.335) was not statistically significant.
Adequate pain relief during the laser procedure was achieved in 53% (8/15) of the 
patients with LT cream and 80% (12/15) of the patients with LP cream (P = 0.289) (Fig.5).
Of all patients, 33% (5/15) rated the side treated with LT cream as least painful vs. 60% 
(9/15) of the patients for LP cream. Seven percent (1/15) of the patients did not have a 
preference for either side. Of all patients, 73% (11/15) were willing to pay €25 for future 
treatment with the cream that provided the best pain relief.
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figure 2. Study A: patients with acne keloidalis nuchae (n=15). Visual Analog Scale scores after applica-
tion of lidocaine/tetracaine (LT) cream (self-occluding) on one treatment side and lidocaine/prilocaine (LP) 
cream under plastic occlusion on the other treatment side (P = 0.001).
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figure 3. Study A: patients with acne keloidalis nuchae (n=15). Percentage of patients who perceived ad-
equate pain relief after application of lidocaine/tetracaine (LT) cream (self-occluding) on one treatment 
side and lidocaine/prilocaine (LP) cream under plastic occlusion on the other treatment side (P < 0.004).
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Local reactions and adverse events of both studies
During examination of the skin immediately after cream removal, the side treated with 
LT cream showed blanching in 0% (0/15), edema in 20% (3/15) and erythema in 27% 
(4/15) in study A, and blanching in 0% (0/15), edema in 13% (2/15) and erythema in 53% 
(8/15) in study B. On the side treated with LP cream no local reactions were seen after 
cream removal in study A, and in study B blanching was seen in 47% (7/15), oedema in 
7% (1/15) and erythema in 0% (0/15) of the patients. These local reactions were all mild 
and transient.
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figure 4. Study B: patients with tattoos (n=15). Visual Analog Scale scores after application of lidocaine/
tetracaine (LT) cream (self-occluding) on one treatment side and lidocaine/prilocaine (LP) cream under 
plastic occlusion on the other treatment side (P = 0.335).
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figure 5. Study B: patients with tattoos (n=15). Percentage of patients who perceived adequate pain relief 
after application of lidocaine/tetracaine (LT) cream (self-occluding) on one treatment side and lidocaine/
prilocaine (LP) cream under plastic occlusion on the other treatment side (P = 0.289).
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Thirteen patients of study A and 13 patients of study B were available for telephone 
consultation one week after treatment. In study A, two patients reported adverse 
events: burning sensation (n=1), and itching and crusting (n=1). In study B, five patients 
reported adverse events: swelling (n=1), itching (n=2) and mild blistering (n=2). All 
adverse events were transient and most likely related to the laser treatments. No serious 
adverse events occurred.
DISCUSSIOn
The main finding of study A was that LP cream provided statistically significant lower 
pain scores than LT cream during the Nd:YAG laser treatment of AKN. Previous studies 
defined the minimal clinically important difference (i.e. the smallest clinically relevant 
change that a patient can detect) on a 100-mm VAS to be between 9 to 18 mm 13, 14. Thus, 
the statistically significant 19-mm VAS difference we found between the two creams 
during the treatment of AKN (favouring LP cream) is also clinically relevant.
The results of study B showed no significant differences between the two creams in 
reducing self-reported pain during the Q-switched Nd:YAG laser treatment of tattoos, 
although the numerical difference appears to be in favour of LP cream. Possibly, the 
lack of statistical significance in this study, compared with study A, is caused by the fact 
that laser-assisted hair removal in AKN is more painful than tattoo removal. Breivik et al. 
showed that the power to detect a difference in pain intensity is higher when there is a 
large difference and a higher baseline pain 15, 16. Terminal hair follicles are located deeper 
in the dermis than tattoo ink particles and, together with the larger spot size and higher 
fluence (causing more volumetric bulk heating of the dermis), treatment with a long-
pulsed Nd:YAG laser for hair removal is associated with more (painful) thermal injury to 
the skin than the ultrashort-pulsed Nd:YAG laser used for tattoo removal. Also, in laser 
tattoo removal there is less photothermal and more of a photoacoustic effect, which is 
less painful. Additionally, the AKN group was very homogeneous group, whereas the 
tattoo group was more heterogeneous, including various anatomic locations, sexes, skin 
types and number of previous laser treatments. These are all factors that could have 
increased the variability and therefore have influenced the statistical significance of the 
results.
The results appear to be in contrast with the only published head-to-head study which 
reported self-occluding LT cream to be superior to LP cream under occlusion, after a 
30 minutes application time, during single-pass CO2-laser skin resurfacing 8. However, 
it might not be possible to extrapolate the results found during this superficial laser 
treatment to treatments with longer wavelength lasers used for both AKN and tattoo 
removal. Longer wavelength lasers penetrate much deeper into the dermis, triggering 
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far more nerves than a single-pass CO2 laser skin ablation. Furthermore, as the label-
recommended application time for LP cream is a minimum of 60 minutes (https://www.
medicines.org.uk), the results of Alster et al. may have been influenced by the shorter 
application time of only 30 minutes.
The effectiveness of an anaesthetic cream mainly depends on the rate of (trans)dermal 
absorption. This absorption rate is determined by the thickness of the stratum corneum, 
and the pKa (acid dissociation constant) of the anaesthetic 2. Penetration through the 
skin can be enhanced by occlusion, which increases temperature and hydration of the 
stratum corneum. The thinner the stratum corneum and the closer the pKa matches the 
pH of the skin (~5.5 17), the better the anaesthetic penetrates through the skin. As every 
patient in both of our studies was his or her own control, the thickness of the stratum 
corneum was equal for both treatment sides. Both creams contained lidocaine (pKa 7.7), 
and the pKa of prilocaine and tetracaine did not differ substantially (7.9 and 8.6, respec-
tively 18). Therefore, the main factor that could have made a difference in (trans)dermal 
absorption between the two creams is the different method of occlusion. The flexible 
film formed by LT cream might not have facilitated optimal drug absorption, and despite 
its higher concentrations of anaesthetics, provided less (deeper) dermal pain reduction.
Besides pain reduction, potential side effects, costs, and ease of use should be taken 
into account when choosing an anaesthetic cream. Mild local reactions were observed 
after cream removal, but no clinically important differences between the two creams 
were evident. In The Netherlands, the retail price of LT cream is approximately 2.5 times 
higher than that of LP cream, and LT cream is not reimbursed by the health insurance. 
In our experience, LT cream was easier to apply, but sometimes difficult to remove. On 
the contrary, LP cream was more difficult to apply using plastic occlusion but easier to 
remove.
Limitations of both studies were the relatively small sample sizes, and that patients 
were not completely blinded as the methods of occlusion were different. However, it 
was assumed patients did not know which method belonged to which cream.
In summary, we conclude that a 60-minute application of LP cream under plastic oc-
clusion is the preferred topical anaesthetic during painful laser procedures targeting 
dermal chromophores.
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abSTRaCT
Lentigo maligna (LM) is considered a precursor to LM melanoma (LMM). We assessed 
trends in LM and LMM incidence rates between 1989 and 2013 in The Netherlands, and 
estimated the risk of an LMM after LM. Data on newly diagnosed LM and LMM were 
obtained from the Netherlands Cancer Registry and PALGA (Dutch Pathology Registry). 
Age-standardized incidence rates (European standardized rate), estimated annual per-
centage changes (EAPC), and the cumulative incidence of LMM after LM were calculated. 
Between 1989 and 2013, 10,545 patients were diagnosed with a primary LM and 2,898 
with a primary LMM in The Netherlands. The age-standardized incidence rate for LM 
increased from 0.72 to 3.84 per 100,000 person-years, and for LMM from 0.24 to 1.19 
between 1989 and 2013. LM incidence increased from 2002 to 2013 with 6.8% annually, 
before an even steeper rise in LMM incidence from 2007 to 2013 (EAPC: 12.4%). The 
cumulative incidence of LMM after a primary LM after 25-years follow-up was 2.0% for 
males and 2.6% for females. The increased incidence of LM and LMM in The Netherlands 
seems, besides increased awareness and increased histological confirmation of LM, to 
reflect a true increase. The absolute risk of an LMM (at any location) after a histologically 
confirmed LM was low (2.0 – 2.6%).
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InTRODUCTIOn
Lentigo maligna (LM) is the most common subtype of melanoma in situ, accounting for 
three-quarters of all cases 1, 2. It is considered a precursor of lentigo maligna melanoma 
(LMM), which represents 4% - 15% of all invasive melanomas 3. Both LM and LMM are 
related to cumulative sun exposure and occur mostly in the head and neck region of 
elderly individuals 4.
Incidence rates of LM and LMM have increased in the recent decades 1, 5. There is 
controversy about whether this represents a truly increased incidence (caused by in-
creased ultraviolet exposure), or that it is caused by a growing awareness of skin cancer 
among both patients and physicians (i.e. increased detection) 6. The stronger increase of 
melanoma in situ incidence than invasive melanoma incidence suggests at least a role 
for earlier detection 7, 8.
Surgical excision is considered the gold standard treatment for LM 9. However, non-
surgical treatment options gain more interest, especially for large facial lesions or elderly 
patients, and even a wait-and-see policy may be considered 9. Choosing less invasive, 
non-surgical treatments is supported by data showing that the estimated lifetime risk 
of LMM in patients with a (clinically defined) LM appears to be low (2.2% to 4.7%) 10. 
However, this risk is based on a single epidemiological study from 1987 10, and has not 
been investigated since.
The aims of this study were to investigate and compare the incidence trends of LM and 
LMM in the Netherlands over a period of 25 years (1989-2013), and to estimate the risk 
of an LMM after a histologically confirmed LM. In addition, the 5-year relative survival of 
both LM and LMM is presented.
METHODS
Data were obtained from the Netherlands Cancer Registry (NCR) on all cases of LM and 
LMM recorded between 1989 and 2013 in the Netherlands. The NCR is based on all 
histologically confirmed malignancies in the Netherlands since 1989 by the automated 
pathological archive (PALGA), a nationwide network and registry of histopathology and 
cytopathology 11. The completeness on skin cancers (excluding basal cell carcinoma) has 
been estimated in 1994 to be 93% 12.
All patients with a first primary diagnosed LM or LMM (International Classification of 
Diseases for Oncology (ICD-O) morphology codes 8742/2 and 8742/3) between 1989 
and 2013 were included. ICD-O topography codes were used to categorize anatomical 
sites: skin of the lip (C44.0), eyelid (C44.1), external ear (C44.2), skin of other and unspeci-
fied parts of the face (C44.3), skin of the scalp and neck (C44.4), skin of the trunk (C44.5), 
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skin of the upper limb and shoulder (C44.6), skin of the lower limb and hip (C44.7), and 
other sites (C44.8-C44.9). The study period was divided into five time periods to study 
trends: 1989-1993, 1994-1998, 1999-2003, 2004-2008, and 2009-2013. Age-specific 
incidence rates were computed for 5-year age groups (0-4, ….,80-84, and 85+). Data 
were stratified by gender.
If a patient with a primary LM had a subsequent diagnosis of a primary LMM, the LM 
and LMM ICD-O topography codes were compared. NCR data were additionally linked 
to PALGA to obtain more specific information on the exact anatomic location, and deter-
mine if both locations were identical.
Statistical analysis
Incidence rates were calculated per 100,000 person-years, using population size (deter-
mined on 1 January each year) derived from Statistics Netherlands, and age-standard-
ized to the European standard population (European Standardized Rate [ESR]), World 
standard population 1968 (World Standardized Rate [WSR]), World (WHO 2000-2025) 
standard population (World Standardized Rate [WSR2000-2025]) and US 2000 standard 
population (United States Standardized Rate [USSR]).
Estimated annual percentage changes (EAPC) with corresponding 95% confidence 
intervals (CI) were calculated to evaluate incidence trends for LM and LMM over time. 
Joinpoint regression analyses were used to identify the years in which a significant 
change in trends occurred.
To estimate the risk of an LMM after a histologically confirmed LM, the cumulative risk 
up to 25 years after diagnosis of the first LM was calculated using a cumulative incidence 
curve taking the competing risk of death into account 13.
Five-year relative survival using traditional cohort analysis was calculated for LM and 
LMM as a proxy for disease-specific survival.
All analyses were carried out using SPSS statistics 21, SAS software (version 4.3, SAS 
Institute, Cary, North Carolina, U.S.A.) and Joinpoint regression program version 4.2.0.1 
14. P-values were two-sided and considered significant if P < 0.05.
RESULTS
Between 1989 and 2013, 10,545 patients were diagnosed with a primary histologically 
confirmed LM in The Netherlands and 2,898 with a primary LMM. Of all patients with 
LM, 58% were female (n = 6,114), which was comparable to the 57% (n = 1,649) females 
among patients with LMM. Most LM (74%, n = 7,845) and LMM (69%, n = 2,002) were 
located in the head and neck region.
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The absolute annual number of patients with a histologically confirmed first primary 
LM increased from 110 in 1989 to 903 in 2013 and for LMM from 38 in 1989 to 292 in 
2013. During the same period the median age at diagnosis of LM increased for men 
(from 68 to 71 years) and women (from 67 to 71 years). For LMM the median age at 
diagnosis increased as well for both men (from 68 to 73 years) and women (from 71 to 
72 years).
Time trends for LM
The age-adjusted incidence rates (ESR) of LM increased between 1989 and 2013 from 
0.68 to 3.57 per 100,000 person-years for males and from 0.76 to 4.16 per 100,000 
person-years for females (Fig. 1). For both sexes combined, the incidence rates increased 
from 0.72 to 3.84 per 100,000 person-years. Incidence rates of LM age-standardized to 
other standard populations can be found in supplementary Table 1.
Incidence rates of LM increased for males between 1989 and 1994 (EAPC 23.8% [95% CI, 
11.9 - 37.1]) and between 2002 and 2013 (EAPC: 7.4% [95% CI, 5.8 - 9.0]), but remained 
stable between 1994 and 2002 (EAPC: 0.8% [95% CI, -3.3 - 4.9]) (Fig. 1.). The same pattern 
with the largest annual increases in incidence rates at the beginning and the end of the 
study period was observed for females (EAPC 1989-1994: 19.0% [95% CI, 12.6 - 25.8], 
EAPC 2007-2013: 8.7% [95% CI, 6.5 - 10.9]). The increase in incidence rates among females 
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figure 1. Lentigo maligna. Age-standardized incidence rates and trends. Age-standardized incidence 
rates per 100,000 person years (ESR) and Joinpoint analyses with Estimated Annual Percentage Changes 
(EAPC) of lentigo maligna in The Netherlands from 1989-2013 in males and females. ESR; European Stan-
dardized Rate.
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was also statistically significant between 1994 and 2007 (EAPC: 2.4% [95% CI,1.4 - 3.4]) 
(Fig. 1). For both sexes combined, the incidence rates increased each year with 22.1% 
(95% CI, 15.2 - 29.4) between 1989 and 1994, 0.5% (95% CI, -1.8 - 2.9) between 1994 and 
2002, and 6.8% (95% CI, 5.9 - 7.7) between 2002 and 2013.
Time trends for LMM
The age-adjusted incidence rates (ESR) of LMM increased between 1989 and 2013 
from 0.26 to 1.25 per 100,000 person-years for males and from 0.22 to 1.18 per 100,000 
person-years for females (Fig. 2). For both sexes combined, the incidence rates increased 
from 0.24 to 1.19 per 100,000 person-years. Incidence rates of LMM age-standardized to 
other standard populations can be found in supplementary Table 2.
Joinpoint regression analyses showed statistically significant increased incidence rates 
among males between 1989 and 2007 (EAPC 4.6% [95% CI, 2.7 - 6.5]) and between 2007 
and 2013 (EAPC: 14.1% [95% CI, 8.2 - 20.2]) (Fig. 2). Among females, the incidence rates 
increased in a similar pattern, with 5.2% (95% CI, 3.9 - 6.5) between 1989 and 2009 and 
14.4% (95% CI, 5.4 - 24.2) between 2009 and 2013 (Fig. 2). For both sexes combined, the 
incidence rates increased between 1989-2007 with 4.8% (95% CI, 3.4 - 6.2) annually, and 
between 2007-2013 with 12.4% (95% CI, 8.0 - 16.9%).
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figure 2. Lentigo maligna melanoma. Age standardized incidence rates and trends. Age standardized in-
cidence rates per 100,000 person years (ESR) and Joinpoint analyses with Estimated Annual Percentage 
Changes (EAPC) of lentigo maligna melanoma in The Netherlands from 1989-2013 in males and females. 
ESR; European Standardized Rate.
Epidemiology of lentigo maligna and lentigo maligna melanoma 113
The age-specific incidence rates of both LM and LMM increased with each study period, 
with the largest increase, for both sexes, during the most recent period (2009-2013), and 
among elderly (data not shown).
Risk of LMM after LM
Of the 10,545 patients diagnosed with LM, 124 were subsequently diagnosed with an 
LMM (at any anatomic location). The 5-year cumulative risk of getting an LMM after a 
histologically confirmed primary LM was 0.7% (95% CI, 0.5 – 1.0) for males and 0.8% 
(95% CI, 0.6 – 1.1) for females. The 10-year cumulative risk was 1.0% (95% CI, 0.6 – 1.3) 
and 1.6% (95% CI, 1.2 – 2.0), the 15-year cumulative risk was 1.4% (95% CI, 0.9 – 1.9) and 
1.9% (95% CI, 1.4 – 2.3), the 20-year cumulative risk was 2.0% (95% CI, 1.2 – 2.8) and 2.2% 
(95% CI, 1.7 – 2.8), and the 25-year cumulative risk 2.0% (95% CI, 1.2 – 2.8) and 2.6% (95% 
CI, 1.9 – 3.3), for males and females, respectively (Fig. 3.).
Of the 124 patients with an LMM after LM, 101 LMMs had the same ICD-O topography 
and laterality codes as the LMs: skin of the lip (n = 1), skin of the external ear (n = 3), skin 
of other and unspecified parts of the face (n = 88), skin of the scalp and neck (n = 4), skin 
of the trunk (n = 3), skin of the upper limb and shoulder (n = 1), and skin of the lower 
limb and hip (n = 1).
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figure 3. Cumulative incidence curve. Cumulative risk of a lentigo maligna melanoma (at any anatomical 
location) after a first histologically confirmed lentigo maligna.
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To determine if the LMM occurred at the exact same anatomical location as the LM, 
these 101 cases were linked to PALGA. The exact locations could be determined in 71 
cases. Of these 71 cases, the LM and subsequent LMM occurred at the same location in 
64 cases. In 7 cases, this location was different. In the remaining 30 cases, the localiza-
tions remained unclear.
Of these 64 cases with similar anatomic locations, the LM and subsequent LMM oc-
curred on the cheek (n = 39), nose (n = 5), forehead (n = 5), temporal area (n = 5), scalp 
(n = 3), ear (n = 3), eyelid (n = 1), upper limb (n = 1), neck (n = 1), and upper lip (n = 1).
Of the 64 LMs, 62 were treated, 51 (80%) with surgery, 7 (11%) with cryosurgery, and 
4 (7%) with other or unknown therapies. The distribution of treatments was different 
compared to LM without LMM at the same location (n = 10,481), of which 10,265 LMs 
were treated, 9,369 (90%) with surgery, 262 (2%) with cryosurgery, and 634 (6%) with 
other or unknown therapies (P = 0.004).
Of all LMMs (n=2,898), 662 (23%) were > 1mm deep. There was no significant differ-
ence between cases with prior LM (28%, 18 of 64) and cases without prior LM (23%, 644 
of 2,834) (P = 0.309).
Relative survival
The 5-year relative survival for LM was 104% (95% CI, 104 - 104), and for LMM 99% (95% 
CI, 97 - 101).
Of the 64 LMs with subsequent LMMs, three patients died in the first 5-year follow-up. 
The group was too small to calculate a 5-year relative survival.
DISCUSSIOn
The results of this large, population-based study showed that the age-standardized 
incidence rates for both LM and LMM in the Netherlands increased between 1989 and 
2013. During the most recent period, incidence rates increased with 7% for LM and 12% 
for LMM. The absolute risk of an LMM (at any anatomical location) after a histologically 
confirmed LM was low (2-3% after 25 years). The 5-year relative survival was high for 
both LM (104%), and LMM (99%).
When examining the rise in LM and LMM incidence over time, there are two interest-
ing periods. The first is the steep increase of LM incidence between 1989 and 1994. Most 
likely, this steep increase could be explained by under-reporting, because completeness 
of the database in the first years is unknown. Also, the inception of higher awareness for 
skin cancer among the population and improved screening 15, 16, leading to an increased 
histological confirmation of LM, may have contributed to this steep rise as well. The 
second interesting period is between 2002 and 2013, where the second increase of LM 
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incidence is seen. This most recent acceleration of LM incidence coincided with an even 
steeper increase in LMM incidence rates; therefore, we think that this reflects, at least in 
part, a true increase. Another explanation could be the changed market forces in The 
Netherlands in 2006, which stimulated clinicians to treat skin cancer more rigorously 
than before 17. Diagnostic drift has also been suggested as an explanation for more 
recent increases in melanoma incidence rates 18, as dermatopathologists are now more 
likely to diagnose melanoma in biopsies than they were 20 years ago 19. Also, because 
immunohistochemistry is nowadays more commonly used in the histopathological 
diagnosis of LM and LMM than before, this has improved identification, and may have 
contributed to an increased detection as well.
Studies on incidence rates of in situ melanoma often do not report on histological 
subtypes specifically 20-22, or the LM subtype is excluded because of concerns about con-
sistency of identification over time 7, 23, 24. Two population-based studies that did report 
on LM subtype both observed an average annual increase in incidence: 3.9% (95% CI, 
1.7 – 6.2) in age-group 45-64 years and 6.8% (95% CI, 5 – 8.7) in age-group ≥ 65 years for 
both sexes in Northern California 1990-2000 1, and 1.7% (95% CI, 0.5 – 3.0) for men and 
2.7% (95% CI, 1.7 – 3.8) for woman in Denmark 1997-2011 5. For LMM, other population 
based studies reported increased incidence rates in the order of 4-6% 1, 25-27, similar to 
our earlier study period. However, as steep as the 12% increase that we found in our 
most recent study period has not been reported previously.
Age-adjusted incidence rates of LM and LMM were almost similar among men and 
women during the study period. This is different compared with cutaneous melanoma in 
which there is a predominance found in women in European countries, and the opposite 
is found in Australia and North America 7, 28-30. Cutaneous melanoma predominates on 
the lower limb in women and the trunk in men, whereas the upper limb and head and 
neck were similar for both sexes 30, 31. LM and LMM occur mostly in the head and neck 
region, which may explain why we found no differences between sexes.
The risk of progression of LM to LMM is an important criterion that clinicians consider 
when deciding on a treatment strategy (e.g. surgical or local treatment). It is, however, 
very difficult to study the risk of progression, because the ideal study would comprise a 
prospective cohort in which LM lesions would be subjected to an intensive wait-and-see 
policy with a very long follow-up. In our study, we could not assess the progression of 
an individual lesion, and also the anatomic locations of LM and their subsequent LMM 
were different in 30 (of 124) cases and remained unknown in another 30 (of 124) cases. 
Therefore, we estimated the risk of a subsequent LMM at any anatomical location after a 
histologically confirmed LM. The cumulative risk of developing an LMM after a primary 
LM was estimated to be between 2% and 3% after 25 years. Whether this is a true risk 
or an overestimation or underestimation is debatable. The number of LM included only 
histologically confirmed LM and is therefore most likely an underestimation of the 
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true number of LM in The Netherlands, caused by elderly patients left undiagnosed, 
or treated (with non-surgical treatments or conservatively) without histopathological 
confirmation of the diagnosis. On the contrary, the registration of LMM is assumed to be 
virtually complete. The under-registration of LM combined with a complete registration 
of LMM may have resulted in an overestimation of the cumulative risk of LMM after LM.
On the other hand, it is also possible that there may be an underestimation of the 
cumulative risk of LMM after LM, because LM is normally treated in The Netherlands, 
which would decrease the risk of progression. Also, some of the LM diagnosed as an in 
situ lesion by initial biopsy or conventional excision may have already had an unrecog-
nized component of dermal invasive melanoma and were actually representing LMM 
32-34. Thirdly, LMM registered without a previous diagnosis of LM would not have been 
included in our analysis and may also have resulted in an underestimation.
Strengths of this study are the use of the national population-based cancer registry in 
the Netherlands that covers the whole Dutch population with high quality of the data 
over a long follow-up time 12. Also, the link with the pathology database to retrieve if LMM 
occurred at the exact same anatomical location as LM provided important additional 
information. A limitation is the lack of information on non-histologically confirmed LM, 
and on LMM without a previous diagnosis of LM, which could have led to an respectively 
overestimation or underestimation of the risk of a subsequent LMM. Finally, the histo-
pathological diagnosis of LM and LMM can be difficult because of sun-damaged skin, 
making these diagnoses challenging 35.
In summary, our results demonstrate an increasing incidence of LM and LMM in The 
Netherlands between 1989 and 2013. Besides factors like increased awareness, increased 
histological examination, diagnostic drift and changed market forces, this increased 
incidence also seems to reflect a true increase as the most recent accelerated increase 
of LM was followed by an even steeper accelerated increase of LMM. The absolute risk 
of an LMM (at any anatomical location) after a histologically confirmed LM was 2-3% 
after 25 years. The relative survival of both patients with LM and those with LMM was 
excellent 5 years after diagnosis. Our data may help physicians and patients to weigh the 
advantages and disadvantages of the different treatments for LM.
aCKnOWLEDGEMEnTS:
The authors thank the registration team of the Netherlands Comprehensive Cancer 
Organization (IKNL) for the collection of data for the Netherlands Cancer Registry as well 
as IKNL staff for scientific advice, and Dr. S. Koljenović (pathologist at the Department of 
Pathology, Erasmus MC) and PALGA (Dutch Pathology Registry) for providing additional 
information on tumor localization.
Epidemiology of lentigo maligna and lentigo maligna melanoma 117
REfEREnCES
 1. Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of lentigo maligna 
melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol. 2005; 
125(4): 685-91.
 2. Hemminki K, Zhang H, Czene K. Incidence trends and familial risks in invasive and in situ cutane-
ous melanoma by sun-exposed body sites. Int J Cancer. 2003; 104(6): 764-71.
 3. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: 
current state of diagnosis and treatment. Dermatol Surg. 2006; 32(4): 493-504.
 4. Smalberger GJ, Siegel DM, Khachemoune A. Lentigo maligna. Dermatol Ther. 2008; 21(6): 439-46.
 5. Toender A, Kjaer SK, Jensen A. Increased incidence of melanoma in situ in Denmark from 1997 to 
2011: results from a nationwide population-based study. Melanoma Res. 2014; 24(5): 488-95.
 6. Higgins HW, 2nd, Lee KC, Galan A, Leffell DJ. Melanoma in situ: Part I. Epidemiology, screening, 
and clinical features. J Am Acad Dermatol. 2015; 73(2): 181-90.
 7. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive mela-
noma in Queensland, Australia, 1982-2002. Cancer Causes Control. 2006; 17(1): 21-7.
 8. Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in 
cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of 
the German Dermatological Society. Cancer. 2005; 103(3): 616-24.
 9. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines 
of care for the management of primary cutaneous melanoma. American Academy of Dermatol-
ogy. J Am Acad Dermatol. 2011; 65(5): 1032-47.
 10. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. 
Br J Dermatol. 1987; 116(3): 303-10.
 11. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathol-
ogy databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide 
histopathology and cytopathology data network and archive. Cell Oncol. 2007; 29(1): 19-24.
 12. Schouten LJ, Straatman H, Kiemeney LA, Gimbrere CH, Verbeek AL. The capture-recapture 
method for estimation of cancer registry completeness: a useful tool? Int J Epidemiol. 1994; 23(6): 
1111-6.
 13. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. 
Clin Cancer Res. 2007; 13(2 Pt 1): 559-65.
 14. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applica-
tions to cancer rates. Stat Med. 2000; 19(3): 335-51.
 15. Krol AD, van der Rhee HJ, Dieleman M, Welvaart K. [The ‘freckle bus’ campaign; an unhealthy 
phenomenon or a sensible experiment?] De ‘sproetenbus’; een ongezond verschijnsel of een 
bezonnen experiment? Ned Tijdschr Geneeskd. 1990; 134(42): 2047-50.
 16. de Rooij MJ, Rampen FH, Schouten LJ, Neumann HA. Skin cancer screening focusing on mela-
noma yields more selective attendance. Arch Dermatol. 1995; 131(4): 422-5.
 17. Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends in Basal cell 
carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol. 2013; 133(4): 
913-8.
 18. van der Leest RJ, Zoutendijk J, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E, et al. Increasing time 
trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations? 
Eur J Cancer. 2015; 51(18): 2833-41.
118 Chapter 4.1
 19. Frangos JE, Duncan LM, Piris A, Nazarian RM, Mihm MC, Jr., Hoang MP, et al. Increased diagnosis of 
thin superficial spreading melanomas: A 20-year study. J Am Acad Dermatol. 2012; 67(3): 387-94.
 20. Vilar-Coromina N, Vilar-Coromina N, Vilardell L, Cano A, Marcos-Gragera R, Marcos-Gragera R. 
[Rapid increase in incidence of melanoma in situ in Girona (Spain), 1994-2005. Effectiveness of 
public education campaigns about early diagnosis] Rapido incremento de la incidencia del mela-
noma in situ en Girona (Espana) 1994-2005. inverted question markEfectividad de la campanas 
de diagnostico precoz? Actas Dermosifiliogr. 2010; 101(6): 561-3.
 21. Lee JA. The systematic relationship between melanomas diagnosed in situ and when invasive. 
Melanoma Res. 2001; 11(5): 523-9.
 22. Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-
based study. Oncologist. 2011; 16(6): 896-903.
 23. Thorn M, Ponten F, Johansson AM, Bergstrom R. Rapid increase in diagnosis of cutaneous mela-
noma in situ in Sweden, 1968-1992. Cancer Detect Prev. 1998; 22(5): 430-7.
 24. Ruiter DJ, van Dijk MC, Ferrier CM. Current diagnostic problems in melanoma pathology. Semin 
Cutan Med Surg. 2003; 22(1): 33-41.
 25. Helvind NM, Holmich LR, Smith S, Glud M, Andersen KK, Dalton SO, et al. Incidence of In Situ and 
Invasive Melanoma in Denmark From 1985 Through 2012: A National Database Study of 24059 
Melanoma Cases. JAMA Dermatol. 2015; 151(10): 1087-95.
 26. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Neth-
erlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J 
Cancer. 2012; 48(13): 2046-53.
 27. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cuta-
neous malignant melanoma in a Swedish population 1976-1994. Acta Oncol. 2002; 41(2): 138-46.
 28. Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence 
and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 
2014; 28(9): 1170-8.
 29. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann 
Oncol. 2009; 20 Suppl 6: vi1-7.
 30. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009; 27(1): 3-9.
 31. Chevalier V, Barbe C, Le Clainche A, Arnoult G, Bernard P, Hibon E, et al. Comparison of anatomical 
locations of cutaneous melanoma in men and women: a population-based study in France. Br J 
Dermatol. 2014; 171(3): 595-601.
 32. Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo ma-
ligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol. 
2008; 58(1): 142-8.
 33. Abdelmalek M, Loosemore MP, Hurt MA, Hruza G. Geometric staged excision for the treatment of 
lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review. 
Arch Dermatol. 2012; 148(5): 599-604.
 34. Iorizzo LJ, Chocron I, Lumbang W, Stasko T. Importance of vertical pathology of debulking speci-
mens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. Dermatol 
Surg. 2013; 39(3 Pt 1): 365-71.
 35. Higgins HW, 2nd, Lee KC, Galan A, Leffell DJ. Melanoma in situ: Part II. Histopathology, treatment, 
and clinical management. J Am Acad Dermatol. 2015; 73(2): 193-203.
Epidemiology of lentigo maligna and lentigo maligna melanoma 119
Supplementary Table 1. Incidence rates (per 100,000 person years) of LM in The Netherlands in males and 
females from 1989-2013, age-standardized to the European standard population (European Standardized 
Rate [ESR]), World standard population 1968 (World Standardized Rate [WSR]), World (WHO 2000-2025) 
standard population (World Standardized Rate [WSR2000-2025]) and US 2000 standard population (United 
States Standardized Rate [USSR])).
Incidence Year Gender ESR WSR WSR2000 USSR
1989 Males 0.68 0.46 0.52 0.71
1990 Males 0.65 0.44 0.49 0.71
1991 Males 0.79 0.56 0.62 0.81
1992 Males 1.13 0.77 0.88 1.17
1993 Males 1.05 0.69 0.81 1.15
1994 Males 1.73 1.17 1.34 1.87
1995 Males 1.65 1.09 1.29 1.83
1996 Males 1.53 1.04 1.20 1.66
1997 Males 2.00 1.34 1.53 2.18
1998 Males 1.85 1.26 1.44 2.00
1999 Males 1.66 1.09 1.26 1.81
2000 Males 1.78 1.18 1.35 1.96
2001 Males 1.62 1.05 1.23 1.81
2002 Males 1.68 1.10 1.30 1.87
2003 Males 1.87 1.23 1.44 2.10
2004 Males 1.73 1.14 1.32 1.92
2005 Males 2.32 1.51 1.76 2.61
2006 Males 2.48 1.64 1.88 2.72
2007 Males 2.73 1.76 2.05 3.09
2008 Males 2.69 1.74 2.04 3.07
2009 Males 2.69 1.82 2.07 2.91
2010 Males 3.16 2.12 2.44 3.46
2011 Males 3.36 2.19 2.54 3.73
2012 Males 3.85 2.54 2.95 4.29
2013 Males 3.57 2.34 2.72 4.00
1989 Females 0.76 0.54 0.60 0.76
1990 Females 0.94 0.69 0.76 0.98
1991 Females 1.19 0.84 0.94 1.21
1992 Females 1.39 0.99 1.09 1.39
1993 Females 1.50 1.05 1.15 1.51
1994 Females 2.22 1.53 1.73 2.33
1995 Females 1.97 1.36 1.54 2.05
1996 Females 1.92 1.33 1.51 2.00
1997 Females 2.05 1.40 1.59 2.19
1998 Females 1.74 1.21 1.37 1.83
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Supplementary Table 1. Incidence rates (per 100,000 person years) of LM in The Netherlands in males and 
females from 1989-2013, age-standardized to the European standard population (European Standardized 
Rate [ESR]), World standard population 1968 (World Standardized Rate [WSR]), World (WHO 2000-2025) 
standard population (World Standardized Rate [WSR2000-2025]) and US 2000 standard population (United 
States Standardized Rate [USSR])). (continued)
Incidence Year Gender ESR WSR WSR2000 USSR
1999 Females 2.25 1.55 1.73 2.27
2000 Females 2.04 1.38 1.56 2.16
2001 Females 2.15 1.47 1.67 2.27
2002 Females 2.23 1.57 1.73 2.25
2003 Females 2.34 1.60 1.80 2.43
2004 Females 2.41 1.67 1.86 2.48
2005 Females 2.57 1.72 1.97 2.70
2006 Females 2.55 1.74 1.96 2.71
2007 Females 2.68 1.82 2.04 2.82
2008 Females 2.75 1.94 2.12 2.80
2009 Females 2.96 2.00 2.25 3.14
2010 Females 3.49 2.38 2.67 3.66
2011 Females 3.48 2.39 2.68 3.66
2012 Females 4.05 2.77 3.11 4.27
2013 Females 4.16 2.82 3.19 4.42
Supplementary table 2. Incidence rates (per 100,000 person years) of LMM in The Netherlands in males 
and females from 1989-2013, age-standardized to the European standard population (European Standard-
ized Rate [ESR]), World standard population 1968 (World Standardized Rate [WSR]), World (WHO 2000-
2025) standard population (World Standardized Rate [WSR2000]) and US 2000 standard population (United 
States Standardized Rate [USSR])).
Incidence Year Gender ESR WSR WSR2000 USSR
1989 Males 0.26 0.18 0.20 0.26
1990 Males 0.23 0.16 0.17 0.22
1991 Males 0.17 0.13 0.14 0.18
1992 Males 0.38 0.25 0.30 0.43
1993 Males 0.31 0.21 0.24 0.34
1994 Males 0.37 0.25 0.28 0.42
1995 Males 0.46 0.30 0.35 0.52
1996 Males 0.27 0.17 0.21 0.33
1997 Males 0.46 0.32 0.35 0.48
1998 Males 0.37 0.23 0.27 0.40
1999 Males 0.43 0.28 0.33 0.50
2000 Males 0.36 0.23 0.27 0.40
2001 Males 0.56 0.37 0.43 0.62
2002 Males 0.62 0.41 0.47 0.70
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Supplementary table 2. Incidence rates (per 100,000 person years) of LMM in The Netherlands in males 
and females from 1989-2013, age-standardized to the European standard population (European Standard-
ized Rate [ESR]), World standard population 1968 (World Standardized Rate [WSR]), World (WHO 2000-
2025) standard population (World Standardized Rate [WSR2000]) and US 2000 standard population (United 
States Standardized Rate [USSR])). (continued)
Incidence Year Gender ESR WSR WSR2000 USSR
2003 Males 0.51 0.31 0.39 0.61
2004 Males 0.49 0.31 0.37 0.57
2005 Males 0.52 0.33 0.40 0.60
2006 Males 0.57 0.38 0.45 0.64
2007 Males 0.49 0.31 0.37 0.58
2008 Males 0.73 0.48 0.56 0.83
2009 Males 0.74 0.48 0.57 0.87
2010 Males 1.03 0.65 0.78 1.20
2011 Males 1.16 0.73 0.87 1.38
2012 Males 1.17 0.75 0.89 1.37
2013 Males 1.25 0.79 0.93 1.46
1989 Females 0.22 0.15 0.17 0.24
1990 Females 0.27 0.19 0.22 0.28
1991 Females 0.22 0.15 0.17 0.22
1992 Females 0.40 0.27 0.31 0.43
1993 Females 0.22 0.15 0.17 0.24
1994 Females 0.38 0.25 0.30 0.42
1995 Females 0.37 0.25 0.29 0.42
1996 Females 0.40 0.27 0.31 0.44
1997 Females 0.46 0.31 0.35 0.49
1998 Females 0.50 0.33 0.39 0.58
1999 Females 0.53 0.36 0.41 0.55
2000 Females 0.51 0.34 0.40 0.60
2001 Females 0.51 0.34 0.39 0.57
2002 Females 0.59 0.41 0.46 0.65
2003 Females 0.48 0.32 0.38 0.54
2004 Females 0.63 0.41 0.48 0.71
2005 Females 0.61 0.42 0.47 0.64
2006 Females 0.61 0.40 0.46 0.65
2007 Females 0.61 0.40 0.46 0.69
2008 Females 0.74 0.50 0.57 0.80
2009 Females 0.74 0.49 0.56 0.84
2010 Females 0.82 0.55 0.62 0.90
2011 Females 1.06 0.70 0.81 1.18
2012 Females 1.29 0.85 1.00 1.45
2013 Females 1.18 0.78 0.89 1.29
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abSTRaCT
background
Although surgery is the recommended treatment for lentigo maligna (LM), it may be less 
desirable for large facial lesions or elderly patients.
Objective
To determine recurrence rates, cosmetic results and patient satisfaction after treatment 
of LM with ablative laser therapy followed by topical imiquimod 5% cream.
Methods
Data were collected from patients with histologically proven LM who had been treated 
with ablative laser therapy followed by imiquimod cream between 2008 and 2014. 
Case records and pathology reports were used to determine histologically proven 
recurrences, cosmetic results (0-10), treatment-related discomfort (0-10) and if patients 
would recommend this treatment to others (yes/no).
Results
Thirty-five patients were identified and evaluated, with a median follow-up time of 19 
(interquartile range [IQR] 13-38) months. Local recurrences were found in six patients, 
two after eight months, one after 12 months, one after 15 months and two after 18 
months follow-up. Five recurrences occurred on the nose. Patients rated the cosmetic 
outcome with a mean score of 8.5 (95% CI, 8.2 to 8.9) and the treatment-related discom-
fort with a mean score of 4.9 (95% CI, 3.9 to 5.9). Ninety percent would recommend this 
treatment to others. None of the patients developed lentigo maligna melanoma.
Conclusions
Ablative laser therapy followed by imiquimod cream is a feasible alternative to surgery 
in patients who are unsuitable for surgical treatment of LM, and on other body sites than 
the nose. Future work should include an analysis of possible differences between LM on 
the nose and other anatomical locations. Until more data are available it is important 
to inform patients about the potential advantages and disadvantages, and it remains 
crucial to follow-up these patients closely.
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InTRODUCTIOn
Lentigo maligna (LM) is the most common subtype of melanoma in situ, with a rapidly 
growing incidence 1, 2. It typically arises in chronically sun-exposed skin of elderly indi-
viduals. Estimates of the lifetime risk of LM progressing to LM melanoma (LMM) vary 
from 2.2 to 4.7% 3. The primary treatment goal is to completely eradicate the lesion 
with prevention of recurrences. Since LM occurs mainly in the head and neck region 4, 
important secondary goals are to minimize functional and cosmetic deformities.
Surgical and non-surgical treatments are available for LM. Although surgical excision is 
the recommended treatment with the lowest recurrence rates 5, it may be less desirable 
in large facial lesions or elderly patients with extensive comorbidities 6, 7. In these cases, 
alternative non-surgical treatments, or even a wait-and-see policy, may be considered 
6, 8-10.
Aiming to find a non-surgical treatment with low recurrence rates and excellent 
cosmetic and functional outcomes, our department has introduced a novel treatment 
combination of ablative laser therapy followed by six weeks of topical imiquimod 5% 
application. In our previous publication we reported the absence of recurrences in 12 
patients after a mean follow-up of 22 months, with good-to-excellent cosmetic results 11.
We have now reviewed 35 patients who were treated in a similar fashion and present 
the recurrence rates and patient satisfaction of this cohort, including the long-term 
follow-up results of the original cohort.
MaTERIaLS anD METHODS
The current investigation involved a retrospective evaluation of the recurrence rates, 
cosmetic results and patient satisfaction after treatment with ablative laser therapy fol-
lowed by topical imiquimod 5% application.
During this treatment, LM lesions were first treated with ablative laser therapy with 
margins of 2-3 cm of adjacent skin to remove the large bulk of atypical melanocytes. The 
epidermis and superficial papillary dermis were ablated with either 2,940 nm erbium-
doped yttrium aluminium garnet (Er:YAG) laser or 10,600 nm CO2 laser. End points of the 
laser treatment were complete pigment clearance and visible punctuate bleeding. After 
laser treatment, patients started daily application of imiquimod 5% cream on the erosive 
skin for five days a week for six weeks. This topical Toll-like receptor 7 and 8 agonist 
induced an inflammatory immune response to clear any residual atypical melanocytes. 
The degree of inflammation was assessed at regular intervals, and depending on the 
local inflammatory reaction the frequency of application was increased to twice daily, 
or reduced to three days a week. Potential flu-like symptoms caused by imiquimod were 
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counteracted by 1 gram of paracetamol 1-2 hours before and 6-8 hours after application 
of imiquimod cream.
All patients with histologically proven LM, who had undergone ablative laser therapy 
followed by imiquimod cream at either the Erasmus University Medical Centre in Rot-
terdam or at DermaTeam Clinic in Middelburg or Vlissingen, between 2008 and 2014, 
were retrospectively identified from our prospectively updated database. All patients 
had declined surgical treatment and were extensively informed about the potential 
advantages and disadvantages of this experimental combination treatment.
Data collected included age, sex, anatomical site of the lesion, histopathological re-
sults, treatment details (laser device, duration and dosing regimen of imiquimod cream), 
follow-up period, biopsies taken after treatment, progression to invasive or metastatic 
melanoma, and disease-related mortality data. Patients who had returned to the care of 
their referring dermatologists were contacted and data were collected.
Patient satisfaction was determined by the cosmetic outcome (0-10, with 10 being 
the best possible cosmetic outcome), treatment-related discomfort (0-10, with 10 being 
the highest degree of discomfort), and whether the patients would recommend this 
treatment to others (yes/no). If this information was not available in the case records, 
patients were contacted by telephone to collect this information.
Statistical analysis
The continuous variables were presented as mean and standard deviation (SD) or me-
dian and interquartile range (IQR). The categorical variables were presented as numbers 
and their corresponding percentages. The risk of recurrence was calculated for different 
time points using a cumulative incidence curve from the cmprsk package from R (http://
cran.r.r-project.org) and the CumIncidence function 12.
RESULTS
Patients
Between 2008 and 2014, 36 patients were identified with histologically proven LM, who 
consented to treatment with ablative laser therapy followed by six weeks treatment 
with imiquimod. One patient was excluded because remaining pigmentation (residue) 
was visible immediately after the (too superficial) laser treatment. He was subsequently 
treated with micrographically controlled staged surgical excision.
Most patients were treated at the Erasmus University Medical Centre in Rotterdam (27 
of 35) and a smaller cohort at the DermaTeam Clinic in Vlissingen (6 of 35) and Middel-
burg (2 of 35). Twelve of the 35 patients were part of the original cohort and described 
in our previous publication 11.
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The demographic details of the study population and treatment details are listed in 
Table 1. Of the 28 primary cases of LM, eight had persistent disease following previ-
ously attempted treatments (two after surgical excision, four after cryotherapy, one after 
monotherapy with topical imiquimod cream and one after electrosurgery and curet-
tage). Of the seven patients with recurrent LM, six were previously treated with surgical 
excision and one with cryotherapy.
Table 1. Patient characteristics and treatment details
35 patients
Sex, n
Male 12
Female 23
age (years), mean (SD) 71 (12)
body site, n
Nose 15
Cheek 12
Frontal area 4
Temporal area 1
Preauricular area 1
Upper lip 1
Leg 1
Cases, n
Primary 28
Recurrent 7
Laser, n
CO2 11
Er:YAG 20
Both 4
Imiquimod
Duration (week), mean 5.7
Intensity (times per week), mean 4.5
follow-up (months), median (IQR)
Original cohort (n = 12) 42 (37-60)
Additional cohort (n = 23) 14 (12-19)
Complete cohort (n = 35) 19 (13-38)
Inflammatory response, n
Yes 35
No 0
Patient satisfaction, mean (95% CI)
Cosmetic result 8.5 (8.2 to 8.9)
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Treatment
All patients responded to imiquimod by developing clear inflammatory reactions. The 
most common adverse reactions to the imiquimod treatment were application site reac-
tions, flu-like symptoms, and general malaise.
Follow-up
Twenty-eight patients had their follow-up at either the Erasmus MC or DermaTeam Clin-
ics and their case records could be evaluated. Five patients were returned to the care of 
their referring dermatologists and follow-up information was collected by telephone. 
There was no additional follow-up information available of two patients from the origi-
nal cohort since last publication. One patient confirmed by telephone that there was 
no new visible pigmentation since treatment, but he declined a visit to the outpatient 
clinic. The other patient had died at the age of 89 years of brain metastases from an 
unknown primary tumour.
The median (IQR) follow-up time of the original cohort of 12 patients was 42 (37-60) 
months. The median (IQR) follow-up time of the 23 additional patients was 14 (12-19) 
months. When we combined all patients (n=35) we calculated a median (IQR) follow-up 
time of 19 (13-38) months.
Response to treatment
We found local, histologically confirmed recurrences in six patients. After one year 
of follow-up (number at risk = 28) there had been three recurrences (two after eight 
months, one after 12 months), and the cumulative incidence of recurrence was 9.4% 
(95% confidence interval [CI], 2.3 - 22.6%). After two years of follow-up (number at risk 
= 13) there had been an additional three recurrences (one after 15 months, two after 18 
months) and the cumulative incidence of recurrence was 23.5% (95% CI, 8.9 - 42.0%). 
Table 1. Patient characteristics and treatment details (continued)
35 patients
Treatment discomfort 4.9 (3.9 to 5.9)
Recommendation to others, % (n = 31)
Yes 90
No 10
Cumulative incidence of recurrence, % (95% CI)
After one year 9.4 (2.3 to 22.6)
After two years 23.5 (8.9 to 42.0)
After three years 23.5 (8.9 to 42.0)
Er:YAG, erbium yttrium aluminium garnet; IQR, interquartile range; CI, confidence interval.
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After three years follow-up (number at risk = 11) there had been no additional recur-
rences and the cumulative incidence of recurrence remained 23.5% (95% CI, 8.9 - 42.0%).
Five of the recurrences were located on the nose (out of the 15 patients with LM on the 
nose) and one of the recurrences was located on the cheek (out of the 12 patients with 
LM on the cheek). No recurrences occurred on other anatomical locations. The recur-
rences were treated as follows; one patient was treated with ablative laser therapy and 
imiquimod for a second time, two patients chose micrographically controlled staged 
surgical excision, one patient received wide local excision and two patients were treated 
with an excisional biopsy, of which one followed by topical imiquimod application for 
six weeks. None of the patients in our cohort developed LMM.
Because of visible pigmentation, biopsies were taken from an additional two patients 
of the extended cohort during follow-up. Histopathological analysis showed a cyst and 
scar tissue. No atypical melanocytes were seen.
Patient satisfaction
Information on patient satisfaction was available for 89% of patients (31 of 35). Patients 
rated the cosmetic outcome with a mean score of 8.5 (95% CI, 8.2 to 8.9) (Fig. 1) and 
treatment-related discomfort with a mean score of 4.9 (95% CI, 3.9 to 5.9). Ninety percent 
would recommend this treatment to other patients with LM. One patient developed 
an ectropion of the left lower eyelid after treatment of LM on the left cheek including 
figure 1. Examples of the cosmetic outcome after ablative laser therapy followed by imiquimod for LM 
unsuitable for surgical excision; (a) before treatment and (b) six months after treatment, (c) before treat-
ment and (d) 13 months after treatment.
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the lower eyelid. The ectropion did not occur until one year after the superficial Er:YAG 
laser treatment. Therefore we do not suspect any causality. None of the other patients 
developed functional deformities.
DISCUSSIOn
Since our previous publication on 12 LM patients who were treated with ablative laser 
therapy followed by imiquimod cream, we have extended our cohort with an additional 
23 patients. With this larger patient number, in combination with the long-term follow-
up time of the original cohort, we now present a more accurate representation of the 
recurrence rate, cosmetic results, and patient satisfaction.
A possible explanation of recurrences after non-surgical treatments may be incomplete 
clearance of atypical melanocytes extending down into the pilosebaceous units (PSU) 
13. Because of the substantial possibility of sampling error and possible compromise 
of the cosmetic result, we decided not to obtain biopsies for microscopic assessment 
after treatment. Therefore, we do not have histopathological evidence that all atypical 
melanocytes are in fact removed, and any residual atypical melanocytes may have led 
to recurrences.
The development of a clinical inflammatory response during imiquimod treatment 
is described as a strong prognostic feature for effective treatment 14. Because the epi-
dermis and reticular dermis are removed by the ablative laser, deeper penetration of 
imiquimod is enabled and it is delivered closer to its target cell (the dermal dendritic 
cell). We observed a strong inflammatory response in 100% of our patients, in contrast 
to imiquimod monotherapy where there are also non-responders (14-31%) 14,15. The 
inflammatory reaction and adverse effects of imiquimod accounted for much of the 
perceived treatment-related discomfort in our cohort. Imiquimod cream applications 
caused stinging and were experienced as painful by most patients.
A recent review on other non-surgical treatments for LM reports mean recurrence 
rates of 11.5% for radiotherapy (up to 31%), 24.5% for topical imiquimod (up to 50%) 
and 34.4% for laser therapy (up to 100%), after variable follow-up durations 8. Combin-
ing ablative laser therapy with imiquimod seems to result in lower recurrence rates 
than both treatments alone. Future work should focus on a randomized controlled trial 
comparing these different second line, non-surgical treatments for LM.
A potential disadvantage of non-surgical treatments is the inherent lack of histo-
pathological control. Without histopathological control, possible misdiagnosed LMM 
cannot be assessed. Hazan et al. 15 found that after excision, 16% of the LM diagnosed 
initially on biopsy had an unrecognized component of dermal invasive melanoma. 
Lower percentages have been reported by Abdelmalek et al. 16 (11.7%) and Iorizzo et al. 
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17 (8.1%). Among our surgical patients we recently found LMM in 4% (4/100) of the LM 
previously diagnosed on biopsy 18. This lower percentage may be due to the fact that our 
pathologists section and examine the complete excision biopsies to rule out LMM. We 
recommend that non-surgical treatment for LM is only considered when the lesions are 
clinically unsuspicious for LMM, that (multiple) biopsies are taken from the darkest (or 
palpable) parts of the lesion for diagnostic purposes and that the excision biopsies are 
sectioned and examined completely.
Since LM mainly occurs in the head and neck region, cosmetic and functional out-
comes play an important role in patients’ satisfaction. The patients in our cohort rated 
the cosmetic outcome with an 8.5 of 10, while surgical treatment at our department has 
an average score of 7.8 of 10 18. The fact that this difference is lower than expected may 
be explained by the patients’ expectations before treatment and our subjective assess-
ment method. For example, patients who refuse surgical treatment are often more con-
cerned about undesirable cosmetic outcomes and may weigh any imperfect outcome 
more severely. On the other hand, patients who underwent surgical excision may be 
expecting a number of negative effects including scarring. If the cosmetic impact is less 
than expected, they might be inclined to inflate a positive evaluation.
The treatment-related discomfort was scored as moderate. The inflammatory reaction 
and side effects of imiquimod cream account for much of the perceived treatment-
related discomfort. Because of pre-treatment with the ablative laser we have chosen a 
shorter treatment duration of imiquimod (six weeks) than described in other literature 
19, which may reduce the discomfort and burden for patients.
A limitation of this study is its retrospective design. A prospective randomized con-
trolled trial (RCT) comparing our combination treatment to surgical excision or to other 
non-surgical treatments could provide better evidence and optimize treatment choice. 
However, in this extended cohort, we have collected relevant information about our 
experimental combination treatment. This has raised new questions about possible dif-
ferences in recurrence risk for different anatomic locations. These questions should first 
be addressed. We are aware that availability of ablative laser therapy may be a limiting 
factor and that the costs of this treatment may be relatively high. Therefore, in addition 
to the recurrence rate and cosmetic outcome, future studies should also include a cost-
effectiveness analysis.
In summary, we conclude that combined treatment of LM with ablative laser therapy 
followed by topical imiquimod cream is a feasible alternative to surgery in patients who 
decline or are unsuitable for surgical treatment, and on other body sites than the nose. 
The major advantages are the cosmetic and functional outcomes. Until more data are 
available it is important to inform patients about the potential advantages and disad-
vantages, and it remains crucial to follow-up these patients closely.
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abSTRaCT
background
A higher incidence of lentigo maligna (LM) recurrences on the nose was previously 
observed in our cohort after non-surgical treatment.
Objectives
To determine histological parameters that might be related to the previously observed 
higher incidence of LM recurrences on the nose after non-surgical treatment.
Methods
We randomly selected 22 surgical specimens of LM on the nose and 22 on the cheek. 
Histopathological analysis was performed on hematoxylin and eosin and microphthal-
mia transcription factor immunohistochemically stained slides. The number of pilose-
baceous units (PSU) per mm, maximum depth of atypical melanocytes along the skin 
appendages, and maximum depth of the PSU itself were determined.
Results
The nose had a significantly higher density of PSU than the cheek. The atypical melano-
cytes extended deeper along the PSU on the nose with a mean (SD) depth of 1.29 mm 
(0.48) vs. a mean depth of 0.72 mm (0.30) on the cheek (P < 0.001). The maximum depth 
of the PSU on the nose was greater than on the cheek, mean (SD) depth of 2.28 mm 
(0.41) vs. 1.65 mm (0.82) (P = 0.003).
Conclusions
The higher recurrence risk of LM on the nose after non-surgical treatment that we 
previously observed in our cohort is most likely based on a higher density of atypical 
melanocytes and also their deeper extension into the follicles. These results shed more 
light on our previous findings and learn that anatomical location is relevant for the risk 
of recurrence of LM after non-surgical treatment.
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InTRODUCTIOn
Lentigo Maligna (LM) is a subtype of melanoma in situ, and although surgical excision is 
the treatment of first choice, non-surgical treatment options are gaining more interest 
1-3. Deciding on the best individual treatment can be guided by the age of the patient, 
comorbidities, size and location of the lesion.
In a previous publication, we introduced a non-surgical combination treatment of ab-
lative laser therapy followed by topical application of imiquimod 5% cream 4. Recently, 
we found six local recurrences in our cohort of 35 patients 5. Five of the six recurrences 
occurred on the nose (out of a total of 15 treated LM on the nose).
We argue that the following factors may contribute to a higher risk of LM recurrence 
on the nose after non-surgical treatment than on other anatomic locations. First, the 
downward extension of atypical melanocytes along the pilosebaceous units (PSU) may 
be an important factor. Non-surgical treatments mainly target the epidermis, while 
atypical melanocytes residing along the PSU may not be completely cleared. It is known 
that the atypical melanocytes of melanomas in the head and neck region tend to extend 
much deeper along the hair follicles than in other regions 6. However, there are currently 
no data available for LM comparing the depth of atypical melanocytes along the PSU for 
different facial regions, or the nose in particular. Second, the density of the PSU may be 
highly relevant. It is known that the PSU density varies for different anatomic locations, 
with the nose having the highest follicle density of the body 7, 8. We hypothesize that 
the recurrence risk of LM after non-surgical treatment may be higher for the nose than 
for other facial regions, because of a higher PSU density that may harbour a consider-
ably greater load of atypical melanocytes in deeper parts of the appendages. Third, the 
maximum depth of the PSU itself may be of importance since this allows the atypical 
melanocytes to penetrate even deeper.
The aims of our study were to determine whether the PSU density, the maximum 
downward extension of atypical melanocytes along the PSU, and the maximum depth 
of the PSU itself differed between LM on the nose and LM on the cheek.
MaTERIaLS anD METHODS
Patient selection
Data on all patients who had undergone staged surgical excision for primary LM on the 
nose or cheek (most common location of LM) at the Erasmus Medical Center between 
January 2001 and December 2015 were obtained using Sympathy 2.8, a program of our 
pathology department that is linked to PALGA (Dutch Pathology Registry).
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Inclusion and exclusion criteria
Exclusion criteria were: unavailability of the slides and corresponding formalin-fixed par-
affin embedded (FFPE) tissue blocks, and presence of invasive melanoma. We decided to 
only use excision specimens and exclude (small) diagnostic biopsies to obtain adequate 
material for a thorough analysis and an accurate measurement of our study parameters.
SPSS Statistics 21 was used to perform random number selection and the patient 
numbers were put in a random order. Two lists were created, one for the nose and one 
for the cheek.
The corresponding surgical specimens were collected and eligibility for inclusion was 
determined starting at the top of each list, until 22 samples of each group were included 
(based on the sample size calculation below). Eligibility was based on histopathological 
review of hematoxylin and eosin (HE) stained slides of the surgical specimens, acquired 
from the pathology archive of the Erasmus MC. Specimens were not eligible if slides 
were cut tangential, or if there was a high presence of scar tissue (causing loss of PSU). 
A central slide was selected from each surgical specimen. For some slides, there was 
no tissue left in the corresponding FFPE block, or there was no LM left after cutting the 
initial HE slides. Those samples had to be excluded as well, because they could not be 
used for immunohistochemical staining.
Histopathological analysis
Blanc slides were cut from the selected corresponding FFPE blocks at 4μm, deparaf-
finized and immunohistochemically stained for microphthalmia transcription factor 
(MITF; mouse monoclonal, Ventana, clone C5/D5, 790-4367 (ready to use)), using the 
Ventana Benchmark Ultra stainer (Ventana Medical Systems,Tucson, AZ, USA). The stain-
ing procedure included pre-treatment with CC1 (Cell Conditioner 1, pH8,4) at 95 °C for 
64 minutes, followed by primary antibody incubation at 36 °C for 16 minutes. Staining 
was visualized using the Ventana Ultraview Universal Alkaline Phosphatase Red Detec-
tion Kit (760-501). The Ventana Amplification Kit (760-080) was used, counterstaining 
was performed with hematoxylin. Normal skin was used as a positive control. MITF is 
a nuclear stain specific for melanocytes, and the most useful immunohistochemical 
staining to detect single epidermal melanocytes 9. With MITF, the nuclear polymorphism 
of melanocytes, which is characteristic for LM, can be demonstrated as well, and these 
atypical melanocytes can be distinguished from the small pre-existent melanocytes 
found in the hair follicle, especially those in the hair bulb.
Study outcomes
The following parameters were scored: number of PSU per epidermal mm, maximum 
depth of downward extension of atypical melanocytes along the skin appendages, and 
maximum depth of the PSU itself.
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As the discrimination between vellus, indeterminate and terminal hairs is sometimes 
difficult because of the one level view of the slides, and as LM extends down into both 
vellus and deeper hair follicles, this distinction was not made. The total number of PSU, 
based on the presence of at least a part of the pilosebaceous unit (i.e. infundibulum, 
isthmus, bulb or sebaceous glands assumed to belong to one PSU) was scored. The num-
ber of PSU was then calculated per linear mm epidermis in one horizontal dimension. We 
also measured the deepest point of any of the PSU, and the maximum depth of atypical 
melanocytes along the skin appendages from the granular layer. If the extension was 
deeper in an appendage other than a PSU (i.e. sweat gland in one case), then this was 
counted as the maximum depth.
Statistical analysis
A sample size of 22 patients per group was estimated to provide 80% power to detect a 
difference in density of approximately 600 follicles (per cm2) 8, and an estimated differ-
ence of ± 0.6 mm (SD 0.7 mm) in depth of atypical melanocytes along the PSU and depth 
of the PSU itself, with a two-sided type I error level of 5%. A t-test for unpaired samples 
was used. To provide enough statistical power for all endpoints the largest group size 
was chosen.
Normality of the variables was tested using a Shapiro-Wilk test. Data that were normally 
distributed were summarized with means and standard deviations (SD), and data that 
were not normally distributed, with medians and interquartile ranges (IQR). Differences 
between the nose and cheek group for normally distributed variables were analysed 
using a t-test for independent samples, and for not normally distributed variables using 
a Mann-Whitney U test.
To calculate the relative extension of atypical melanocytes down the PSU, the exten-
sion of atypical melanocytes along the PSU was divided by the depth of the PSU itself. 
P-values less than or equal to 0.05 were considered statistically significant. Additional 
false discovery rate control did not require significance level adjustment 10. Statistical 
analysis of data was performed using SPSS Statistics 21.
RESULTS
Between January 2001 and December 2015, 122 patients were diagnosed with an LM on 
the nose and 315 with LM on the cheek. Of the 122 LM on the nose, 54 slides or blocks 
were unavailable, 13 had an invasive component, and 16 were biopsies. Of the 315 LM 
on the cheek, 103 slides or blocks were unavailable, 23 had an invasive component and 
58 were biopsies. After exclusion of these cases, eligibility was assessed until 44 LM cases 
were randomly selected; 22 located on the nose and 22 located on the cheek.
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The mean (SD) age in the nose group was 76 (14) years and in the cheek group 73 (13) 
years. Gender distribution in the nose group was 14 female, eight male; and in the cheek 
group 15 female and seven male.
Number of PSU per mm (density)
The median number of PSU was significantly higher on the nose than on the cheek 
(Table 1).
Maximum depth of atypical melanocytes along the PSU
The mean maximum depth of atypical melanocytes along the PSU was greater on the 
nose than on the cheek (Table 1), with a mean nose vs. cheek difference of 0.57 mm (95% 
CI, 0.33 to 0.82).
Maximum depth of PSU
The mean maximum depth of the PSU itself was greater on the nose than on the cheek 
(Table 1), with a mean nose vs. cheek difference of 0.63 mm (95% CI, 0.23 to 1.03).
The atypical melanocytes extended, on average, 57% down the PSU on the nose and 
49% down the PSU on the cheek (nose vs. cheek difference, 8% [95% CI, -5 to 20]; P = 
0.237).
Figures 1-4 show histological images of HE and MITF stains of the downward extension 
of atypical melanocytes along the PSU and an example of occasional extension along 
sweat glands.
Table 1. Differences between the nose and the cheek.
Variables nose Cheek P-value
Number of PSU/mm 
(median (IQR))
1.84/mm (1.53 – 2.63) 1.45/mm (1.07 – 1.64) 0.001
Maximum downward 
extension of atypical 
melanocytes along the 
PSU (mean (SD))
1.29 mm (0.48) 0.72 mm (0.30) < 0.001
Maximum depth of PSU 
itself (mean (SD))
2.28 mm (0.41) 1.65 mm (0.82) 0.003
PSU; pilosebaceous units, IQR; interquartile range, SD; standard deviation.
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figure 1. Lentigo maligna; continuous proliferation of atypical melanocytes along the dermo-epidermal 
junction. Clear extension downward, along the hair follicle is shown. In the background, severe solar elas-
tosis. Arrows point out atypical melanocytes (HE 100x).
figure 2. Very deep extension along pilosebaceous units. Arrows point out atypical melanocytes (HE 50x).
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figure 3 (a,b). Microphthalmia transcription factor (MITF) immunohistochemistry, emphasizing the num-
ber of continuous atypical melanocytes extending downward. The positive staining cells in the stroma are 
macrophages. (a) MITF 50x, (b) MITF 100x.
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DISCUSSIOn
Our study shows that both the density of the PSU, and the maximum downward exten-
sion of atypical melanocytes along the PSU are higher on the nose than on the cheek. 
This results in a considerably higher load of atypical melanocytes in deeper parts of the 
appendages, and may explain why LM recurrences occurred almost exclusively on the 
nose after our non-surgical treatment method 5.
The maximum absolute depth of the PSU itself was found to be greater on the nose 
than the cheek, while we did not find a statistically significant difference in the ratio of 
extension of atypical melanocytes down the PSU between the nose and the cheek. This 
suggests that the melanocytes extended deeper on the nose than the cheek, simply 
because the PSU are deeper on the nose, and that there seems to be no intrinsic differ-
ence in behaviour of atypical melanocytes between these two sites.
To the best of our knowledge, anatomic location has not yet been evaluated as a 
potential prognostic factor for recurrences of LM after non-surgical treatments. Gautschi 
et al. assessed the maximal epidermal depth of the melanocytes (this was usually the 
maximal depth along the hair follicle), as well as follicle involvement (affected vs. not af-
fected) as potential risk factors for LM recurrence after imiquimod monotherapy, but did 
not find statistically significant differences 11. However, the authors did not specify the 
different anatomical facial regions (only ‘head’ or ‘other locations’), which could explain 
figure 4. Microphthalmia transcription factor (MITF) immunohistochemistry. In one of the samples the 
downward growth along the sweat glands was even deeper than along the pilosebaceous units (MITF 
100x).
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the difference with the results found in this study. A factor that is considered to be a 
strong predictor of LM recurrence is melanocyte count 11, 12, which is in accordance with 
the higher ‘load’ of atypical melanocytes we found in this study, although we did not 
measure melanocyte count specifically. Powell et al. reported that the development of 
an inflammatory reaction to imiquimod was a strong predictor of therapeutic benefit, 
but did not find any histological features of prognostic significance 13. Mora et al. found 
that cumulative dose and treatment intensity of imiquimod monotherapy was associ-
ated with tumour clearance 14. Unfortunately, specific anatomic locations (e.g. the nose) 
are not mentioned in these previous publications.
A higher risk of recurrence on the nose after non-surgical treatment may influence 
the choice of treatment for this location. Either a surgical treatment can be chosen, 
which remains the treatment of first choice for LM, or in specific cases, considering the 
good cosmetic and functional outcomes of non-surgical treatments, the latter should 
be adapted for this location. In case of our combined ablative laser therapy followed by 
topical imiquimod cream, both the laser and imiquimod treatment protocols could be 
adapted.
Two types of ablative lasers are generally used, the erbium-doped yttrium aluminium 
garnet (Er:YAG) laser (2,940 nm) and the carbon dioxide (CO2) laser (10,600 nm), both 
of which have been used to treat LM in our study population. The Er:YAG laser removes 
approximately 15-25 µm per pass, and the CO2 laser approximately 100-150 µm per pass 
15, 16. On the nose, we found a mean maximum depth of atypical melanocytes extending 
along the PSU of 1.29 mm. To reach this depth, approximately ten passes of the CO2 
laser are needed, and many more using the Er:YAG laser, which in addition would be 
hampered by bleeding because there is less coagulation with this type of laser 17, 18. The 
CO2 laser would be more efficacious in removing a higher load of atypical melanocytes 
and has good coagulation enabling deeper ablation without bleeding complications. 
For these reasons, we propose to use the CO2 laser as ablative laser for the treatment 
of LM located on the nose. However, this has to be further validated in future studies. 
Passes should be applied until all visible pigment has been cleared, keeping in mind that 
scarring should be prevented.
Mora et al. showed that cumulative dose (>60 total applications) and treatment inten-
sity (>5 applications per week) of imiquimod as monotherapy affects tumor clearance 14. 
The findings of Kirtschig et al. also suggest that a higher treatment intensity of daily ap-
plications for 12 weeks may improve the efficacy of imiquimod 19. It should be taken into 
account that prolonged imiquimod treatment will significantly enhance the patients’ 
discomfort. In our treatment protocol, we therefore reduced imiquimod applications 
to 6 weeks (five times per week), because the major part of the LM melanocytes were 
removed by laser ablation. Also, since the epidermis and reticular dermis are removed, 
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deeper penetration of imiquimod is enabled and it is delivered closer to the target cells 
(the dermal dendritic cells).
Based on the findings with imiquimod monotherapy, it is conceivable that extending 
the duration of imiquimod treatment would achieve better tumour clearance, and this 
may be considered for LM on the nose, in case too many laser passes are expected to 
lead to a high risk of scarring.
A limitation of our study is that we could only revise vertical but not horizontal sec-
tions, because the surgical materials were treated according to the standard protocols 
with respect to examining LM and resection margins. Therefore, we are limited to a one-
dimensional quantification of the PSU density. Also, with our method we were limited to 
two-dimensional sections, while sometimes stereology or confocal laser scanning can 
be used to estimate three-dimensional characteristics and allow for better understand-
ing of the distribution 20, 21. However, since the aim of our study was to find a difference 
between the nose and cheek regions, and both were measured in a similar way, this 
would not have influenced our conclusions. Another limitation is the use of a different 
population to determine the histological parameters (surgical patients) than the cohort 
on which our hypothesis was based (laser and imiquimod patients).
In summary, we conclude that the higher recurrence risk of LM on the nose after non-
surgical treatment is most likely based on the higher load of atypical melanocytes in 
deeper parts of the appendages. This higher load is a result of a higher PSU density on 
the nose, a deeper follicular extension of atypical melanocytes and a greater absolute 
depth of the PSU. This should be taken into account when making a choice of treatment 
for this specific location.
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abSTRaCT
background
Lentigo maligna (LM) is a slowly growing melanoma in situ. Current guidelines advise 
wide local excision with a margin of 5 mm as the treatment of first choice, which has 
recurrence rates ranging from 6% to 20%.
Objective
To determine retrospectively the recurrence rate of LM after staged surgical excision.
Methods
Records of all patients with LM treated with our method of staged surgical excision 
between 2002 and 2011 were retrieved. To identify recurrences, we used the computer 
program Sympathy®, which is linked to PALGA, a nationwide network and registry of 
histopathology and cytopathology in the Netherlands.
Results
We identified 100 patients, who were treated with staged surgical excision with 100% 
immunohistopathological control of lateral margins. Digital pictures were used to fa-
cilitate orientation during the several stages of surgery. After a mean follow-up of 60 
months, four patients had a recurrence, after 37, 58, 74 and 77 months of follow-up.
Conclusion
Staged surgical excision is superior in clearance and recurrence rates to wide local 
excision for LM and should be considered as treatment of first choice in national and 
international guidelines.
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InTRODUCTIOn
Lentigo maligna (LM) is a melanoma in situ clinically characterized by a slowly growing 
pigmented macular lesion on sun-exposed skin, most commonly in the face. The inci-
dence increases with age, reaching 5 per 100,000 in the 45-64-year-old age group 1, 2. For 
individuals aged > 65 years, the incidence is about 23 per 100,000 1, 2. Lentigo maligna is 
an epidermal lesion. When atypical melanocytes have invaded the dermis, the lesion has 
progressed to LM melanoma (LMM). As LM is regarded as melanoma in situ, treatment is 
usually recommended.
The treatment of first choice, according to the current guidelines, is wide local excision 
3, 4. However, clinical margins are often difficult to delineate, and wide local excision with 
a margin of 5 mm is often inadequate, with clearance rates ranging from 24% to 70% 
of cases and recurrence rates ranging from 6 to 20% 5, 6. Therefore, several methods for 
staged surgical excision (SSE) have been used. Also, some surgeons have used Mohs 
micrographic surgery (MMS) to treat LM, or have modified this technique and used 
permanent sections, a technique referred to as ‘slow Mohs’.
We analysed our results after ten years’ experience with a modified method of SSE 
with paraffin-embedded histological sections, allowing for standard haematoxylin and 
eosin and immunohistological examinations, and compared our results with previously 
published data on SSE methods and MMS.
MaTERIaLS anD METHODS
Inclusion of patients
Records of all patients diagnosed with LM between 2002 and 2011 were retrieved from 
our Electronic Health Record system. The correspondence to general practitioners was 
searched for the terms ‘lentigo maligna’, ‘Hutchinson’s melanotic freckle’, ‘Dubreuilh’ and 
‘melanosis precancerosa’. The files were reviewed and all patients treated with SSE were 
included.
Surgical procedure
In all patients the diagnosis of LM was made by microscopic examination of histological 
sections from at least one diagnostic biopsy by a dermatopathologist. After confirma-
tion of the diagnosis, SSE was performed. Immediately prior to excision, the lesion 
was marked with a margin of 3 mm (Fig. 1). This relatively small margin was chosen to 
conserve as much tissue as possible.
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In general, no Wood’s lamp was used to delineate subclinical margins prior to the first 
excision. Subsequently, the marked area was excised and pinned on a piece of card-
board, marked and oriented according to the in vivo orientation (Fig. 2).
figure 1: Markings on the skin immediately prior to the first stage of excision.
figure 2: The excised material is pinned on a piece of cardboard, marked and oriented according to the 
in vivo orientation.
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Stitches were used to maintain the in vivo orientation. Also, pictures were taken from the 
wound and the excised skin on the cardboard to help maintain orientation. The resulting 
skin defects were not closed, but covered instead with non-adherent bandages (Fig. 3).
The margins were examined histologically by one of our three dermatopathologists 
within one week. Instead of examination by conventional vertical ‘bread-loaf’ sectioning 
through the material, strips of skin along the surgical margins of the resected specimen 
were separated from the central portion, fixed in formalin and embedded in paraffin. 
Sections of tissue were cut from each of the peripheral margins in a direction parallel to 
the margin, and stained with hematoxylin and eosin, for en face margin assessment of 
lateral margins. Slides were also stained using S100 and MelanA stains. In this way 100% 
of the lateral margins could be examined (Fig 4).
Although LM is an epidermal lesion, the central portion of the specimen, including the 
deep margin, was examined using conventional serial vertical sections (‘bread-loaf’ 
sectioning) in order to exclude invasive melanoma (i.e. LMM).
After a week, patients returned to our department. If any residual LM was found upon 
histological examination of the margins, an additional 5 mm of tissue was excised at that 
specific location where the LM was seen. The pictures taken during the first excision facili-
tated orientation. After excision of the additional tissue, the wound was photographed 
figure 3: The resulting skin defect is covered with non-adherent bandages. Stitches are used both to keep 
bandages in place and to maintain orientation during the week the patient is sent home. If any residual LM 
is found during histopathological examination, an additional 5 mm of tissue is excised at the specific loca-
tion where the LM was seen.
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again and then covered with non-adherent bandages for another week. This procedure 
was repeated until all margins were free of LM and subsequently closed. Generally, no 
prophylactic antibiotics were prescribed during or in between surgery sessions.
Most patients were seen for follow-up after three months, and if there were no prob-
lems the patients were discharged and were followed up by their referring physicians/
dermatologists.
Evaluation of recurrences
Most patients returned to their referring dermatologist for follow-up after treatment. 
Therefore, we used Sympathy 2.8, a program of our pathology department that is linked 
to PALGA, a nationwide network and registry of histopathology and cytopathology in 
the Netherlands, to search for any biopsies taken from the same patient because of 
suspicion of a LM in the time period after the procedure, in order to assess recurrence 
rates. If a patient had died in the period between surgical treatment and the moment 
Excision of the lesion.
Conventional ‘bread loaf’ sectioning of the central part to exclude lentigo maligna melanoma.
Sections cut parallel to surgical margins, with in this case a second round needed A-B.
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figure 4: Sectioning and visualization of peripheral margins and central portion of the lesion.
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we searched in the Sympathy database, the period between surgical treatment and date 
of death was used as the follow-up period. In these cases, the cause of death was noted.
Patient satisfaction
During evaluation of the results of our procedure, we contacted a random sample of 
one in three patients who had undergone SSE at our department. We questioned them 
about their satisfaction with the procedure and the cosmetic results, and asked them to 
rate this with a score from 0 to 10.
RESULTS
Patient archives from our electronic health record system were searched for patients 
with a histopathologically proven LM treated with our method for SSE. Using these cri-
teria we found 100 patients. In addition, we found 17 patients with clinically diagnosed 
LM that proved to be LMM on biopsy, who were also treated using our method for SSE 
described above (Table 1). These patients were not included in our results.
Of the 100 patients with LM, 42 patients were male and 58 patients were female. All 
but three lesions were located on the face or scalp. The mean size of the lesion (larg-
est diameter) was 20.1 mm (range 4 - 50 mm, eight data missing). Twelve patients 
were referred to our department with a recurrent LM, while the other 88 patients had 
primary disease. Five patients had LM in the diagnostic biopsy, but LMM was found in 
the excision material (with Breslow thicknesses of 0.35 mm, 0.5 mm, 0.7 mm, 0.9 mm 
and 1.4 mm). As decision for surgical treatment was based on the biopsy, we included 
Table 1. Staged surgical excision for lentigo maligna melanoma
Total number of patients 17
Male/female ratio 4/13
Primary disease/recurrent disease 3/14
Breslow thickness on biopsy, range 0.46-2.53 mm
Size of lesion at baseline (largest diameter), mean (range) 23.75 mm (6-50 mm)*
Breslow thickness after excision, range 0.4-2.5 mm
Rounds needed to achieve free margins, mean (range) 1.9 (1-5 rounds)
Number of recurrences 0
Complications Infraorbital lymphedema (n = 1)
Revision of scar after healing (n = 3)
Mean follow-up 58 months (4.8 years)
*Data on one patient missing.
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these patients in our study. After the first round, 49 lesions (49%) had free margins. This 
relatively low clearance rate after the first round may be due to the fact we chose 3 mm 
as the first margin, especially in areas were the cosmetic and functional outcome is very 
important. A second round was needed to achieve free margins in 39 patients (39%) and 
a third round in nine patients (9%). Three patients (3%) had free margins after a fourth 
round (Table 2).
Several patients had complications after surgery. Nine had a wound infection which 
needed treatment with oral antibiotics. Two patients had post-surgical bleeding. In 
one patient, the excised material was erroneously sectioned using the conventional 
bread-loafing technique without en face margin assessment of the lateral margins. 
Consequently, another round was needed to ensure complete removal of LM. In one 
patient, the temporal branch of the facial nerve was damaged leading to impairment 
of the frontalis muscle. Two patients developed mild lymphoedema of the cheek for 
which lymph drainage was started. Three patients developed ectropion. In addition, in 
18 patients the scar was considered suboptimal due to thickening, trapdoor deformity, 
colour mismatch between graft and surrounding skin or functional impairment. Of 
these, 12 underwent scar revision or were referred to a plastic surgeon. Four patients 
had visible terminal hairs in their grafts or reconstruction flap, which were eliminated 
using laser hair removal.
The mean follow-up was 60 months (5 years). In this period, four patients had a recur-
rence, after 37, 58, 74 and 77 months. In these patients, LM was located in the temporal 
area (one patient) or on the cheek (three patients). One patient had recurrent disease 
on presentation at our department, and the other three had primary disease. All four 
patients with a recurrence had LM on biopsy and did not have an invasive melanoma in 
the excision specimen. Six patients had died from other causes in the period between 
surgical treatment and the time we searched in the Sympathy database.
The interviewed patients rated their satisfaction with the procedure with a mean 
score of 7.8 out of 10 and the cosmetic end result also with a mean score of 7.8 out of 10.
Table 2. Number of stages and cumulative margin needed to achieve free margins.
Number of stages Cumulative margin (mm) Percentage of free margins
1 3 mm 49
2 8 mm 88
3 13 mm 97
4 18 mm 100
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DISCUSSIOn
In our series, the recurrence rate of LM after SSE with a 100% immunohistopathological 
control of the peripheral margins was four out of 100. Using our technique, the lateral 
margins were examined for a full 100% control. Deep, central margins were examined 
using conventional vertical sections. As LM is an epidermal disorder we did not expect 
the deep margin to contain tumour. However, examination of the central portion of the 
lesion remains important, as several authors found that some lesions had to be upstaged 
to invasive melanoma based on the excision specimen. Abdelmalek et al. reported that 
11.7% of lesions that were diagnosed as LM had an invasive component that was dis-
covered after the excisionn7. Iorizzo et al. found that 8.1% of LM and melanoma in situ, 
diagnosed on biopsy, were invasive melanoma after examination of excision specimen 
8. In our series, five out of 100 lesions (5%) diagnosed as LM were diagnosed as LMM 
after excision. This number is lower than reported in literature. One explanation for this 
finding may be that, in the diagnostic work-up of LM, our pathologists usually section 
the whole biopsy to search for an invasive component.
By using the Sympathy program to identify recurrences, we could find only recurrences 
that were proven histologically. Patients who develop LM are typically elderly. Therefore, 
some patients with recurrences may not have visited their dermatologist or could have 
been treated by any physician using alternative treatments such as cryotherapy or local 
treatment with imiquimod. Also, if patients moved abroad, histopathological examina-
tion of a recurrence is not listed in the database we used, which is linked to a Dutch 
national database. Therefore, our recurrence rate may be somewhat underestimated.
We compared our results to previously published data on other surgical techniques. 
Wide local excision showed relatively low clearance and high recurrence rates that may 
be explained by the presence of subclinical (for the naked eye invisible) areas with atypi-
cal melanocytes, and lack of 100% histopathological margin control 5, 6. Several methods 
have been described to achieve more thorough histological examination, including 
MMS with frozen sections, MMS with paraffin sections (‘slow Mohs’) and several types of 
SSE. Staged surgical excision uses paraffin-embedded, permanent sections for histologi-
cal evaluation of the margins. Final closure is delayed until free margins are achieved.
Several different methods of SSE are available. In the square method, a square is drawn 
around the lesion and the presumed adequate margin. Two parallel blades are used to 
excise the square perimeter, and the excised tissue is sectioned en face. After achieving 
free margins the central portion is excised and subsequently examined conventionally. 
Some tissue has to be sacrificed with this method, especially for large lesions. Therefore, 
some surgeons excise the entire lesion in a geometric (for example triangle, rectangle, 
hexagon) fashion, or use the spaghetti technique to match the contour of the lesion. 
Cut-off strips from the margins are then oriented and processed for en face margin 
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examination. Permanent sections or rush permanent sections can be used. The central 
portion can be left in place until free margins are achieved, or, during the first step the 
tumour and margins can be excised en bloc. Leaving the central portion in place until 
free margins are achieved has the advantage that the wound can be closed during the 
subsequent rounds of the procedure. However, staging of the tumour is only done after 
the last round. The deep portion can be sectioned using the conventional ‘bread-loaf’ 
technique, or by horizontal sections 6.
For SSE where en face sections were used, recurrence rates ranged from 0% to 9.7% 
after mean follow-up periods of 4.7 - 96 months 6. Recently, Abdelmalek et al. reported 
a 1.7% (four of 239) recurrence rate after a mean follow up period of 32.3 months after 
treatment using geometric staged excision 7. To our knowledge, only Walling et al. have 
reported a series of patients treated with some form of SSE with a follow-up longer than 
that in our study 9. In their study, 41 patients were treated with SSE, and after a mean 
follow-up of 95 months, three recurrences were found (7.3%).
Instead of permanent sections, MMS uses frozen sections, with the advantage that 
the definitive excision and closure can be performed on the same day. For MMS, recur-
rence rates of 0% - 33% are reported with mean follow up periods of 22 - 117 months. 
If one study with 18 patients is excluded, recurrence rates for MMS are 0% - 6.3% after a 
follow-up period of 22 - 108 months 6. Kunishige et al. reported a 0.3% recurrence rate 
after MMS for 1,120 in situ melanomas, with a mean follow up of 4.7 years 10. The major 
disadvantage of MMS is the difficulty in accurate diagnosis of melanocytic lesions on 
haematoxylin and eosin frozen sections, which could explain the discrepancy in recur-
rence rates. MMS can be combined with direct immunohistochemical stains 11, 12, which 
showed promising results in a recent study 13, with recurrence rates of 0.34% (two of 
597) with a mean follow-up of 2.8 years. However, as MMS facilities and experienced and 
skilled staff are not widely available, SSE provides a good alternative in the treatment of 
LM, with favourable recurrence rates compared with wide local excision.
The National Comprehensive Cancer Network mentions wide local excision with a 
margin of 5 mm as the treatment of first choice for LM in their guideline on melanoma, 
published in 2008. However, for large melanoma in situ, LM type, it is advised to consider 
wider margins and more thorough histological examination 4. The European guideline 
on melanoma treatment also advises wide local excision with a margin of ≥ 5 mm as the 
treatment of first choice for LM 3. In this guideline the micrographic control of margins 
is suggested to achieve free margins. Compared to wide local excision with vertical 
sectioning of the excised material, techniques whereby the peripheral margins are ex-
amined for a full 100% have lower recurrence rates. However, the costs for SSE are higher 
than for wide local excision. At our department, the costs for SSE are comparable with 
those of MMS. The costs for MMS are about four times higher than costs for wide local 
excision with primary closure, and about 2.5 times higher than for wide local excision 
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followed by closure with flaps or grafts. Although these procedures are more expensive, 
they may lead to a higher quality of life for treated patients, as less anxiety is expected 
for (unplanned) resections of residual or recurrent LM.
Importantly, in the European guideline on melanoma treatment, the need to respect 
the anatomy of the face, including functional and cosmetic results in patients with LM, is 
stressed, and topical treatment with imiquimod is mentioned as an alternative to surgi-
cal treatment in selected cases. Clearance rates of 53 - 82% are reported after treatment 
with imiquimod, which is lower than after SSE 14. However, when compared with surgery, 
a better cosmetic result may be achieved, as no scar will be formed. Most alternative 
options, including topical treatment with imiquimod, cryotherapy, radiation therapy or 
ablative laser therapy, have the possibility to treat wide margins around the lesion. A 
major disadvantage of topical treatments is the lack of histologic control of margins. 
Also, cryotherapy and radiation therapy may still lead to scar formation. Ablative laser 
therapy as monotherapy may fail to treat atypical melanocytes residing along skin 
appendages. A promising treatment modality for patients in whom surgery would be 
disfiguring or who are unwilling to undergo surgery may be ablative laser therapy fol-
lowed by topical treatment with imiquimod,15 but the efficacy of this treatment modal-
ity needs to be demonstrated in a larger cohort. However, as LM is an in situ malignancy 
with a low estimated chance of progression to invasive malignancy, in some patients 
the functional and cosmetic risks of surgery may outweigh the advantage of achieving 
100% free margins. This argument may even lead to the decision not to offer treatment 
to patients with limited life expectancy from other causes, for whom the treatment may 
be worse than the risks associated with the disease.
In conclusion, compared with conventional excision, our technique has the advantage 
of 100% immunohistopathological control of the peripheral margins, leading to a high 
clearance and low recurrence rate. The conventional sections of the central parts of the 
lesion enable the detection of an invasive component. The main disadvantages are the 
need for patients to visit our department repeatedly and discomfort of the open wound 
in the time period between visits. As MMS with direct immunohistochemical stains is not 
widely available, we feel that our technique is very useful and superior to conventional 
wide excision, with a low recurrence rate (four of 100) after a mean follow-up period of 
5 years. Our data support the recommendation of SSE as primary treatment method for 
LM, and it should be incorporated into national and international guidelines.
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Lasers have gained an important role in dermatology and are increasingly used for both 
medical and cosmetic purposes. However, it is still a developing field, and many treat-
ments can often be improved with regard to treatment efficacy and procedure-related 
discomfort.
Different approaches have been undertaken to optimize laser treatments for derma-
tological indications. First, different laser devices can be combined. For example, in the 
treatment of port wine stains (PWS) a dual-wavelength approach has been developed 
combining a 585-597 nm Pulsed Dye Laser (PDL) and a 1,064 nm neodymium-doped 
yttrium aluminium garnet (Nd:YAG) laser 1. The theory behind this approach is that when 
the PDL pulse is fired first, a chromatic shift in blood takes place converting oxyhemo-
globin to methemoglobin. The methemoglobin absorption coefficient aligns with the 
Nd:YAG laser wavelength, which is fired as a second pulse. However, no RCTs comparing 
standard of care PDL treatment to this dual-wavelength approach have been published 
thus far. Other examples of dual wavelength approaches are combinations of the 532 
nm potassium titanyl phosphate (KTP) laser and 1,064 nm Nd:YAG laser for the treatment 
of hyperpigmentation/rejuvenation 2, the fractional Q-switched ruby laser and intense 
pulsed light for melasma 3, and the long-pulsed 755 nm alexandrite laser and 1,064 nm 
Nd:YAG laser for rosacea 4.
Second, laser treatments can be optimized by combining lasers with various topical 
drugs. This has been investigated for multiple indications, including melasma 5, hypopig-
mented scars 6, actinic keratosis 7, hair removal 8, 9, psoriasis 10, 11, vitiligo 12, 13, rosacea 
14, tattoos 15, and onychomycosis 16. Lasers may also be combined with oral drugs, for 
example in the treatment of onychomycosis 17.
Third, enhancements in laser technology can optimize treatments, for example the 
development of ultra-short pulse duration (picosecond) lasers for the treatment of tat-
toos. Although the evidence for the claimed higher efficacy of this treatment is sparse 18.
A fourth optimization strategy for laser treatments in general is minimizing general 
discomforts like pain, downtime, adverse events, and treatment duration. An example is 
the introduction of epidermal cooling, which minimized both adverse events and pain. 
Also, the development of non-ablative lasers and fractional ablative lasers for resurfacing 
resulted in treatments with less downtime, pain, adverse events and a shorter treatment 
duration than with ablative lasers 19, 20.
Fifth, lasers can be used to assist in drug delivery. Ablative lasers and fractional 
ablative lasers can remove the stratum corneum and enhance dermal drug delivery 21. 
For example, laser-assisted corticosteroid delivery for hypertrophic scars 22, fractional 
laser-assisted topical imiquimod treatment for recalcitrant warts 23, and fractional CO2 
laser-assisted delivery of topical anaesthetics 24.
In this thesis different optimization strategies were evaluated: optimizing the efficacy 
of laser treatments through the addition of topical drugs, optimizing the efficacy of a 
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topical drug through optimizing its penetration through the stratum corneum by laser 
ablation, and optimizing treatment-related discomfort by minimizing pain during laser 
treatments.
PORT WInE STaInS
Port wine stains are among the oldest and most common indications for laser therapy. 
Throughout the years, laser treatment for PWS has significantly improved. However, with 
0-22% complete clearance rates 25-29, and 14-40% treatment-resistant PWS after gold 
standard PDL treatment 30, there is clearly room for further improvement. Adjuvant treat-
ment with the anti-angiogenic agent sirolimus (rapamycin) was considered to be one of 
the most promising treatment options for PWS. Therefore, we conducted a prospective, 
intra-patient, randomized controlled trial to evaluate the efficacy of PDL treatment 
followed by application of topical sirolimus (Rapamune® 0.1%), with and without laser 
ablation of the stratum corneum (Chapter 2.1). Topical sirolimus was applied under 
occlusion and left in situ for seven days. Patients received a total of five treatments with 
two week intervals. Our results showed no improvement of PWS blanching by using ad-
juvant topical sirolimus after PDL treatment. Moreover, treatment with topical sirolimus 
was associated with frequent local skin reactions that hampered its use.
One other clinical trial (randomized, double-blind, intra-individual placebo-controlled) 
has evaluated the efficacy of PDL combined with topical sirolimus in 23 patients with 
PWS in Sturge-Weber syndrome 31. In this study, a formulation of 1% sirolimus cream was 
fabricated and applied daily for 12 weeks. In contrast to our study results, this did appear 
to be an effective treatment.
There may be a true lack of efficacy of sirolimus in PWS blanching, or the commercially 
available (oral) solution of sirolimus (Rapamune® 0.1%) that we used may not have been 
optimal for topical use due to its relatively low concentration and frequent local skin 
reactions (that interfered with our efficacy measurements as well). Another reason why 
the sirolimus treatment areas were not positively impacted in our study may be that 
sirolimus was applied only once under occlusion, and this could have led to a shorter 
and thus insufficient suppression of the mammalian target of rapamycin pathway.
Furthermore, one of our patients developed an allergic contact dermatitis to topically 
applied sirolimus (Chapter 2.2). Although there are some reports of skin irritation to 
topical sirolimus 32, 33, to our knowledge this is the first report of a true allergic contact 
dermatitis. Since topical sirolimus is gaining more interest in the treatment of PWS, and 
also of angiofibromas 32, the risk of allergic contact dermatitis should also be taken into 
account.
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Future research
Future studies should focus on further determining the efficacy of sirolimus in PWS 
blanching. Oral sirolimus has shown promising results in one patient 34, and should be 
further investigated regarding efficacy, adverse effects, and cost effectiveness. Deter-
mining the efficacy of different concentrations of topically applied sirolimus and the 
appropriate excipient for topical application may provide important additional informa-
tion.
Study protocols of two RCTs, comparing PDL monotherapy with PDL followed by topi-
cal sirolimus application, and PDL monotherapy with PDL followed by oral sirolimus, are 
published in an American clinical trial registry (www.clinicaltrials.gov). These studies 
are completed, but have not been published at present. However, after contacting the 
principal investigator of the studies, we were informed that there was a clear lack of 
efficacy of sirolimus, either applied topically or given orally, and that both studies were 
closed due to lack of efficacy. Publication of these studies needs to be awaited to obtain 
more information. A first careful conclusion may be that from these unpublished studies 
it appears there is a true lack of efficacy of sirolimus in the treatment of PWS, which is in 
agreement with the findings of our study.
Interestingly, other studies have recently been published investigating the efficacy 
of different treatments for PWS, including the 532 nm Nd:YAG for superficial bright red 
facial PWS 35, the 755 nm Alexandrite laser for hypertrophic, dark and/or resistant PWS 
36, 37, photodynamic therapy (PDT) 38, 39, hemoporfin-mediated PDT 40, PDL combined 
with imiquimod 41, 42, and fractional ablative lasers 43. Some of these treatments have 
been compared to gold standard PDL treatment and are intriguing, however, clinical 
validation in larger patient samples is required. Furthermore, protocols have been 
published (clinicaltrials.gov) of studies investigating new treatment options for PWS, 
including Bosentan (oral inhibitor of endothelin), electroporation in combination with 
bleomycin sclerotherapy (‘electrosclerotherapy’), brimonidine gel, and combined PDL 
and PDT treatment. An improved understanding of the genetic, molecular, and cellular 
changes causing the localized capillary and venular dilatation in PWS may lead to other 
innovative solutions 44.
PaIn ManaGEMEnT
Pain is a common side-effect of virtually all dermatological laser procedures. In order to 
optimize patient satisfaction and efficacy of laser treatments, procedure-related pain 
should be minimized. Different non-invasive anaesthetic drugs and procedures are 
available, which are painless to administer compared to the more invasive injectable 
anaesthetics. We performed a systematic review summarizing the available data on the 
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efficacy and safety of non-invasive anaesthetic methods that were used to reduce pain 
during dermatological laser procedures (Chapter 3.1). In general, active non-invasive 
anaesthetic methods (i.e. topical drugs, skin cooling, pneumatic skin flattening) ap-
peared to provide favourable results compared to placebo or no anaesthesia. Therefore, 
when patients experience pain during laser therapy, non-invasive anaesthesia may be 
considered to improve patient satisfaction and treatment efficacy. In addition, topical 
anaesthetic drugs and pneumatic skin flattening appeared to result in a better pain re-
duction than skin cooling. However, all of the studies we assessed had an unclear or high 
risk of bias and the overall quality of evidence was low. Therefore, no recommendations 
for daily clinical practice could be provided. No serious adverse events occurred in any 
of the included studies.
In Chapter 3.2 we compared the efficacy and safety of two commonly used local 
anaesthetics in daily clinical practice: 2.5% lidocaine / 2.5% prilocaine cream under oc-
clusion (EMLA®, henceforth referred to as ‘LP cream’), and self-occlusive 7% lidocaine / 
7% tetracaine cream (Pliaglis®, henceforth referred to as ‘LT cream’), in two RCTs. The ef-
ficacy of the creams was evaluated during the treatment of two painful laser indications: 
acne keloidalis nuchae (AKN) and tattoo removal. We found that 60 minutes of LP cream 
under plastic occlusion resulted in lower pain scores than 60 minutes of self-occlusive 
LT cream during these painful laser procedures targeting dermal chromophores. These 
(unexpected) results may be explained by the fact that the effectiveness of an anaes-
thetic cream also depends on the rate of (trans)dermal absorption. We believe that the 
main contributing factor in the difference in (trans)dermal absorption between the two 
creams may be related to the different methods of occlusion. The flexible film formed 
by LT cream might not have facilitated optimal drug absorption, and despite its higher 
concentrations of anaesthetic drugs provided less (deeper) dermal pain reduction.
Most other studies have compared LT cream with placebo (showing superiority) 45-48, 
and in only one other study LT cream was compared with LP cream after 30 minutes 
application during (superficial) single-pass CO2-laser skin resurfacing 49. In this study, LT 
cream resulted in lower pain scores than LP cream. However, it may not be possible to 
extrapolate these results to treatments with longer wavelength lasers used for both AKN 
and tattoo removal. Longer wavelength lasers penetrate much deeper into the dermis, 
triggering far more nerves than a single pass CO2 laser skin ablation. Furthermore, since 
the per label recommended application time for LP cream is a minimum of 60 minutes, 
their results may have been influenced by the shorter application time of only 30 min-
utes.
Future research
We established that self-occlusive LT cream was not superior to LP cream under plastic 
occlusion in reducing self-reported pain during painful laser procedures targeting 
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dermal chromophores. It would be interesting to evaluate if LT cream applied under 
occlusion would optimize drug absorption and result in deeper dermal pain reduction. 
However, the risk of excessive systemic absorption and ease of use in daily clinical prac-
tice should be considered.
More high quality head-to-head RCTs are needed to provide recommendations about 
non-invasive anaesthesia for daily clinical laser practice. In contrast to our study, (pub-
lished) industry-sponsored studies appear to systematically yield favourable results for 
the sponsors 50. Therefore, future studies should preferably not be industry-sponsored.
A study protocol has been published of a trial currently also investigating LP cream 
vs. LT cream and placebo during Q-switched 532 nm laser treatment of lentigines and/
or photorejuvenation. These (future) results may add additional knowledge to this 
topic. Future studies should also evaluate sex differences in pain perception, and not 
only report and address statistically significant differences, but also clinically important 
differences since only this translates to real life situations in clinical practice.
To improve general discomforts during laser treatments the focus for future research 
should be, besides pain, on minimizing side effects, treatment duration, and downtime 
as well. For example, a recent study has been published investigating risk factors for 
known intense pulsed light (IPL)-induced side effects, and found that skin pigmentation 
and IPL fluence were major determinants of side effects after IPL exposure, while expo-
sure to ultraviolet radiation at 30 minutes or 24 hours after treatment did not amplify 
side effects 51.
LEnTIGO MaLIGna
Lentigo maligna (LM) is the most common subtype of melanoma in situ and considered a 
precursor to LM melanoma (LMM). In Chapter 4.1, we investigated and compared trends 
in LM and LMM incidence rates in The Netherlands over a period of 25 years (1989-2013). 
In this period, the age-adjusted incidence rates (European standardized rate [ESR]) of LM 
increased from 0.72 to 3.84 per 100,000 person-years, and for LMM from 0.24 to 1.19 per 
100,000 person-years. The LM incidence increased from 2002 to 2013 with 6.8% (95% CI, 
5.9 – 7.7) annually, prior to the 12.4% (95% CI, 8.0 – 16.9%) rise in LMM incidence from 
2007 to 2013. Besides factors like increased awareness, increased histological examina-
tion, diagnostic drift and changed market forces, this increased incidence also seemed 
to reflect a true increase as the most recent accelerated increase of LM was followed 
by an even steeper accelerated increase of LMM. Other population-based studies that 
reported on LM also observed an average annual increase in incidence: 3.9% (95% CI, 
1.7 – 6.2) in age-group 45-64 years and 6.8% (95% CI, 5 – 8.7) in age-group ≥ 65 years for 
both sexes in Northern California between 1990 and 2000 52, and 1.7% (95% CI, 0.5 – 3.0) 
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for men and 2.7% (95% CI, 1.7 – 3.8) for woman in Denmark between 1997 and 2011 
53. For LMM, other population-based studies reported increased incidence rates in the 
order of 4-6% 52, 54-56.
Surgical excision is considered the gold standard treatment for LM. However, alter-
native non-surgical treatment options are gaining more interest, especially for large 
lesions in cosmetically sensitive areas. The main concern in the treatment of LM is the 
risk of developing an LMM. We estimated the absolute risk of an LMM (at any anatomical 
location) after an LM to be 2-3% after 25 years (Chapter 4.1). This low percentage is in 
accordance with the 2.2% to 4.7% lifetime risk estimated by Weinstock et al. in 1987 57. 
This data may help physicians and patients to weigh the advantages and disadvantages 
of the different treatments for LM, especially when choosing an alternative non-surgical 
treatment.
An example of an alternative non-surgical treatment for LM is ablative laser therapy 
followed by topical imiquimod 5% application 58. In order to further investigate this two-
stage treatment, we increased the size and the follow-up time of our cohort (Chapter 
4.2). A total of 35 patients were treated with a median (interquartile range [IQR]) follow-
up time of 19 (13-38) months. Recurrences were found in 6 patients, two after eight 
months, one after 12 months, one after 15 months and two after 18 months follow-up. 
Five of the six recurrences occurred on the nose (out of the 15 patients with LM on the 
nose). Patients rated the cosmetic outcome with a mean score of 8.5 of 10 (95% CI, 8.2 
to 8.9). We concluded that combined treatment of ablative laser therapy followed by 
topical imiquimod cream for six weeks is a feasible alternative to surgery, in patients that 
decline or are unsuitable for surgical treatment of LM with special caution for LM on the 
nose. The major advantages are the cosmetic and functional outcomes.
Since we found that recurrences of LM after our non-surgical combination treatment 
occurred almost exclusively on the nose, we investigated histological parameters that 
might be related to a higher recurrence risk on this anatomic location. In Chapter 4.3, 
we compared specimens of LM on the nose with specimens of LM on the cheek and 
found that the nose had a significantly higher density of pilosebaceous units (PSU) than 
the cheek. Also, the atypical melanocytes extended deeper along the PSU on the nose, 
with a mean (SD) depth of 1.29 mm (0.48) vs. a mean depth of 0.72 mm (0.30) on the 
cheek (P < 0.001). The maximum depth of the PSU itself was greater on the nose than on 
the cheek, with a mean (SD) depth of 2.28 mm (0.41) vs. 1.65 mm (0.82), respectively (P 
= 0.003). Therefore, we concluded that the higher recurrence risk of LM on the nose after 
non-surgical treatment is most likely based on the higher load of atypical melanocytes 
in deeper parts of the appendages. These results indicate that anatomic location is rel-
evant for the risk of recurrence of LM after non-surgical treatment. This should be taken 
into account when deciding on the treatment for the nose specifically, and highlighted 
the need for adaptation of our current treatment protocol. The adapted protocol now 
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recommends the use of the CO2 laser instead of the Erbium YAG laser. The CO2 laser 
is more efficacious in removing a higher load of atypical melanocytes and has good 
coagulation properties, enabling deeper ablation without bleeding complications 59, 60.
In order to put the recurrence rates of our non-surgical combination treatment for LM in 
perspective to the surgical treatment performed at our department, we determined the 
recurrence rate of LM after staged surgical excision (Chapter 4.4). Compared to conven-
tional excision, this technique has the advantage of a 100% immuno-histopathological 
control of the peripheral margins, and the conventional sections of the central parts of 
the lesion enable the detection of an invasive component. We found recurrences in four 
out of 100 patients, after a mean follow-up period of five years.
Future research
Recently, Marsden et al. published a study that reported on the efficacy of imiquimod as 
primary treatment for LM 61. Patients were treated with 60 imiquimod applications over 
12 weeks followed by a clinical assessment of response, post-treatment biopsies, and 
subsequent radical resection. They found that the apparent clinical complete response 
rate and negative targeted biopsies were an unreliable predictor of the pathological 
complete response (pCR) rate, as only 7 of 11 cases of complete clearance were con-
firmed as pCR. They also found a pCR rate of 37% (10 of 27), which was considered insuf-
ficient to justify a future study investigating imiquimod vs. surgery.
However, with our combination treatment the large bulk of atypical melanocytes 
is first removed by ablative laser therapy. Because the epidermis and reticular dermis 
are removed by laser ablation, deeper penetration of imiquimod is enabled and it is 
delivered closer to its target cell (dermal dendritic cell). Also, removal of Langerhans 
cells in the epidermis may prevent suppression of an inflammatory immune response 
62. Therefore, we found 0% non-responders to imiquimod in our study, in contrast to 
the 27% (8 of 29) with an absent or mild local site reaction reported by Marsden et al. 
Other studies reporting on imiquimod monotherapy reported non-responder rates of 
14-31% 63, 64. Furthermore, Marsden et al. reported 47% (9 of 19) of their patients that 
had a moderate or severe local site reaction to imiquimod, to have a pCR, whereas 13% 
(1 of 8) of the patients with mild or no reaction had a pCR. Therefore, we expect to find 
higher clearance rates. However, this has to be further investigated in a clearance rate 
assessment study for ablative laser therapy followed by topical imiquimod application.
The next step in the development of our combination treatment of ablative laser 
therapy and imiquimod for LM would then be a randomized controlled trial comparing 
this two-stage treatment to surgical excision. Future research should also determine if 
the adaption of our treatment protocol has led to fewer LM recurrences on the nose. It is 
debatable whether non-surgical approaches need to be as effective as surgery, provided 
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treatment failure could be recognised (especially progression to invasive melanoma), 
and surgery could be performed subsequently.
Imiquimod has also been used as an adjuvant to surgical excision, which may decrease 
the surgical defect size 65, 66. However, these patients would still have the disadvantages of 
imiquimod treatment (i.e. side-effects, treatment duration), as well as the risks (although 
possibly smaller) of functional impairments and cosmetic deformities after surgery.
Since LM is a pre-malignant lesion, the most significant clinical outcome is the preven-
tion of progression to invasive melanoma. However, since non-surgical treatments have 
an inherent lack of histopathological control, possible misdiagnosed LMM cannot be as-
sessed. Hazan et al. found that after excision, 16% of the LM diagnosed initially on biopsy 
had an unrecognized component of dermal invasive melanoma 67. Lower percentages 
(11.7%) have been reported by Abdelmalek et al. 68, and Iorizzo et al. (8.1%) 69. Among 
our surgical patients, we found LMM in 4% (4 of 100) of the LM previously diagnosed on 
biopsy 70. This lower percentage may be due to the fact that our pathologists section and 
examine the complete punch biopsies to rule out LMM, which is not standard of care in 
other institutions. We recommend that non-surgical treatment for LM is only considered 
when the lesions are clinically unsuspicious for LMM, that (multiple) biopsies are taken 
from the darkest (or palpable) parts of the lesion for diagnostic purposes, and that the 
punch biopsies are sectioned and examined completely. Until more data are available 
it is important to inform patients about the potential advantages and disadvantages of 
non-surgical treatments for LM and it remains crucial to follow-up these patients closely.
LaSERS In DERMaTOLOGY
Future research
Lasers can be used for numerous dermatological indications, and new opportunities 
keep being developed either for laser as the primary treatment or as an adjuvant to 
other treatments. However, decision-making in laser dermatology is often still based on 
expert opinions only. In order to yield strong recommendations for daily clinical practice, 
a more ‘evidence-based medicine’ approach is needed in the field of laser dermatology. 
The future use of evidence from well-designed and conducted research, including RCTs, 
systematic reviews and meta-analyses, should be emphasized.
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Chapter 1 contains the general introduction and general outline of this thesis. Today, la-
sers are increasingly used for different medical and cosmetic purposes and have gained 
an important role in dermatology. Although laser treatments have improved in the last 
few decades, and more safe and effective lasers were created after the development 
of selective photothermolysis, treatment results are not always optimal. In this thesis 
we aimed to develop optimization strategies for laser therapy in dermatology. Three 
different strategies were followed: optimizing an established laser treatment (for port 
wine stains), optimizing laser treatment-related pain, and optimizing innovative laser 
treatments as alternative for a surgical treatment indication (lentigo maligna).
In Chapter 2.1 we evaluated the efficacy of adjuvant use of (commercially available) 
topical sirolimus (rapamycin) after Pulsed Dye Laser (PDL) treatment in patients with 
port wine stains (PWS). We conducted a prospective, intra-patient, randomized study, 
in which four treatment areas of 1 cm2 were created in each PWS. PDL monotherapy 
was compared to the following three treatments: PDL + rapamycin, PDL + Erbium YAG 
laser ablation of the stratum corneum + rapamycin, and rapamycin monotherapy. We 
also compared PDL + Erbium YAG + rapamycin with PDL + rapamycin. The primary 
endpoint was the percentage clearance assessed colorimetrically at six months follow-
up. Fourteen patients completed the six months follow-up. The highest percentage 
clearance was achieved with PDL monotherapy (mean [SD] 16% [34]), but there were no 
statistically significant differences between treatments. Application-site pruritus was a 
frequent occurring adverse event. There were no serious adverse events. We concluded 
that topical application of the commercially available solution of rapamycin (Rapamune® 
0.1%) as an adjuvant to PDL treatment did not appear to improve PWS blanching.
In Chapter 2.2 we described a case of allergic contact dermatitis caused by sirolimus 
(Rapamune® 0.1% oral solution) which was used as an adjuvant topical treatment of a 
PWS during the above-mentioned study. Although there are some reports of skin irrita-
tion caused by topical sirolimus, to our knowledge this is the first report of a true allergic 
contact dermatitis.
In Chapter 3.1 we summarized the available data on the efficacy and safety of non-
invasive anaesthetic methods during dermatological laser procedures by means of a 
systematic review. Randomized and non-randomized controlled clinical trials (RCTs and 
CCTs) were included. Twenty RCTs and 12 CCTs were included, involving nine different 
laser indications: hair removal (n = 9), resurfacing/rejuvenation (n = 5), port wine stains 
(n = 8), leg telangiectasia (n = 3), facial telangiectasia (n = 2), tattoo removal (n = 2), 
nevus of Ota (n = 1), solar lentigines (n = 1), and human papilloma virus lesions (n = 
1). The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, 
and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, 
and types of pain scales varied widely among the included studies. In general, active 
non-invasive anaesthetic methods seemed to provide favourable results compared to 
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placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in 
a better pain reduction than skin cooling. However, all of the studies had an unclear 
or high risk of bias and the overall quality of evidence was rated as low. We concluded 
that the current evidence is insufficient to provide recommendations for daily clinical 
practice, and that there is a need for more high quality (head-to-head) RCTs.
In Chapter 3.2 we compared the efficacy of lidocaine/tetracaine cream (Pliaglis®) and 
lidocaine/prilocaine cream (EMLA®) in reducing self-reported pain during dermal laser 
treatments. We conducted two randomized, double-blind, controlled clinical trials with 
intra-patient, split-lesion design: study A in patients with acne keloidalis nuchae (AKN) 
(n = 15), and study B in patients with black tattoos (n = 15). The primary endpoint was 
the patients’ self-reported pain on a 10 cm visual analog scale (VAS). Secondary objec-
tives were the percentage of patients with adequate pain relief, and safety of the creams. 
In both studies, VAS scores were lower for lidocaine/prilocaine cream, with a mean VAS 
difference in study A of 1.9 (95% confidence interval [CI], 1.0 to 2.8) and in study B of 
0.6 (95% CI, -0.7 to 1.9). In study A, adequate pain relief was achieved in 13% (2/15) 
with lidocaine/tetracaine cream versus 73% (11/15) with lidocaine/prilocaine cream (P 
= 0.004), and in study B in 53% (8/15) versus 80% (12/15) (P = 0.289), respectively. No 
serious adverse events occurred. We concluded that lidocaine/prilocaine cream under 
plastic occlusion is the preferred topical anaesthetic during painful laser procedures 
targeting dermal chromophores.
In Chapter 4.1 we assessed trends in lentigo maligna (LM) and lentigo maligna 
melanoma (LMM) incidence rates between 1989 and 2013 in The Netherlands, and we 
estimated the risk of an LMM after LM. Data on newly diagnosed LM and LMM were 
obtained from the Netherlands Cancer Registry and PALGA (Dutch Pathology Database). 
Age-standardized incidence rates adjusted to the European standard population (Euro-
pean standardized rate [ESR]), estimated annual percentage changes (EAPC), and the 
cumulative incidence of LMM after LM were calculated. In addition, the 5-year relative 
survival of both LM and LMM was presented. Between 1989 and 2013, 10,545 patients 
were diagnosed with a primary LM and 2,898 with a primary LMM in the Netherlands. 
The ESR for LM increased from 0.72 to 3.84 per 100,000 person-years, and for LMM from 
0.24 to 1.19 per 100,000 person-years between 1989 and 2013. LM incidence increased 
from 2002 to 2013 with 6.8% annually, prior to the – even steeper – rise in LMM incidence 
from 2007 to 2013 (EAPC: 12.4%). The cumulative incidence of LMM after a primary LM 
after 25 years follow-up was 2.0% for males and 2.6% for females. The 5-year relative 
survival was high for both LM (104%) and LMM (99%). We concluded that the increased 
incidence of LM and LMM in The Netherlands seemed, besides increased awareness and 
increased histological confirmation of LM, to reflect a true increase. The absolute risk of 
an LMM (at any location) after a histologically confirmed LM was low. Our data may help 
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physicians and patients to weigh the advantages and disadvantages of the different 
treatments for LM.
In Chapter 4.2 we determined recurrence rates, cosmetic results and patient satisfac-
tion after treatment of LM with ablative laser therapy followed by topical imiquimod 
5% cream. Data were collected on patients with histologically proven LM who had been 
treated with ablative laser therapy followed by six weeks imiquimod cream between 
2008 and 2014. Case records and pathology reports were used to determine histo-
logically proven recurrences, cosmetic results (0-10), treatment related discomfort (0-10) 
and if patients would recommend this treatment to others (yes/no). Thirty-five patients 
were identified and evaluated, with a median (interquartile range [IQR]) follow-up of 19 
(13-38) months. Local recurrences were found in six patients. Five of the six recurrences 
were located on the nose (out of the 15 patients with LM on the nose). Patients rated the 
cosmetic outcome with a mean score of 8.5 (95% CI, 8.2 to 8.9) and the treatment related 
discomfort with a mean score of 4.9 (95% CI, 3.9 to 5.9). Ninety percent of the patients 
would recommend this treatment to others. None of the patients developed LMM. We 
concluded that ablative laser therapy followed by imiquimod cream is a feasible alterna-
tive to surgery in patients that decline or are unsuitable for surgical treatment, and on 
other body sites than the nose. The major advantages are the cosmetic and functional 
outcomes. However, until more data are available it is important to inform patients 
about the potential advantages and disadvantages, and it remains crucial to follow-up 
these patients closely.
In Chapter 4.3 we investigated histological parameters that might be related to the 
previously observed higher incidence of LM recurrences on the nose after ablative laser 
therapy followed by topical imiquimod cream. We randomly selected 22 surgical speci-
mens of LM on the nose and 22 on the cheek. Histopathological analysis was performed 
on hematoxylin and eosin and microphthalmia transcription factor immunohistochemi-
cally stained slides. The number of pilosebaceous units (PSU) per mm, maximum depth 
of atypical melanocytes along the skin appendages, and maximum depth of the PSU 
itself were determined. We found that the nose had a significantly higher density of PSU 
than the cheek. The atypical melanocytes extended deeper along the PSU on the nose 
with a mean (SD) depth of 1.29 mm (0.48) versus a mean depth of 0.72 mm (0.30) on 
the cheek (P < 0.001). The maximum depth of the PSU on the nose was greater than on 
the cheek, with a mean (SD) depth of 2.28 mm (0.41) versus 1.65 mm (0.82) (P = 0.003). 
We concluded that the higher recurrence risk of LM on the nose after non-surgical 
treatment, which we previously observed in our cohort, is most likely based on a higher 
density of atypical melanocytes and also their deeper extension into the follicles. These 
results have shed more light on our previous findings and learned that anatomical loca-
tion is relevant for the risk of recurrence of LM after non-surgical treatment and have led 
to an adaptation of our treatment protocol.
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In Chapter 4.4 we retrospectively determined the recurrence rate of LM after staged 
surgical excision. Records of all patients with LM, treated with our method of staged sur-
gical excision between 2002 and 2011, were retrieved. To identify recurrences, we used 
the computer programme Sympathy®, which is linked to PALGA, a nationwide network 
and registry of histopathology and cytopathology in The Netherlands. We identified 100 
patients who were treated with staged surgical excision with 100% immuno-histopath-
ological control of lateral margins. After a mean follow-up of 60 months, four patients 
had a recurrence; after 37, 58, 74 and 77 months follow-up. We concluded that staged 
surgical excision is superior in clearance and recurrence rate to wide local excision for 
LM and should be considered as treatment of first choice in national and international 
guidelines.
In Chapter 5 we discussed the main findings of the studies presented in this thesis 
and placed them into perspective. Also, we argued on future considerations for the 
treatment of PWS, pain and other discomforts during laser treatment, the treatment of 
LM, and optimizing laser treatments and laser research in general. Lasers can be used 
for numerous dermatological indications and new opportunities keep being developed, 
either for laser as the primary treatment or as an adjuvant to other treatments. However, 
decision-making in laser dermatology is often based on expert opinions only. In order 
to yield strong recommendations for daily clinical practice, a more ‘evidence based 
medicine’ approach is needed in the field of laser dermatology. The use of evidence from 
well-designed and conducted research, including RCTs, systematic reviews and meta-
analyses, should be emphasized.
Summary / Samenvatting 185
SaMEnVaTTInG
Hoofdstuk 1 geeft een algemene introductie van dit proefschrift. Lasers worden 
tegenwoordig in toenemende mate gebruikt voor verschillende medische en cosme-
tische indicaties en hebben een belangrijke rol verkregen binnen de dermatologie. 
Hoewel lasers de afgelopen decennia zijn verbeterd en er veiligere en effectievere 
lasers zijn gecreëerd na de ontwikkeling van selectieve fotothermolyse, zijn de be-
handelresultaten niet altijd optimaal. In dit proefschrift hebben we ernaar gestreefd 
om verbeterstrategieën te ontwikkelen voor laserbehandelingen in de dermatologie. 
Drie verschillende strategieën werden gevolgd: verbetering van een reeds gevestigde 
laserbehandeling (voor wijnvlekken), verbetering van pijn tijdens laserbehandelingen, 
en het optimaliseren van innovatieve laserbehandelingen als alternatieve therapie voor 
een chirurgische behandeling (voor lentigo maligna).
In hoofdstuk 2.1 evalueren we de effectiviteit van het adjuvant gebruik van (com-
mercieel beschikbaar) topicaal sirolimus (rapamycine) na de Pulsed Dye Laser (PDL) be-
handeling van patiënten met wijnvlekken. We hebben een prospectieve, intra-patiënt, 
gerandomiseerde studie uitgevoerd, waarbij vier behandelgebieden van 1 cm2 in elke 
wijnvlek werden gecreëerd. PDL monotherapie werd vergeleken met de volgende drie 
behandelingen: PDL + rapamycine, PDL + Erbium YAG laser ablatie van het stratum 
corneum + rapamycine, en rapamycine monotherapie. PDL + Erbium YAG + rapamycine 
werd ook vergeleken met PDL + rapamycine. Het primaire eindpunt was het percentage 
verbleking dat zes maanden na de behandeling werd vastgesteld door middel van een 
kleurmeter. Veertien patiënten voltooiden de zes maanden follow-up. Het hoogste per-
centage verbetering werd bereikt met de PDL monotherapie (gemiddeld [SD] 16% [34]), 
maar er was geen statistisch significant verschil tussen de verschillende behandelingen. 
Jeuk in het applicatie gebied was een vaak voorkomende bijwerking. Er waren geen 
serieuze bijwerkingen. We concludeerden dat het topicaal aanbrengen van de com-
mercieel beschikbare oplossing van rapamycine (Rapamune® 0.1%), als aanvulling op 
de PDL behandeling, het oplichten van de wijnvlek niet lijkt te verbeteren.
In hoofdstuk 2.2 beschrijven we een casus van een allergische contact dermatitis 
veroorzaakt door sirolimus (Rapamune® 0.1% drank), welke was gebruikt als aanvul-
lende lokale behandeling van een wijnvlek tijdens de bovengenoemde studie. Hoewel 
er een aantal meldingen zijn van huidirritatie veroorzaakt door lokaal sirolimus is dit, 
voor zover ons bekend, de eerste melding van een daadwerkelijke allergische contract 
dermatitis.
In hoofdstuk 3.1 vatten we de beschikbare gegevens met betrekking tot de effectiv-
iteit en veiligheid van niet-invasieve methoden van anesthesie tijdens dermatologische 
laser behandelingen samen door middel van een systematische review. Gerandomiseerd 
en niet-gerandomiseerd gecontroleerde klinische trials (RCTs en CCTs) werden geïnclu-
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deerd. Twintig RCTs en 12 CCTs werden geïncludeerd betreffende negen verschillende 
laser indicaties: ontharing (n = 9), resurfacing/rejuvenation (n = 5), wijnvlekken (n = 8), 
teleangiëctasieën op het been (n = 3), teleangiëctasieën in het gelaat (n = 2), tatoeages 
(n = 2), nevus van Ota (n = 1), lentigo solaris (n = 1), en humaan papillomavirus laesies 
(n = 1). De niet-invasieve methoden van anesthesie (d.w.z. lokale verdovende middelen, 
huid koeling, en pneumatic skin flattening [PSF]), soorten lasers, laser instellingen, ap-
plicatie tijd en soorten pijnschalen varieerden tussen de geïncludeerde studies. In het 
algemeen leken actieve methoden van anesthesie betere resultaten op te leveren dan 
placebo of geen anesthesie en leken lokale verdovende middelen en PSF te resulteren in 
een betere pijnreductie dan koeling van de huid. Alle studies hadden een onduidelijk tot 
hoog risico op bias en de algehele kwaliteit van de studies was laag. We concludeerden 
dat het huidige bewijs onvoldoende is om aanbevelingen te doen voor de dagelijkse 
klinische praktijk en dat er meer vergelijkende studies van hoge kwaliteit nodig zijn.
In hoofdstuk 3.2 vergeleken we de effectiviteit van lidocaine/tetracaine crème (Plia-
glis®) en lidocaine/prilocaine crème (EMLA®) in het verminderen van zelf-gerapporteerde 
pijn tijdens dermale laserbehandelingen. We voerden twee gerandomiseerde, dub-
belblind, gecontroleerde klinische studies uit met een intra-patiënt, split-laesie design: 
studie A in patiënten met acne keloidalis nuchae (AKN) (n = 15), en studie B in patiënten 
met zwarte tatoeages (n = 15). Het primaire eindpunt was de zelf-gerapporteerde pijn 
van de patiënt op een 10 cm visual analog scale (VAS). De secundaire eindpunten waren 
het percentage patiënten met adequate pijnbestrijding en de veiligheid van de crèmes. 
In beide studies waren de VAS scores lager voor lidocaine/prilocaine crème, met een 
gemiddeld verschil in studie A van 1,9 (95% betrouwbaarheid interval [BI], 1,0 – 2,8) 
en in studie B van 0,6 (95% BI, -0,7 – 1,9). In studie A werd de pijnbestrijding adequaat 
bevonden in 13% (2/15) van de patiënten met lidocaine/tetracaine crème versus 73% 
(11/15) met lidocaine/prilocaine crème (P = 0,004) en in studie B in 53% (8/15) versus 
80% (12/15) (P = 0.289), respectievelijk. Er waren geen serieuze bijwerkingen. We 
concludeerden dat lidocaine/prilocaine crème, aangebracht onder plastic occlusie, 
het voorkeursmiddel is voor lokale verdoving tijdens pijnlijke laserbehandelingen van 
dermale chromoforen.
In hoofdstuk 4.1 onderzochten we de incidentietrends van lentigo maligna (LM) 
en lentigo maligna melanoom (LMM) tussen 1989 en 2013 in Nederland en schatten 
we het risico op een LMM na een LM. Gegevens over nieuw gediagnosticeerde LM en 
LMM werden verkregen via de Nederlandse Kanker Registratie en PALGA (Nederlandse 
pathologie database). Leeftijd-gestandaardiseerde incidentiecijfers aangepast voor de 
Europese standaardbevolking (ESR), geschatte jaarlijkse procentuele veranderingen 
(EAPC), en de cumulatieve incidentie van LMM na LM werden berekend. Daarnaast 
presenteerden we de 5-jaarsoverleving van zowel LM als LMM. Tussen 1989 en 2013 
werden er in Nederland 10.545 patiënten gediagnostiseerd met een primair LM en 2.898 
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met een primair LMM. Tussen 1989 en 2013 steeg de ESR voor LM van 0,72 naar 3,84 
per 100.000 persoonsjaren, en voor LMM van 0,24 naar 1,19 per 100.000 persoonsjaren. 
De incidentie van LM steeg van 2002 tot 2013 met 6,8% per jaar, voorafgaand aan de 
nog steilere stijging van de incidentie van LMM tussen 2007 en 2013 (EAPC: 12,4%). 
De cumulatieve incidentie van LMM na een primair LM na 25 jaar follow-up was 2,0% 
voor mannen en 2,6% voor vrouwen. De 5-jaarsoverleving was hoog voor zowel LM 
(104%) als LMM (99%). We concludeerden dat de gestegen incidentie van LM en LMM in 
Nederland, naast een toegenomen bewustzijn en toegenomen histologische bevestig-
ing van LM, een werkelijke stijging lijkt weer te geven. Het absolute risico op een LMM 
(op elke locatie) na een histologisch bevestigd LM was laag. De resultaten van deze 
studie kunnen artsen en patiënten helpen om de voor- en nadelen van de verschillende 
behandelingen voor LM tegen elkaar af te wegen.
In hoofdstuk 4.2 bepaalden we de recidiefkans, het cosmetisch resultaat en de 
patiënttevredenheid van de behandeling van LM met de ablatieve laser gevolgd door 
zes weken lokaal imiquimod 5% crème. De gegevens van patiënten met histologisch 
bewezen LM, die tussen 2008 en 2014 waren behandeld met de ablatieve laser gevolgd 
door imiquimod crème, werden verzameld. Patiëntendossiers en pathologie verslagen 
werden gebruikt om histologisch bewezen recidieven, cosmetische resultaten (0-10), 
behandeling gerelateerd ongemak (0-10), en of patiënten de behandeling aan anderen 
zouden aanbevelen (ja/nee), te bepalen. Vijfendertig patiënten werden geïdentificeerd 
en geëvalueerd, met een mediane (IQR) follow-up tijd van 19 (13-38) maanden. Lokale 
recidieven werden gevonden in zes patiënten. Vijf van deze zes recidieven waren gelo-
kaliseerd op de neus (van de in totaal 15 patiënten met LM op de neus). Patiënten gaven 
het cosmetisch resultaat een gemiddelde score van 8,5 (95% BI, 8,2 – 8,9) en het onge-
mak tijdens de behandeling een gemiddelde score van 4,9 (95% BI, 3,9 – 5,9). Negentig 
procent van de patiënten zou deze behandeling aanbevelen aan anderen. Geen van 
de patiënten ontwikkelden een LMM. We concludeerden dat ablatieve laserbehandel-
ing gevolgd door imiquimod crème een redelijk alternatief is voor LM patiënten die 
ongeschikt zijn voor chirurgische behandeling of die deze behandeling weigeren, op 
lokalisaties anders dan de neus. De grootste voordelen zijn de cosmetische en functio-
nele resultaten. Echter, totdat er meer gegevens beschikbaar zijn is het belangrijk om 
de patiënten te informeren over de potentiële voor- en nadelen van de behandeling en 
blijft het cruciaal om deze patiënten intensief te vervolgen.
In hoofdstuk 4.3 onderzochten we histologische parameters die mogelijk gerelateerd 
zijn aan de eerder geobserveerde hogere incidentie van LM recidieven op de neus na 
ablatieve laser behandeling gevolgd door lokaal imiquimod crème. We selecteerden 
willekeurig materiaal van 22 chirurgische excisies van LM op de neus en 22 van LM op 
de wang. Histologische analyses werden uitgevoerd op hematoxyline en eosine en 
microphthalmia transcription factor immunohistochemisch gekleurde slides. Het aantal 
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haar-talgklier-complexen (pilosebaceous units [PSU]) per mm, de maximale extensie 
van atypische melanocyten langs de huidadnexen en de maximale diepte van de PSU 
zelf werden bepaald. De neus had een significant hogere dichtheid van PSU dan de 
wang. De atypische melanocyten breidden zich dieper uit langs de PSU op de neus, 
met een gemiddelde (SD) diepte van 1,29 mm (0,48) versus een gemiddelde diepte van 
0,72 mm (0,30) op de wang (P < 0,001). De maximale diepte van de PSU op de neus was 
groter dan die op de wang, met een gemiddelde (SD) diepte van 2,28 mm (0,41) versus 
1,65 mm (0,82) (P = 0,003). We concludeerden dat het hogere recidief risico voor LM op 
de neus na niet-chirurgische behandeling, welke we eerder observeerden in ons cohort, 
het meest waarschijnlijk wordt veroorzaakt door een hogere densiteit van atypische 
melanocyten en hun diepere extensie in de follikels. Deze resultaten geven meer inzicht 
in onze eerdere bevindingen, laten zien dat de anatomische locatie relevant is voor 
het recidief risico van LM na niet-chirurgische behandeling en hebben geleid tot een 
aanpassing van ons behandelprotocol.
In hoofdstuk 4.4 bepaalden we retrospectief de recidiefkans van LM na gefaseerde 
micrografische chirurgie (volgens ‘Breuninger’). Gegevens van alle patiënten met LM die 
waren behandeld met onze methode van gefaseerde chirurgische excisie tussen 2002 
en 2011 werden verzameld. Om recidieven te identificeren gebruikten we het computer 
programma Sympathy®, wat gelinkt is aan PALGA, een nationaal netwerk en register 
van histo- en cytopathologie in Nederland. We identificeerde 100 patiënten die waren 
behandeld met gefaseerde chirurgische excisie met 100% immuno-histopathologische 
controle van de laterale marges. Na een gemiddelde follow-up duur van 60 maanden 
werd er bij vier patiënten een recidief gevonden, na 37, 58, 74 en 77 maanden follow-
up. We concludeerden dat gefaseerde chirurgische excisie superieur is ten opzichte 
van ruime lokale excisie voor LM en zou moeten worden overwogen als eerste keus 
behandeling in nationale en internationale richtlijnen.
In hoofdstuk 5 bediscussiëren we de belangrijkste bevindingen van de studies in 
dit proefschrift en plaatsen we deze in perspectief. Daarnaast bespreken we onze over-
wegingen voor de toekomst wat betreft de behandeling van wijnvlekken, van pijn en 
andere ongemakken tijdens laser behandelingen, van LM, en van het verbeteren van 
laserbehandelingen en laseronderzoek in het algemeen.
Lasers kunnen worden gebruikt voor vele dermatologische indicaties en nieuwe 
mogelijkheden voor laser als primaire behandeling of als aanvulling op andere 
behandelingen worden steeds ontwikkeld. Echter, het maken van beslissingen in de 
laserdermatologie is vaak gebaseerd op de ervaringen en meningen van experts. Om 
goed onderbouwde aanbevelingen te kunnen doen voor de dagelijkse klinische praktijk 
is een meer evidence-based medicine (‘geneeskunde op basis van bewijs’) benadering 
nodig. Het toepassen van bewijs van goed ontworpen en goed uitgevoerd onderzoek, 
inclusief RCTs, systematische reviews en meta-analyses, moet worden benadrukt.
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abbREVIaTIOnS
AKN acne keloidalis nuchae
CCT controlled clinical trial
CI confidence interval
CIE Commission International de l’Eclairage
CO2 carbon dioxide
COX cyclo-oxygenase
EAPC estimated annual percentage change
EF energy fluence
Er:YAG erbium-doped yttrium aluminium garnet
ESR European standardized rate
HE hematoxylin and eosin
HIF-1α hypoxia-inducible factor 1-alpha
HPV human papilloma virus
ICDO International Classification of Diseases for Oncology
IPL intense pulsed light
IQR interquartile range
KTP potassium titanyl phosphate
LASER light amplification by the stimulated emission of radiation
LM lentigo maligna
LMM lentigo maligna melanoma
LP lidocaine/prilocaine
LT lidocaine/tetracaine
MITF microphthalmia transcription factor
MMS Mohs micrographic surgery
mTOR mammalian target of rapamycin
NCR Netherlands cancer registry
Nd:YAG neodymium-doped yttrium aluminium garnet
NRS numeric rating scale
NSAID non-steroidal anti-inflammatory drug
pCR pathological complete response
PDL pulsed dye laser
PDT photo dynamic therapy
pKa acid dissociation constant
PSF pneumatic skin flattening
PSU pilosebaceous unit
PWS port wine stain
RCT randomized controlled trial
194 Abbreviations
RPM rapamycin
SD standard deviation
SSE staged surgical excision
TLR Toll-like receptor
TRT thermal relaxation time
USSR United States standardized rate
VAS visual analog scale
VEGF vascular endothelial growth factor
WSR World standardized rate
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